Baxter (BAX)

Company ID: 113 | CIK: 0000010456
10-Q view:
No 10-K data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-K data
No 10-Q YTD data
No 10-Q 3M data
No 10-K data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
Segments are charted by their disclosed metrics (revenue, segment profit, etc.). Each line is a single segment. Reconciliation/corporate items are excluded. Major customers are shown as a percentage of revenue. Operational KPIs are grouped by metric concept; sub-metrics appear as separate lines.

Geographic Segments

No 10-Q data
No 10-Q data
No 10-Q data

Business Unit / Product Segments

Major Customers (% of Revenue)

No 10-Q data

Operational KPIs

Contract liabilities (backlog)

No 10-K data

Plasma centers (branches)

No 10-K data

Factor concentrate claimant groups eligible (claims_count)

No 10-K data

Common stockholders (customers)

No 10-Q data

Employees (headcount)

Inventories (inventory_units)

No 10-K data

6060 pumps in use (other)

No 10-Q data

6060 pumps installed base (other)

No 10-Q data

ADVATE net sales (other)

No 10-Q data

ADVATE sales (other)

Allowance for doubtful accounts (other)

No 10-K data

Annual pretax savings from business optimization (other)

No 10-Q data

Annualized inventory turns (other)

No 10-K data

Annualized savings per diluted share (other)

No 10-K data

Baxalta retained shares held (other)

No 10-K data

Baxalta shares distributed (other)

No 10-K data

Baxalta shares retained (other)

No 10-K data

Baxter Ventures commitment (other)

No 10-Q data

Business optimization annualized savings (other)

No 10-K data

Business optimization cash reserve (other)

No 10-K data

Business optimization cash reserves (other)

No 10-K data

Business optimization charges (other)

No 10-K data

Business optimization costs (other)

No 10-K data

Business optimization costs incurred (other)

No 10-K data

Business optimization cumulative costs (other)

No 10-K data

Business optimization expected annual savings (other)

No 10-K data

Business optimization pre-tax savings (other)

No 10-K data

Business optimization reserve (other)

No 10-K data

Business optimization reserves (other)

No 10-K data

Business optimization savings (other)

COLLEAGUE and SYNDEO pump reserves (other)

No 10-K data

COLLEAGUE cash reserve utilized (other)

No 10-K data

COLLEAGUE infusion pump reserves (other)

No 10-K data

COLLEAGUE infusion pumps in U.S. market (other)

No 10-K data

COLLEAGUE pump remediation reserve utilized (other)

No 10-K data

COLLEAGUE pumps in U.S. market (other)

No 10-K data

COLLEAGUE pumps in use (other)

COLLEAGUE pumps removed from use (other)

No 10-K data

COLLEAGUE pumps seized (other)

No 10-K data

COLLEAGUE/SYNDEO infusion pump reserve (other)

No 10-K data

COLLEAGUE/SYNDEO infusion pump reserves (other)

No 10-K data

Capital Expenditures (other)

No 10-Q data

Capital expenditures (other)

No 10-Q data

Capital expenditures and R&D (other)

No 10-K data

Cash Dividends Paid (other)

No 10-Q data

Cash and cash equivalents (other)

No 10-K data

Cash and equivalents (other)

No 10-K data

Cash dividends declared per share (other)

No 10-K data

Cash flow from operations (other)

No 10-K data

Claimant groups eligible (other)

No 10-K data

Claimant groups paid (other)

No 10-K data

Commercial paper outstanding (other)

No 10-K data

Common shareholders of record (other)

No 10-Q data

Common shares outstanding (other)

No 10-K data

Common stockholders of record (other)

No 10-Q data

Constant currency sales growth (other)

No 10-K data

Contingent payment probability (other)

No 10-K data

Contingent payments related to acquisitions (other)

No 10-K data

Contract assets (other)

No 10-K data

Contract liabilities (other)

No 10-K data

Countries Sold In (other)

No 10-Q data

Countries manufactured in (other)

No 10-Q data

Countries manufacturing (other)

No 10-Q data

Countries of Operation (other)

No 10-Q data

Countries of manufacture (other)

No 10-Q data

Countries of operation (other)

No 10-Q data

Countries of sale (other)

No 10-Q data

Countries selling (other)

No 10-Q data

Countries served (other)

No 10-Q data

Countries sold in (other)

No 10-Q data

Countries with manufacturing (other)

No 10-Q data

Countries with product sales (other)

No 10-Q data

Countries with sales (other)

No 10-Q data

Cumulative business optimization costs (other)

No 10-K data

Days payable outstanding (other)

No 10-K data

Days payables outstanding (other)

No 10-Q data

Days sales outstanding (other)

Distribution facilities (other)

No 10-Q data

Dividends declared per share (other)

No 10-K data

Domestic sales growth (other)

No 10-K data

Effective income tax rate (other)

Effective tax rate (other)

No 10-K data

Eligible factor concentrate claimant groups (other)

No 10-K data

Eligible settlement claimants (other)

No 10-K data

Environmental reserves (other)

No 10-K data

Equipment leased or rented to customers (other)

No 10-Q data

Equipment leased to customers (other)

No 10-Q data

Equity forward agreement shares (other)

No 10-K data

Expected annual pre-tax cost savings (other)

No 10-K data

Expected annual pre-tax savings (other)

No 10-K data

Expected annual pretax savings (other)

No 10-K data

Factor claimants paid (other)

No 10-K data

Factor concentrate claimant groups (other)

No 10-K data

Factor concentrate claimant groups paid (other)

No 10-K data

Factor concentrate lawsuits (other)

No 10-K data

Factor concentrate litigation (other)

No 10-K data

Factor settlement claimants (other)

No 10-K data

Gambro sales contribution (other)

No 10-K data

Gammagard IVIG claims (other)

No 10-K data

Gammagard IVIG lawsuits (other)

No 10-K data

Gammagard claims (other)

No 10-K data

Gammagard hepatitis C litigation (other)

No 10-K data

Gammagard lawsuits (other)

No 10-K data

Gross margin (other)

Gross margin ratio (other)

No 10-K data

Gross profit margin (other)

No 10-K data

Hazardous waste cleanup sites (other)

No 10-K data

Hazardous waste sites (other)

No 10-K data

HemAssist manufacturing facility book value (other)

No 10-K data

Holders of record (other)

No 10-Q data

Hurricane Helene charges (other)

No 10-K data

Hurricane Helene pre-tax charges (other)

No 10-K data

IPR&D project completion (other)

No 10-K data

Immuno sales contribution (other)

No 10-K data

Income from continuing operations growth (other)

No 10-K data

Infusion pump cash reserve (other)

No 10-K data

Infusion pump cash reserves (other)

No 10-K data

Infusion pumps in use (other)

No 10-Q data

Insurance recoveries paid, committed and projected (other)

No 10-K data

Interest coverage ratio (other)

International revenue share (other)

No 10-Q data

International sales growth (other)

No 10-K data

Inventories (other)

No 10-K data

Inventory turns (other)

Japan claims settled (other)

No 10-K data

Japan factor concentrate plaintiffs (other)

No 10-K data

Japan factor plaintiffs (other)

No 10-K data

Japan factor plaintiffs settled (other)

No 10-K data

Japan plaintiffs (other)

No 10-K data

Latex glove lawsuits (other)

No 10-K data

Latex glove litigation (other)

No 10-K data

Lease revenue (other)

No 10-K data

Legal and environmental reserves (other)

No 10-K data

Mammary implant claims (other)

No 10-K data

Mammary implant lawsuits (other)

No 10-K data

Mammary implant litigation (other)

No 10-K data

Mammary implant plaintiffs (other)

No 10-K data

Manufacturing countries (other)

No 10-Q data

Manufacturing facilities (other)

No 10-Q data

Marketing and admin expense ratio (other)

No 10-K data

Marketing and administrative expense ratio (other)

No 10-K data

Marketing and administrative expenses (other)

No 10-K data

Marketing and administrative expenses as % of sales (other)

No 10-K data

Net debt to capital (other)

No 10-K data

Net debt to capital ratio (other)

Net debt to net capital (other)

No 10-K data

Net debt to net capital ratio (other)

No 10-K data

Net income growth (other)

No 10-K data

Net investment in leases (other)

No 10-K data

Net investment in sales-type leases (other)

No 10-K data

Net monetary assets (other)

No 10-K data

Net receivables from public sector (other)

No 10-K data

Net sales growth (other)

No 10-K data

Net sales growth (constant currency) (other)

No 10-K data

Net sales growth constant currency (other)

No 10-K data

Net sales growth excluding acquisitions (other)

No 10-K data

Net-debt-to-capital ratio (other)

Net-debt-to-net-capital ratio (other)

No 10-K data

New products approved (other)

No 10-Q data

Nonvested restricted stock and RSUs (other)

No 10-K data

Number Of Reportable Segments (other)

Number of Reportable Segments (other)

Operating assets per employee (other)

No 10-Q data

Operating cash flow (other)

No 10-Q data

Operational cash flow (other)

Operational sales growth (other)

No 10-K data

Opt-out plaintiffs (other)

No 10-K data

Organic sales growth (other)

No 10-K data

Outstanding stock options (other)

No 10-K data

Pending claims - Gammagard hepatitis C (other)

No 10-K data

Pending claims - hemophilia factor concentrate (other)

No 10-K data

Pending claims - mammary implants (other)

No 10-K data

Pending latex glove lawsuits (other)

No 10-K data

Pending lawsuits (other)

No 10-K data

Pending lawsuits - Gammagard hepatitis C (other)

No 10-K data

Pending lawsuits - hemophilia factor concentrate (other)

No 10-K data

Pending lawsuits - mammary implants (other)

No 10-K data

Pending mammary implant lawsuits (other)

No 10-K data

Pending plasma therapies lawsuits (other)

No 10-K data

Pension funded status (other)

No 10-Q data

Plaintiffs in mammary implant litigation (other)

No 10-K data

Plaintiffs with product ID (other)

No 10-K data

Plasma collection centers closed (other)

Plasma therapies claims (other)

No 10-K data

Plasma therapies lawsuits (other)

No 10-K data

Plasma therapy claims (other)

No 10-K data

Plasma therapy lawsuits (other)

No 10-K data

Plasma-based therapies claims (other)

No 10-K data

Plasma-based therapies lawsuits (other)

No 10-K data

Plasma-based therapy lawsuits (other)

No 10-K data

Positions eliminated (other)

Premier sales concentration (other)

No 10-Q data

Products manufactured in (other)

No 10-Q data

Products offered (other)

No 10-Q data

Products with Y2000 issues (other)

No 10-K data

Products with Y2K issues (other)

Products with Year 2000 issues (other)

No 10-K data

Public sector receivables (other)

Public sector receivables exposure (other)

No 10-K data

Pumps seized by FDA (other)

No 10-K data

R&D Expenditures (other)

No 10-Q data

R&D as percent of sales (other)

No 10-K data

R&D centers (other)

No 10-Q data

R&D expenditures (other)

No 10-Q data

R&D expense as percent of sales (other)

No 10-K data

R&D expense ratio (other)

No 10-K data

R&D pipeline projects (other)

No 10-Q data

RTS clinic countries (other)

No 10-Q data

Ratio of earnings to fixed charges (other)

Receivables sold and serviced (other)

No 10-K data

Remaining business optimization costs (other)

No 10-K data

Remaining repurchase authorization (other)

No 10-K data

Remaining share repurchase authorization (other)

No 10-K data

Remaining stock repurchase authorization (other)

No 10-K data

Reported hepatitis C transmissions (other)

No 10-K data

Research and development centers (other)

No 10-Q data

Research and development expenditures (other)

No 10-Q data

Research and development expense (other)

No 10-Q data

Research and development expense ratio (other)

No 10-K data

Research and development expenses (other)

No 10-Q data

Research and development ratio (other)

No 10-K data

Research and development spend (other)

No 10-Q data

Research centers (other)

No 10-Q data

Restricted stock outstanding (other)

No 10-Q data

Restructuring completion (other)

No 10-K data

Restructuring liability (other)

No 10-K data

Restructuring liability balance (other)

No 10-K data

Restructuring position eliminations (other)

No 10-Q data

Restructuring positions affected (other)

No 10-K data

Restructuring positions eliminated (other)

Restructuring pretax savings (other)

No 10-K data

Restructuring reserve (other)

No 10-K data

Restructuring reserve balance (other)

No 10-K data

Restructuring reserve utilization (other)

No 10-K data

Restructuring reserves (other)

No 10-K data

Restructuring reserves utilized (other)

No 10-K data

Restructuring savings (other)

No 10-K data

Restructuring savings target (other)

No 10-K data

Revolver capacity (other)

No 10-K data

Revolving credit facilities (other)

No 10-K data

SYNDEO PCA pumps in use (other)

No 10-K data

Sales countries (other)

No 10-Q data

Sales markets (other)

No 10-Q data

Sales per employee (other)

No 10-Q data

Share repurchase amount (other)

No 10-K data

Share repurchase authorization (other)

No 10-K data

Share repurchase authorization remaining (other)

No 10-K data

Shared Investment Plan guarantees (other)

No 10-K data

Shared Investment Plan shares (other)

No 10-K data

Shared Investment Plan shares purchased (other)

No 10-K data

Shareholders of record (other)

No 10-Q data

Shares outstanding (other)

Shares purchased under Shared Investment Plan (other)

No 10-K data

Shares repurchased (other)

Shares subject to equity forward agreements (other)

No 10-K data

Significant R&D projects (other)

No 10-Q data

Stock options exercisable (other)

No 10-K data

Stock options outstanding (other)

Stock repurchased (other)

No 10-K data

Stock repurchases (other)

No 10-K data

Stock shares repurchased (other)

No 10-K data

Stockholders of record (other)

No 10-Q data

Superfund sites (other)

No 10-K data

Supplier Y2000 response rate (other)

No 10-K data

Supplier questionnaire response (other)

No 10-K data

Targeted positions eliminated (other)

No 10-K data

Thimerosal-related lawsuits (other)

No 10-K data

Total business optimization charges (other)

No 10-K data

Total lease revenue (other)

No 10-K data

Treasury shares repurchased (other)

No 10-K data

Unallocated Hillrom costs (other)

No 10-K data

Uncertain tax position reserves (other)

No 10-K data

Weighted-average discount rate (other)

No 10-K data

Weighted-average remaining lease term (other)

No 10-K data

Y2000 critical changes (other)

No 10-K data

Y2000 program cost (other)

No 10-K data

Y2000 system implementations (other)

No 10-K data

Y2K IT system upgrade cost (other)

No 10-K data

Y2K date-dependent changes implemented (other)

No 10-K data

Y2K major system implementations complete (other)

No 10-K data

Y2K product modifications complete (other)

No 10-K data

Y2K supplier questionnaire response rate (other)

No 10-K data

Year 2000 IT system remediation cost (other)

No 10-K data

Year 2000 compliance (other)

No 10-K data

Year 2000 critical items (other)

No 10-K data

Year 2000 program cost (other)

No 10-K data

Extraneal patients (patients)

Dialyzers manufactured (production_volume)

No 10-Q data

R&D centers (properties)

Remaining performance obligations (rpo)

Common Stock Shares Outstanding (shares)

No 10-Q data

Colleague pump channels placed (units_shipped)

No 10-Q data
Human capital disclosures. Workforce totals and demographics are point-in-time. Flow metrics use the year-to-date period for 10-Q and full year for 10-K. Workforce actions (RIFs, restructurings, acquisition-related changes) are listed in the table at the bottom.

Workforce Totals

No 10-Q data

Demographics

No demographic data found.

Workforce Breakdowns

No 10-Q data
No 10-Q data

HCM Metrics — Point-in-Time

No point-in-time HCM metrics found.

HCM Metrics — Flow (Annual / YTD)

No flow HCM metrics found.

Workforce Actions

Period EndTypeStatusAffected% WorkforceAnnouncedExpected CompletionGeographySegment / FunctionChargeSourceNote
2026-06-30restructuringin_progress2027-12-31Enterprise-wide (COGS, SG&A, R&D functions)USD 58 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Six months ended June 30, 2026 restructuring charges were $63M, of which $58M was employee termination costs tied to post-Kidney Care sale cost-structure initiatives; Q2 2026 restructuring charges were $2M. Restructuring liability was $98M at 2026-06-30 (charges $69M, payments $96M in the period). No employee count disclosed; substantially all cash payments expected by end of 2027.
2026-06-30restructuringin_progressEnterprise-wideUSD 34 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Business transformation charges of $34M for six months ended June 30, 2026 ($23M in Q2 2026) for enterprise-wide initiatives to modernize systems, redesign operating models, and improve process efficiency; disclosed as a special item distinct from business optimization/restructuring charges. No employee count disclosed.
2026-06-30restructuringin_progress2027-12-31GlobalVarious (COGS, SG&A, R&D)USD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Q2 2026 restructuring charges of $2M recorded. Total liability balance $98M as of June 30, 2026, substantially all related to employee termination costs. Payments expected by end of 2027.
2026-06-30restructuringin_progress2027-12-31GlobalVarious (COGS, SG&A, R&D)USD 63 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		YTD 2026 restructuring charges of $63M recorded. Includes $58M in employee termination costs related to post-Kidney Care separation cost structure reduction.
2026-06-30restructuringin_progressBusiness Optimization Programs [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-06-30restructuringin_progressEmployee Severance [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-06-30restructuringin_progressContract Termination And Other Costs [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-06-30restructuringin_progressUSD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-06-30restructuringin_progressAsset Write Offs [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-06-30restructuringin_progressReduced Employee Expenses [Member] / Employee Severance [Member] / Kidney Care [Member]USD 58,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-06-30restructuringin_progressSeverance, Contract Termination, And Other Employee Related Costs [Member]USD 69,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-03-31restructuringin_progressNot specifiedEnterprise-wide; includes COGS, SG&A and R&D functionsUSD 68 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 2026 charges comprised $61M restructuring (incl. $58M employee termination costs) and $7M implementation costs; no headcount affected disclosed. Restructuring liability rose from $133M to $144M; substantially all expected to be paid by end of 2026.
2026-03-31restructuringin_progressNot specifiedEnterprise-wide business transformation initiativesUSD 11 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Newly launched enterprise-wide initiatives to modernize systems and redesign operating models; disclosed as a special item distinct from restructuring charges. No employee counts given.
2026-03-31restructuringin_progressUSD 61 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Includes $58 million in employee termination costs related to cost structure reduction following Kidney Care sale. Employee count not disclosed.
2026-03-31restructuringin_progressUSD 7 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Costs to implement business optimization programs, primarily external consulting and transition costs including employee compensation.
2026-03-31restructuringin_progressBusiness Optimization Programs [Member]USD 61,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-03-31restructuringin_progressCost of Sales [Member] / Employee Severance [Member]USD 10,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-03-31restructuringin_progressSelling, General and Administrative Expenses [Member] / Employee Severance [Member]USD 35,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-03-31restructuringin_progressResearch and Development Expense [Member] / Employee Severance [Member]USD 13,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-03-31restructuringin_progressEmployee Severance [Member]USD 58,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-03-31restructuringin_progressCost of Sales [Member] / Contract Termination And Other Costs [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-03-31restructuringin_progressSelling, General and Administrative Expenses [Member] / Contract Termination And Other Costs [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-03-31restructuringin_progressResearch and Development Expense [Member] / Contract Termination And Other Costs [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-03-31restructuringin_progressContract Termination And Other Costs [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-03-31restructuringin_progressCost of Sales [Member] / Asset Write Offs [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-03-31restructuringin_progressSelling, General and Administrative Expenses [Member] / Asset Write Offs [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-03-31restructuringin_progressResearch and Development Expense [Member] / Asset Write Offs [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-03-31restructuringin_progressAsset Write Offs [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-03-31restructuringin_progressCost of Sales [Member]USD 11,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-03-31restructuringin_progressSelling, General and Administrative Expenses [Member]USD 36,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-03-31restructuringin_progressResearch and Development Expense [Member]USD 14,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-03-31restructuringin_progressUSD 61,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-03-31restructuringin_progressReduced Employee Expenses [Member] / Employee Severance [Member] / Kidney Care [Member]USD 58,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-03-31restructuringin_progressSeverance, Contract Termination, And Other Employee Related Costs [Member]USD 60,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-12-31divestiture_reductioncompleted2024-08-122025-01-31GlobalFormer Kidney Care segment (now Vantive Health LLC)discontinued_operations_footnote
f5-10k / GLM-5.3-flash-HTML		Sale of Kidney Care business to Carlyle affiliates completed January 31, 2025 for a $3.80 billion aggregate purchase price; transfer of the segment's workforce to Vantive is not quantified in this filing. Year-end headcount of approximately 37,500 reflects removal of the Kidney Care workforce. FY2025 pre-tax gain on sale of $97 million after final working capital and other adjustments.
2025-12-31restructuringin_progressGlobalEnterprise-wide cost-structure reduction following Kidney Care saleUSD 100 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		FY2025 employee termination costs for initiatives to reduce cost structure after the Kidney Care sale; component of $162M FY2025 restructuring charges ($178M total business optimization charges including $16M implementation costs). Item 1 separately references ongoing streamlining via elimination of managerial layers. Headcount affected not disclosed; company expects ~$2M additional implementation cash costs and substantially all remaining restructuring liability ($133M at year-end) disbursed by end of 2026.
2025-12-31restructuringin_progressSingle manufacturing facility (location not disclosed)Exit of a product line at one manufacturing facilityUSD 28 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		FY2025 charges comprise $14M asset impairments, $9M contract termination and other costs, and $5M employee termination costs. Headcount affected not disclosed.
2025-12-31divestiture_reductioncompleted2024-08-122025-01-31GlobalKidney Care segment (Vantive)discontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Sale of the Kidney Care business to Carlyle closed 2025-01-31 for $3.80 billion; headcount transferred not disclosed. Separation-related costs of $37 million were recorded in SG&A for 2025.
2025-12-31restructuringin_progressGlobalEnterprise — cost structure following Kidney Care saleUSD 100 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2025 employee termination costs of $100 million tied to post-divestiture cost-structure reduction; employee counts not disclosed. Approximately $2 million of additional pre-tax cash costs expected to complete initiatives launched before 2025-12-31.
2025-12-31restructuringin_progressNot specifiedManufacturing — exit of a product line at one manufacturing facilityUSD 28 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2025 charges comprise $14 million asset impairment, $9 million contract termination and other costs, and $5 million employee termination costs; employee counts not disclosed.
2025-12-31restructuringcompletedGlobalMultiple segmentsUSD 178 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Charges primarily related to initiatives to reduce cost structure following the sale of Kidney Care segment and exit of a product line. Employee termination costs were $109 million. Filing does not disclose specific headcount affected.
2025-12-31divestiture_reductioncompleted2025-01-312025-01-31GlobalKidney Carediscontinued_operations_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Sale of Kidney Care business completed January 31, 2025. Headcount removed not explicitly quantified in filing.
2025-12-31restructuringcompleted2025-01-012025-12-31GlobalVariousUSD 178 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Total business optimization charges of $178 million in 2025. Includes $100 million for cost structure reduction following Kidney Care sale and $28 million for product line exit. Employee termination costs were $109 million. Specific headcount affected not disclosed.
2025-12-31divestiture_reductioncompleted2025-01-312025-01-31GlobalKidney Carediscontinued_operations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Sale of Kidney Care business completed on January 31, 2025. Headcount removed not explicitly quantified in the filing, but total employee count of 37,500 is stated 'after giving effect to the Kidney Care sale'.
2025-12-31restructuringin_progressUSD 162,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-12-31restructuringin_progressCost of Sales [Member] / Employee Severance [Member]USD 36,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-12-31restructuringin_progressSelling, General and Administrative Expenses [Member] / Employee Severance [Member]USD 62,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-12-31restructuringin_progressResearch and Development Expense [Member] / Employee Severance [Member]USD 11,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-12-31restructuringin_progressEmployee Severance [Member]USD 109,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-12-31restructuringin_progressCost of Sales [Member] / Contract Termination And Other Costs [Member]USD 11,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-12-31restructuringin_progressSelling, General and Administrative Expenses [Member] / Contract Termination And Other Costs [Member]USD 4,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-12-31restructuringin_progressResearch and Development Expense [Member] / Contract Termination And Other Costs [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-12-31restructuringin_progressContract Termination And Other Costs [Member]USD 15,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-12-31restructuringin_progressCost of Sales [Member] / Asset Impairment [Member]USD 19,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-12-31restructuringin_progressSelling, General and Administrative Expenses [Member] / Asset Impairment [Member]USD 19,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-12-31restructuringin_progressResearch and Development Expense [Member] / Asset Impairment [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-12-31restructuringin_progressAsset Impairment [Member]USD 38,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-12-31restructuringin_progressCost of Sales [Member]USD 66,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-12-31restructuringin_progressSelling, General and Administrative Expenses [Member]USD 85,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-12-31restructuringin_progressResearch and Development Expense [Member]USD 11,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-12-31restructuringin_progressKidney Care [Member] / Employee Severance [Member] / Initiatives To Reduce Cost Structure [Member]USD 100,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-12-31restructuringin_progressStreamline Of Manufacturing Footprint [Member]USD 28,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-12-31restructuringin_progressAsset Impairment [Member] / Streamline Of Manufacturing Footprint [Member]USD 14,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-12-31restructuringin_progressContract Termination And Other Costs [Member] / Streamline Of Manufacturing Footprint [Member]USD 9,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-12-31restructuringin_progressEmployee Severance [Member] / Streamline Of Manufacturing Footprint [Member]USD 5,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-12-31restructuringin_progressSeverance And Other Employee Related Costs [Member]USD 137,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-09-30divestiture_reductioncompleted2024-08-122025-01-31GlobalKidney Care segment (now Vantive Health LLC)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale to Carlyle closed 2025-01-31 for $3.80B; headcount transferred not disclosed. Separation-related costs of $40M recorded in SG&A for 9M 2025.
2025-09-30restructuringin_progress2026-12-31GlobalCorporate / enterprise-wide (post-Kidney Care dis-synergy cost reduction)USD 41 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Employee termination costs of $41M for 9M 2025 ($10M in Q3) tied to cost-structure actions after the Kidney Care sale; no employee counts disclosed. Restructuring liability was $93M at 2025-09-30, substantially all expected to be paid by end of 2026.
2025-09-30plant_closurein_progressUnited StatesManufacturing — exit of a product line at one manufacturing facilityUSD 24 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		9M 2025 charges of $24M ($11M asset impairments, $8M contract termination, $5M employee termination) for a product-line exit; Q3 alone was $21M. Employee headcount affected not disclosed.
2025-09-30restructuringin_progressGlobalEnterprise-wide business optimization programsUSD 100 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Total business optimization charges of $100M for 9M 2025 ($38M in Q3), comprising $95M restructuring and $5M implementation costs; consolidated total shown here because the filer does not disaggregate employee counts. Approximately $1M of additional pre-tax costs expected to complete initiatives underway.
2025-09-30restructuringin_progress2026-12-31GlobalCorporate / UnallocatedUSD 37 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Q3 2025 charges include $18M employee termination costs, $10M contract termination, and $9M asset write-offs. Includes $10M related to Kidney Care separation and $21M related to product line exit. Substantially all cash payments expected by end of 2026.
2025-09-30restructuringin_progress2026-12-31GlobalCorporate / UnallocatedUSD 95 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		YTD 2025 charges include $49M employee termination costs, $14M contract termination, and $32M asset write-offs. Includes $41M related to Kidney Care separation and $24M related to product line exit. Substantially all cash payments expected by end of 2026.
2025-09-30restructuringin_progressBusiness Optimization Programs [Member]USD 37,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-09-30restructuringin_progressCost of Sales [Member] / Employee Severance [Member]USD 8,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-09-30restructuringin_progressSelling, General and Administrative Expenses [Member] / Employee Severance [Member]USD 8,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-09-30restructuringin_progressResearch and Development Expense [Member] / Employee Severance [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-09-30restructuringin_progressEmployee Severance [Member]USD 18,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-09-30restructuringin_progressCost of Sales [Member] / Contract Termination And Other Costs [Member]USD 8,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-09-30restructuringin_progressSelling, General and Administrative Expenses [Member] / Contract Termination And Other Costs [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-09-30restructuringin_progressResearch and Development Expense [Member] / Contract Termination And Other Costs [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-09-30restructuringin_progressContract Termination And Other Costs [Member]USD 10,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-09-30restructuringin_progressCost of Sales [Member] / Asset Write Offs [Member]USD 9,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-09-30restructuringin_progressSelling, General and Administrative Expenses [Member] / Asset Write Offs [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-09-30restructuringin_progressResearch and Development Expense [Member] / Asset Write Offs [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-09-30restructuringin_progressAsset Write Offs [Member]USD 9,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-09-30restructuringin_progressCost of Sales [Member]USD 25,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-09-30restructuringin_progressSelling, General and Administrative Expenses [Member]USD 10,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-09-30restructuringin_progressResearch and Development Expense [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-09-30restructuringin_progressUSD 37,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-09-30restructuringin_progressReduced Employee Expenses [Member] / Employee Severance [Member] / Kidney Care [Member]USD 10,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-09-30restructuringin_progressExit Of Product Line [Member]USD 21,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-09-30restructuringin_progressAsset Impairment [Member] / Exit Of Product Line [Member]USD 8,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-09-30restructuringin_progressContract Termination And Other Costs [Member] / Exit Of Product Line [Member]USD 8,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-09-30restructuringin_progressEmployee Severance [Member] / Exit Of Product Line [Member]USD 5,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-09-30restructuringin_progressSeverance, Contract Termination, And Other Employee Related Costs [Member]USD 70,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-06-30restructuringin_progressGlobalEnterprise-wideUSD 62 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Six months ended 2025 charges of $62M ($58M restructuring, $4M implementation costs); $31M of restructuring charges related to post-Kidney Care cost reduction. Substantially all restructuring liabilities relate to employee termination costs. No employee count disclosed.
2025-06-30divestiture_reductioncompleted2024-08-122025-01-31GlobalKidney Care segment (sold to Carlyle / Vantive)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Kidney Care business sale completed 2025-01-31; headcount transferred not disclosed in this filing. Included as context for restructuring activity.
2025-06-30restructuringin_progressUSD 14 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Q2 2025 restructuring charges of $14M included $5M employee termination costs. $6M of total Q2 restructuring charges related to cost structure reduction following Kidney Care sale.
2025-06-30restructuringin_progressUSD 58 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		YTD 2025 restructuring charges of $58M included $31M employee termination costs. $31M of total YTD restructuring charges related to cost structure reduction following Kidney Care sale.
2025-06-30restructuringin_progressBusiness Optimization Programs [Member]USD 14,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-06-30restructuringin_progressCost of Sales [Member] / Employee Severance [Member]USD -1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-06-30restructuringin_progressSelling, General and Administrative Expenses [Member] / Employee Severance [Member]USD 6,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-06-30restructuringin_progressEmployee Severance [Member]USD 5,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-06-30restructuringin_progressCost of Sales [Member] / Contract Termination And Other Costs [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-06-30restructuringin_progressSelling, General and Administrative Expenses [Member] / Contract Termination And Other Costs [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-06-30restructuringin_progressContract Termination And Other Costs [Member]USD 4,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-06-30restructuringin_progressCost of Sales [Member] / Asset Write Offs [Member]USD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-06-30restructuringin_progressSelling, General and Administrative Expenses [Member] / Asset Write Offs [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-06-30restructuringin_progressAsset Write Offs [Member]USD 5,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-06-30restructuringin_progressCost of Sales [Member]USD 4,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-06-30restructuringin_progressSelling, General and Administrative Expenses [Member]USD 10,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-06-30restructuringin_progressUSD 14,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-06-30restructuringin_progressResearch and Development Expense [Member] / Employee Severance [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-06-30restructuringin_progressResearch and Development Expense [Member] / Contract Termination And Other Costs [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-06-30restructuringin_progressResearch and Development Expense [Member] / Asset Write Offs [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-06-30restructuringin_progressResearch and Development Expense [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-06-30restructuringin_progressEmployee Severance [Member] / Kidney Care [Member]USD 6,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-06-30restructuringin_progressSeverance, Contract Termination, And Other Employee Related Costs [Member]USD 42,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-03-31divestiture_reductioncompleted2024-08-122025-01-31GlobalKidney Care segmentother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale of Kidney Care business to Carlyle completed 2025-01-31; headcount transferred not disclosed.
2025-03-31restructuringin_progress2025-12-31GlobalCorporate / cross-segmentUSD 44 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 2025 restructuring charges of $44M ($26M employee termination, $18M asset write-offs); $25M of employee termination costs related to post-Kidney Care cost reduction. Employee counts not disclosed.
2025-03-31restructuringin_progressGlobalCorporate / cross-segmentUSD 4 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Additional pre-tax costs of approximately $4M expected through completion of currently underway initiatives; employee counts not disclosed.
2025-03-31restructuringin_progressUSD 44 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Includes $25 million in employee termination costs related to cost structure reduction following Kidney Care sale; total restructuring charges were $44 million.
2025-03-31divestiture_reductioncompleted2025-01-312025-01-31Kidney Carediscontinued_operations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Sale of Kidney Care business completed; headcount removed not explicitly quantified in this filing.
2025-03-31restructuringin_progressBusiness Optimization Programs [Member]USD 44,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-03-31restructuringin_progressCost of Sales [Member] / Employee Severance [Member]USD 12,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-03-31restructuringin_progressSelling, General and Administrative Expenses [Member] / Employee Severance [Member]USD 13,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-03-31restructuringin_progressResearch and Development Expense [Member] / Employee Severance [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-03-31restructuringin_progressEmployee Severance [Member]USD 26,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-03-31restructuringin_progressCost of Sales [Member] / Asset Write Offs [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-03-31restructuringin_progressSelling, General and Administrative Expenses [Member] / Asset Write Offs [Member]USD 17,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-03-31restructuringin_progressResearch and Development Expense [Member] / Asset Write Offs [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-03-31restructuringin_progressAsset Write Offs [Member]USD 18,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-03-31restructuringin_progressCost of Sales [Member]USD 13,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-03-31restructuringin_progressSelling, General and Administrative Expenses [Member]USD 30,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-03-31restructuringin_progressResearch and Development Expense [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-03-31restructuringin_progressUSD 44,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-03-31restructuringin_progressEmployee Severance [Member] / Kidney Care [Member]USD 25,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-03-31restructuringin_progressSeverance, Contract Termination, And Other Employee Related Costs [Member]USD 26,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-12-31divestiture_reductioncompleted2024-08-122025-01-31GlobalKidney Care (reported as discontinued operations; now Vantive)discontinued_operations_footnote
f5-10k / GLM-5.3-flash-HTML		Sale of Kidney Care business to Carlyle for $3.80 billion closed January 31, 2025; the segment's workforce transferred with the sale but affected headcount was not quantified. Year-end total headcount in Item 1 is presented as if this divestiture had already occurred.
2024-12-31restructuringin_progressEnterprise-wide cost structure reduction following Kidney Care saleUSD 45 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		FY2024 employee termination costs tied to initiatives to reduce the cost structure after agreeing to sell Kidney Care; company continues pursuing cost savings to offset expected dis-synergies.
2024-12-31restructuringin_progressHealthcare Systems & TechnologiesUSD 46 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		FY2024 segment business optimization charges comprising $21M long-lived asset impairments, $9M inventory write-downs and $2M severance from discontinuing a product line, plus $14M severance for other initiatives. Related 2024 narrative also cites rationalization of certain manufacturing and distribution facilities; company expects roughly $4M of remaining cash implementation costs across ongoing programs.
2024-12-31restructuringin_progressGlobalCorporate / enterprise-wide — cost structure reduction following the Kidney Care segment saleUSD 45 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2024 employee termination costs within the $146M of total restructuring charges; part of $162M total FY2024 business optimization charges. Company expects roughly $4M of additional pre-tax cash costs to complete initiatives underway.
2024-12-31restructuringin_progressGlobalHealthcare Systems & TechnologiesUSD 46 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2024 charges include $21M long-lived asset impairments, $9M inventory write-downs, $2M employee termination tied to discontinuing a product line, and $14M employee termination for other initiatives; includes rationalization of manufacturing and distribution facilities.
2024-12-31divestiture_reductioncompleted2024-08-122025-01-31GlobalKidney Care segment (sold to Carlyle; now Vantive Health LLC)discontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Sale closed 2025-01-31 for $3.80B cash; headcount transferred not quantified. Company states it has begun and will need to undertake further actions to right-size cost structure after the sale, with dis-synergies expected.
2024-12-31restructuringcompleted2024-01-012024-12-31GlobalMultipleUSD 162 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Includes $45M related to Kidney Care sale cost reduction and $46M within Healthcare Systems & Technologies segment. Employee termination costs were $98M.
2024-12-31divestiture_reductioncompleted2024-08-122025-01-31GlobalKidney Carediscontinued_operations_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Sale of Kidney Care business completed Jan 31, 2025. Headcount removed from consolidated totals.
2024-12-31restructuringin_progress2024-01-01GlobalVariousUSD 162 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Total restructuring charges of $162 million in 2024. Includes $45 million related to cost structure reduction following Kidney Care sale and $46 million within Healthcare Systems & Technologies segment. Employee termination costs were $98 million.
2024-12-31restructuringin_progressUSD 146,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-12-31restructuringin_progressCost of Sales [Member] / Employee Severance [Member]USD 20,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-12-31restructuringin_progressSelling, General and Administrative Expenses [Member] / Employee Severance [Member]USD 48,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-12-31restructuringin_progressResearch and Development Expense [Member] / Employee Severance [Member]USD 30,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-12-31restructuringin_progressEmployee Severance [Member]USD 98,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-12-31restructuringin_progressCost of Sales [Member] / Contract Termination And Other Costs [Member]USD 3,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-12-31restructuringin_progressSelling, General and Administrative Expenses [Member] / Contract Termination And Other Costs [Member]USD 6,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-12-31restructuringin_progressResearch and Development Expense [Member] / Contract Termination And Other Costs [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-12-31restructuringin_progressContract Termination And Other Costs [Member]USD 9,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-12-31restructuringin_progressCost of Sales [Member] / Asset Impairment [Member]USD 39,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-12-31restructuringin_progressSelling, General and Administrative Expenses [Member] / Asset Impairment [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-12-31restructuringin_progressResearch and Development Expense [Member] / Asset Impairment [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-12-31restructuringin_progressAsset Impairment [Member]USD 39,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-12-31restructuringin_progressCost of Sales [Member]USD 62,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-12-31restructuringin_progressSelling, General and Administrative Expenses [Member]USD 54,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-12-31restructuringin_progressResearch and Development Expense [Member]USD 30,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-12-31restructuringin_progressKidney Care [Member] / Employee Severance [Member] / Restructuring Within HST Segment [Member]USD 45,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-12-31restructuringin_progressStreamline Of Manufacturing Footprint [Member]USD 46,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-12-31restructuringin_progressAsset Impairment [Member] / Streamline Of Manufacturing Footprint [Member]USD 21,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-12-31restructuringin_progressEmployee Severance [Member] / Streamline Of Manufacturing Footprint [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-12-31restructuringin_progressEmployee Severance [Member] / Restructuring Within HST Segment [Member]USD 14,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-12-31restructuringin_progressSeverance And Other Employee Related Costs [Member]USD 116,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-09-30restructuringin_progressGlobalMultiple segments including Healthcare Systems and TechnologiesUSD 15 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q3 2024 restructuring charges of $15M ($12M employee termination, $3M contract termination); YTD charges $36M. No employee counts disclosed. Additional pre-tax costs of ~$5M expected to complete current initiatives.
2024-09-30divestiture_reductionannounced2024-08-12GlobalKidney Care (Vantive)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Pending sale of Kidney Care business to Carlyle for $3.80B; expected close late 2024 or early 2025. Headcount impact not disclosed. Separation-related costs of $69M (Q3) and $236M (YTD) in discontinued operations SG&A.
2024-09-30plant_closurein_progress2024-09-30United States (Marion, North Carolina)Medical Products and Therapies / Kidney Care — North Cove facilityUSD 25 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Hurricane Helene damaged North Cove facility; operations disrupted. Q3 net charge $25M ($44M write-offs less $19M insurance receivable). Q4 expected sales impact ~$200M and additional charges of $350-400M. No workforce reduction disclosed.
2024-09-30restructuringin_progressHealthcare Systems and TechnologiesUSD 7 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Employee termination costs related to business optimization initiatives within the Healthcare Systems and Technologies segment for the three months ended Sept 30, 2024.
2024-09-30restructuringin_progressCorporate / New Operating ModelUSD 7 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Employee termination costs related to the recent implementation of a new operating model intended to simplify and streamline operations for the nine months ended Sept 30, 2024.
2024-09-30restructuringin_progressCorporate / New Operating ModelUSD 11 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Employee termination costs related to the implementation of the previously announced new operating model for the three months ended Sept 30, 2023.
2024-09-30restructuringin_progressCorporate / New Operating ModelUSD 79 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Employee termination costs related to the implementation of the previously announced new operating model for the nine months ended Sept 30, 2023.
2024-09-30restructuringin_progressBusiness Optimization Programs [Member]USD 15,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-09-30restructuringin_progressCost of Sales [Member] / Employee Severance [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-09-30restructuringin_progressSelling, General and Administrative Expenses [Member] / Employee Severance [Member]USD 10,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-09-30restructuringin_progressEmployee Severance [Member]USD 12,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-09-30restructuringin_progressCost of Sales [Member] / Contract Termination And Other Costs [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-09-30restructuringin_progressSelling, General and Administrative Expenses [Member] / Contract Termination And Other Costs [Member]USD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-09-30restructuringin_progressContract Termination And Other Costs [Member]USD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-09-30restructuringin_progressCost of Sales [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-09-30restructuringin_progressSelling, General and Administrative Expenses [Member]USD 13,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-09-30restructuringin_progressUSD 15,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-09-30restructuringin_progressEmployee Severance [Member] / Restructuring Within HST Segment [Member]USD 7,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-09-30restructuringin_progressEmployee Severance [Member] / New Operating Model [Member]USD 7,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-09-30restructuringin_progressSeverance, Contract Termination, And Other Employee Related Costs [Member]USD 42,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-06-30restructuringin_progressGlobalMultiple — manufacturing footprint, R&D centralization, new operating modelUSD 20 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q2 2024 charges: $9M restructuring (incl. $8M asset impairments from manufacturing line transfer) plus $11M implementation costs. Employee termination costs net to $(2)M in Q2. No employee counts disclosed.
2024-06-30restructuringin_progressGlobalMultiple — manufacturing footprint, R&D centralization, new operating modelUSD 77 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		YTD 2024 charges: $56M restructuring (employee termination $34M, contract termination $9M, asset impairments $13M) plus $21M implementation costs. $27M related to R&D centralization and new operating model. Restructuring liability $114M at 2024-06-30; substantially all cash payments expected by end of 2025. Approximately $7M additional pre-tax costs expected for initiatives underway. No employee counts disclosed.
2024-06-30divestiture_reductionin_progress2023-01-012025-03-31GlobalKidney CareUSD 173 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Separation of Kidney Care via sale or spinoff expected late 2024 or early 2025; $173M separation-related costs YTD 2024 ($81M in Q2). No headcount impact quantified.
2024-06-30plant_closurecompleted2023-04-012023-12-31United States — Opelika, AlabamaKidney Care — Chronic Therapies (dialyzer production)USD 243 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Dialyzer production ceased near end of 2023; $243M long-lived asset impairment recognized in Q2 2023 (prior-year period, referenced for context only). No employee count disclosed.
2024-06-30restructuringin_progressUSD 9 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Q2 2024 restructuring charges included $6M asset impairments for manufacturing line transfer and $3M employee termination costs. Employee count not disclosed.
2024-06-30restructuringin_progressUSD 56 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		YTD 2024 restructuring charges included $13M asset impairments and $34M employee termination costs related to R&D centralization and new operating model. Employee count not disclosed.
2024-06-30restructuringin_progressBusiness Optimization Programs [Member]USD 9,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-06-30restructuringin_progressCost of Sales [Member] / Employee Severance [Member]USD -2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-06-30restructuringin_progressSelling, General and Administrative Expenses [Member] / Employee Severance [Member]USD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-06-30restructuringin_progressResearch and Development Expense [Member] / Employee Severance [Member]USD -3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-06-30restructuringin_progressEmployee Severance [Member]USD -2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-06-30restructuringin_progressCost of Sales [Member] / Contract Termination And Other Costs [Member]USD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-06-30restructuringin_progressSelling, General and Administrative Expenses [Member] / Contract Termination And Other Costs [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-06-30restructuringin_progressResearch and Development Expense [Member] / Contract Termination And Other Costs [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-06-30restructuringin_progressContract Termination And Other Costs [Member]USD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-06-30restructuringin_progressCost of Sales [Member] / Asset Impairment [Member]USD 8,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-06-30restructuringin_progressSelling, General and Administrative Expenses [Member] / Asset Impairment [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-06-30restructuringin_progressResearch and Development Expense [Member] / Asset Impairment [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-06-30restructuringin_progressAsset Impairment [Member]USD 8,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-06-30restructuringin_progressCost of Sales [Member]USD 9,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-06-30restructuringin_progressSelling, General and Administrative Expenses [Member]USD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-06-30restructuringin_progressResearch and Development Expense [Member]USD -3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-06-30restructuringin_progressUSD 9,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-06-30restructuringin_progressAsset Impairment [Member] / New Operating Model [Member]USD 6,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-06-30restructuringin_progressEmployee Severance [Member] / New Operating Model [Member]USD 27,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-06-30restructuringin_progressSeverance And Other Employee Related Costs [Member]USD 60,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-03-31restructuringin_progressResearch & Development; corporate functionsUSD 47 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 2024 restructuring charges of $47M (employee termination $36M, contract termination $6M, asset impairments $5M); $24M tied to centralizing R&D activities and implementing a new operating model. Employee headcount affected not disclosed. Restructuring liability balance $136M at 2024-03-31; substantially all cash payments expected by end of 2024.
2024-03-31restructuringin_progressEnterprise-wide business optimization programsUSD 57 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Total business optimization charges of $57M in Q1 2024 ($47M restructuring + $10M implementation costs), down from $134M in Q1 2023. Company expects approximately $15M of additional pre-tax costs to complete initiatives currently underway. No employee counts disclosed.
2024-03-31divestiture_reductionin_progress2024-03-012024-12-31GlobalKidney Care segmentUSD 92 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		In March 2024 company announced discussions with private equity investors to explore a sale of the Kidney Care segment in lieu of the previously proposed spinoff; separation expected to complete in H2 2024. Q1 2024 separation-related costs of $92M (primarily external advisors). Headcount associated with the segment not disclosed; dis-synergies and cost-structure actions post-separation flagged but not quantified.
2024-03-31divestiture_reductioncompleted2023-09-292023-09-29GlobalBioPharma Solutions (BPS) businessother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		BPS sale completed 2023-09-29; results reported as discontinued operations. No employee counts disclosed in this filing. Included for context on workforce removals affecting the continuing entity.
2024-03-31restructuringin_progressUSD 47 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges related to centralizing R&D activities and implementing a new operating model. Employee count not disclosed.
2024-03-31restructuringin_progressUSD 10 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Costs to implement business optimization programs, primarily external consulting and transition costs.
2024-03-31restructuringin_progressBusiness Optimization Programs [Member]USD 47,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-03-31restructuringin_progressCost of Sales [Member] / Employee Severance [Member]USD 5,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-03-31restructuringin_progressSelling, General and Administrative Expenses [Member] / Employee Severance [Member]USD 15,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-03-31restructuringin_progressResearch and Development Expense [Member] / Employee Severance [Member]USD 16,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-03-31restructuringin_progressEmployee Severance [Member]USD 36,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-03-31restructuringin_progressCost of Sales [Member] / Contract Termination And Other Costs [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-03-31restructuringin_progressSelling, General and Administrative Expenses [Member] / Contract Termination And Other Costs [Member]USD 5,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-03-31restructuringin_progressResearch and Development Expense [Member] / Contract Termination And Other Costs [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-03-31restructuringin_progressContract Termination And Other Costs [Member]USD 6,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-03-31restructuringin_progressCost of Sales [Member] / Asset Impairment [Member]USD 5,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-03-31restructuringin_progressSelling, General and Administrative Expenses [Member] / Asset Impairment [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-03-31restructuringin_progressResearch and Development Expense [Member] / Asset Impairment [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-03-31restructuringin_progressAsset Impairment [Member]USD 5,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-03-31restructuringin_progressCost of Sales [Member]USD 11,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-03-31restructuringin_progressSelling, General and Administrative Expenses [Member]USD 20,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-03-31restructuringin_progressResearch and Development Expense [Member]USD 16,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-03-31restructuringin_progressUSD 47,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-03-31restructuringin_progressEmployee Severance [Member] / New Operating Model [Member]USD 24,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-03-31restructuringin_progressSeverance And Other Employee Related Costs [Member]USD 42,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-12-31restructuringin_progress2023-01-01GlobalEnterprise-wide — new operating modelUSD 111 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2023 employee termination costs tied to implementing the new operating model announced January 2023; part of $534M total FY2023 business optimization charges. No headcount affected disclosed.
2023-12-31plant_closurein_progress2023-04-012023-12-31United States — Opelika, AlabamaKidney Care — hemodialysis (HD) / dialyzer manufacturingUSD 267 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Decision made in Q2 2023 to cease dialyzer production at Opelika near end of 2023. FY2023 charges comprise $243M long-lived asset impairment, $14M other asset write-downs and $10M employee termination costs. Announcement date is quarter-level approximation.
2023-12-31divestiture_reductioncompleted2023-05-012023-09-29United States (Bloomington, Indiana) and Germany (Halle)BioPharma Solutions (BPS) — contract manufacturing and developmentdiscontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		BPS sale to Advent International and Warburg Pincus closed 2023-09-29 for $3.96B cash proceeds; business and its workforce removed from continuing operations. Held-for-sale classification concluded May 2023. No headcount disclosed.
2023-12-31restructuringannounced2023-12-31GlobalEnterprise-wide — business optimization programsUSD 50 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Forward-looking: approximately $50M of additional pre-tax cash costs expected through completion of initiatives currently underway, including actions to mitigate spinoff dis-synergies.
2023-12-31restructuringcompleted2023-01-012023-12-31GlobalVariousUSD 534 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Total restructuring charges of $534 million incurred in 2023. Includes $111 million for new operating model implementation and $267 million for decision to cease production at one U.S. manufacturing facility. Employee termination costs were $174 million.
2023-12-31restructuringcompleted2023-01-012023-12-31GlobalVariousUSD 534 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Total restructuring charges of $534 million in 2023. Includes $111 million for new operating model implementation and $267 million for ceasing dialyzer production at Opelika facility. Employee termination costs were $174 million. Specific headcount affected not disclosed.
2023-12-31restructuringin_progressUSD 478,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-12-31restructuringin_progressCost of Sales [Member] / Employee Severance [Member]USD 47,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-12-31restructuringin_progressSelling, General and Administrative Expenses [Member] / Employee Severance [Member]USD 115,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-12-31restructuringin_progressResearch and Development Expense [Member] / Employee Severance [Member]USD 12,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-12-31restructuringin_progressEmployee Severance [Member]USD 174,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-12-31restructuringin_progressCost of Sales [Member] / Contract Termination And Other Costs [Member]USD 6,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-12-31restructuringin_progressSelling, General and Administrative Expenses [Member] / Contract Termination And Other Costs [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-12-31restructuringin_progressResearch and Development Expense [Member] / Contract Termination And Other Costs [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-12-31restructuringin_progressContract Termination And Other Costs [Member]USD 8,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-12-31restructuringin_progressCost of Sales [Member] / Asset Impairment [Member]USD 289,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-12-31restructuringin_progressSelling, General and Administrative Expenses [Member] / Asset Impairment [Member]USD 7,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-12-31restructuringin_progressResearch and Development Expense [Member] / Asset Impairment [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-12-31restructuringin_progressAsset Impairment [Member]USD 296,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-12-31restructuringin_progressCost of Sales [Member]USD 342,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-12-31restructuringin_progressSelling, General and Administrative Expenses [Member]USD 124,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-12-31restructuringin_progressResearch and Development Expense [Member]USD 12,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-12-31restructuringin_progressPreviously Announced New Operating Model [Member]USD 111,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-12-31restructuringin_progressStreamline Of Manufacturing Footprint [Member]USD 267,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-12-31restructuringin_progressAsset Impairment [Member] / Streamline Of Manufacturing Footprint [Member]USD 243,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-12-31restructuringin_progressEmployee Severance [Member] / Streamline Of Manufacturing Footprint [Member]USD 10,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-12-31restructuringin_progressSeverance And Other Employee Related Costs [Member]USD 212,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-09-30plant_closurein_progress2023-12-31United StatesKidney Care — Hemodialysis manufacturingUSD 243 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Decision to cease dialyzer production at Opelika, Alabama facility near end of 2023; $243M noncash impairment recognized in Q2 2023 plus $10M employee termination costs in 9M 2023 restructuring charges. No employee headcount disclosed.
2023-09-30restructuringin_progressGlobalEnterprise-wide — new operating modelUSD 111 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Employee termination costs of $111M in 9M 2023 ($14M in Q3) related to implementation of new operating model. No employee headcount disclosed. Additional ~$25M pre-tax costs expected for programs underway.
2023-09-30divestiture_reductioncompleted2023-05-312023-09-29United States, GermanyBioPharma Solutions (discontinued operations)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale of BPS business completed 2023-09-29 for $3.96B cash proceeds; $2.89B pre-tax gain. Facilities in Bloomington, IN and Halle, Germany transferred. No employee headcount disclosed.
2023-09-30restructuringin_progressGlobalEnterprise-wide — business optimization programsUSD 508 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Total business optimization charges of $508M in 9M 2023 ($81M in Q3), comprising $461M restructuring and $47M implementation costs. Includes Opelika closure and new operating model actions. No employee headcount disclosed.
2023-09-30restructuringin_progressGlobalVarious (COGS, SG&A, R&D)USD 64 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Q3 2023 restructuring charges of $64M include $55M employee termination costs, $2M contract termination, and $7M asset impairments. Part of ongoing new operating model implementation.
2023-09-30restructuringin_progressGlobalVarious (COGS, SG&A, R&D)USD 461 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		YTD 2023 restructuring charges of $461M include $170M employee termination costs, $7M contract termination, and $284M asset impairments. Includes $243M impairment for Opelika facility closure.
2023-09-30plant_closurein_progress2023-12-31Opelika, Alabama, USAKidney Care (Hemodialysis)USD 243 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Decision to cease dialyzer production at Opelika facility near end of 2023. Recognized $243M impairment charge in Q2 2023.
2023-09-30divestiture_reductioncompleted2023-09-292023-09-29Global (Bloomington, IN; Halle, Germany)BioPharma Solutions (BPS)discontinued_operations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Sale of BPS business completed Sept 29, 2023. Workforce transferred to buyer. No specific headcount disclosed.
2023-09-30restructuringin_progressBusiness Optimization Programs [Member]USD 64,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-09-30restructuringin_progressCost of Sales [Member] / Employee Severance [Member]USD 17,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-09-30restructuringin_progressSelling, General and Administrative Expenses [Member] / Employee Severance [Member]USD 33,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-09-30restructuringin_progressResearch and Development Expense [Member] / Employee Severance [Member]USD 5,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-09-30restructuringin_progressEmployee Severance [Member]USD 55,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-09-30restructuringin_progressCost of Sales [Member] / Contract Termination And Other Costs [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-09-30restructuringin_progressSelling, General and Administrative Expenses [Member] / Contract Termination And Other Costs [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-09-30restructuringin_progressResearch and Development Expense [Member] / Contract Termination And Other Costs [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-09-30restructuringin_progressContract Termination And Other Costs [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-09-30restructuringin_progressCost of Sales [Member] / Asset Impairment [Member]USD 7,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-09-30restructuringin_progressSelling, General and Administrative Expenses [Member] / Asset Impairment [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-09-30restructuringin_progressResearch and Development Expense [Member] / Asset Impairment [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-09-30restructuringin_progressAsset Impairment [Member]USD 7,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-09-30restructuringin_progressCost of Sales [Member]USD 24,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-09-30restructuringin_progressSelling, General and Administrative Expenses [Member]USD 35,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-09-30restructuringin_progressResearch and Development Expense [Member]USD 5,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-09-30restructuringin_progressUSD 64,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-09-30restructuringin_progressEmployee Severance [Member] / New Operating Model [Member]USD 14,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-09-30restructuringin_progressExit Of Manufacturing Facility [Member]USD 253,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-09-30restructuringin_progressAsset Impairment [Member] / Exit Of Manufacturing Facility [Member]USD 243,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-09-30restructuringin_progressEmployee Severance [Member] / Exit Of Manufacturing Facility [Member]USD 10,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-09-30restructuringin_progressSeverance And Other Employee Related Costs [Member]USD 189,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-06-30plant_closurein_progress2023-06-302023-12-31United States (Opelika, Alabama)Renal Care — dialyzer manufacturingUSD 243 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Decision to cease dialyzer production at Opelika near end of 2023; $243M noncash PP&E impairment plus $10M employee termination costs ($253M total related charges). No employee count disclosed.
2023-06-30restructuringin_progress2023-01-01GlobalEnterprise-wide — new operating modelUSD 97 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Six months ended June 30, 2023: $97M of employee termination costs related to implementing the new operating model ($19M in Q2). No employee counts disclosed; further charges expected during 2023.
2023-06-30divestiture_reductionin_progress2023-05-012023-12-31United States (Bloomington, Indiana); Germany (Halle)BioPharma Solutions (BPS)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to sell BPS to Advent International and Warburg Pincus for $4.25B; expected close in second half of 2023. No headcount associated with the divestiture disclosed.
2023-06-30divestiture_reductionannounced2023-01-012024-07-31GlobalRenal Care and Acute Therapies product categories (proposed spinoff)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Proposed spinoff into a new publicly traded kidney care company, targeted for completion by July 2024; no headcount impact disclosed.
2023-06-30restructuringin_progress2024-12-31GlobalCorporate and Other / ManufacturingUSD 287 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Q2 2023 charges include $243M asset impairment for Opelika facility closure and $28M employee termination costs. Substantially all cash payments expected by end of 2024.
2023-06-30restructuringin_progress2024-12-31GlobalCorporate and Other / ManufacturingUSD 397 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		YTD 2023 charges include $269M asset impairments and $115M employee termination costs. Includes $97M related to new operating model implementation.
2023-06-30restructuringin_progressBusiness Optimization Programs [Member]USD 287,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-06-30restructuringin_progressCost of Sales [Member] / Employee Severance [Member]USD 9,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-06-30restructuringin_progressSelling, General and Administrative Expenses [Member] / Employee Severance [Member]USD 19,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-06-30restructuringin_progressResearch and Development Expense [Member] / Employee Severance [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-06-30restructuringin_progressEmployee Severance [Member]USD 28,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-06-30restructuringin_progressCost of Sales [Member] / Contract Termination And Other Costs [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-06-30restructuringin_progressSelling, General and Administrative Expenses [Member] / Contract Termination And Other Costs [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-06-30restructuringin_progressResearch and Development Expense [Member] / Contract Termination And Other Costs [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-06-30restructuringin_progressContract Termination And Other Costs [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-06-30restructuringin_progressCost of Sales [Member] / Asset Impairment [Member]USD 257,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-06-30restructuringin_progressSelling, General and Administrative Expenses [Member] / Asset Impairment [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-06-30restructuringin_progressResearch and Development Expense [Member] / Asset Impairment [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-06-30restructuringin_progressAsset Impairment [Member]USD 257,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-06-30restructuringin_progressCost of Sales [Member]USD 266,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-06-30restructuringin_progressSelling, General and Administrative Expenses [Member]USD 21,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-06-30restructuringin_progressResearch and Development Expense [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-06-30restructuringin_progressUSD 287,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-06-30restructuringin_progressEmployee Severance [Member] / New Operating Model [Member]USD 19,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-06-30restructuringin_progressExit Of Manufacturing Facility [Member]USD 253,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-06-30restructuringin_progressAsset Impairment [Member] / Exit Of Manufacturing Facility [Member]USD 243,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-06-30restructuringin_progressEmployee Severance [Member] / Exit Of Manufacturing Facility [Member]USD 10,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-06-30restructuringin_progressSeverance And Other Employee Related Costs [Member]USD 132,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-03-31restructuringin_progressGlobalCorporate-wide; new operating model implementationUSD 110 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 2023 restructuring charges of $110M (incl. $87M employee termination costs); no headcount affected disclosed. $78M related to new operating model.
2023-03-31restructuringin_progressGlobalBusiness optimization programsUSD 24 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 2023 costs to implement business optimization programs; additional ~$24M expected to complete initiatives underway.
2023-03-31divestiture_reductionannounced2023-012024-07-31GlobalRenal Care and Acute Therapies (proposed spinoff)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Spinoff announced January 2023, targeted completion by July 2024; $16M divestiture-related costs in Q1 2023; no headcount disclosed.
2023-03-31otherannounced2023-01GlobalBioPharma Solutions (potential sale)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Strategic alternatives including potential sale announced January 2023; no headcount impact disclosed.
2023-03-31restructuringin_progressUSD 110 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Includes $87M employee termination costs, $20M asset impairments, and $3M contract termination costs. $78M of termination costs related to new operating model implementation.
2023-03-31restructuringin_progressBusiness Optimization Programs [Member]USD 110,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-03-31restructuringin_progressCost of Sales [Member] / Employee Severance [Member]USD 17,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-03-31restructuringin_progressSelling, General and Administrative Expenses [Member] / Employee Severance [Member]USD 63,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-03-31restructuringin_progressResearch and Development Expense [Member] / Employee Severance [Member]USD 7,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-03-31restructuringin_progressEmployee Severance [Member]USD 87,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-03-31restructuringin_progressCost of Sales [Member] / Contract Termination And Other Costs [Member]USD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-03-31restructuringin_progressSelling, General and Administrative Expenses [Member] / Contract Termination And Other Costs [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-03-31restructuringin_progressResearch and Development Expense [Member] / Contract Termination And Other Costs [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-03-31restructuringin_progressContract Termination And Other Costs [Member]USD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-03-31restructuringin_progressCost of Sales [Member] / Asset Impairment [Member]USD 12,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-03-31restructuringin_progressSelling, General and Administrative Expenses [Member] / Asset Impairment [Member]USD 8,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-03-31restructuringin_progressResearch and Development Expense [Member] / Asset Impairment [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-03-31restructuringin_progressAsset Impairment [Member]USD 20,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-03-31restructuringin_progressCost of Sales [Member]USD 32,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-03-31restructuringin_progressSelling, General and Administrative Expenses [Member]USD 71,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-03-31restructuringin_progressResearch and Development Expense [Member]USD 7,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-03-31restructuringin_progressUSD 110,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-03-31restructuringin_progressEmployee Severance [Member] / New Operating Model [Member]USD 78,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-03-31restructuringin_progressSeverance And Other Employee Related Costs [Member]USD 93,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-12-31restructuringin_progress2015USD 163 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		FY2022 restructuring charges of $163M (employee termination $129M, contract termination/other $22M, asset impairments $12M) plus $62M implementation costs = $225M total business optimization charges. Of the restructuring charges, $85M related to Hillrom integration ($55M employee termination, $22M contract/other, $8M asset impairments). Program cumulative pre-tax cost ~$1.4B since second half of 2015; ~$46M additional pre-tax cash costs expected; restructuring liability $107M at December 31, 2022. No employee counts disclosed.
2022-12-31divestiture_reductionannounced2023-012024-06-30Renal Care and Acute Therapies product categoriessubsequent_events
f5-10k / GLM-5.3-flash-HTML		Proposed tax-free spinoff into an independent publicly traded kidney-care company; targeted for first half of 2024 (12–18 months from announcement). These categories generated $4.4B of 2022 net sales (~29% of consolidated). Subject to Board approval, Form 10 effectiveness, IRS ruling/tax opinions, financing, works-council consultations and regulatory approvals; significant separation costs expected in 2023 and Q1 2024. No employee counts disclosed.
2022-12-31divestiture_reductionannounced2023-01BioPharma Solutions (BPS) product categorysubsequent_events
f5-10k / GLM-5.3-flash-HTML		Pursuing strategic alternatives including a potential sale of the BPS contract-manufacturing business ($644M of 2022 net sales, ~4% of consolidated); no definitive transaction announced. No employee counts disclosed.
2022-12-31restructuringannounced2023-012023-12-31Company-wide operating model and manufacturing footprintsubsequent_events
f5-10k / GLM-5.3-flash-HTML		New simplified operating model across four global business units, including realignment of manufacturing footprint and supply chain; organizational designs to be substantially finalized in Q2 2023 and broader changes, including updated segment reporting, fully implemented in the second half of 2023. Company expects to incur additional restructuring charges during 2023. No employee counts or charge amounts disclosed.
2022-12-31plant_closurecompleted2022-09-30ArgentinaUSD 65 (millions)MD&A
f5-10k / GLM-5.3-flash-HTML		Wind-down of Argentina operations begun in early 2021; net assets determined substantially liquidated in Q3 2022, triggering reclassification of a $65M cumulative translation loss from AOCI to other (income) expense, net. No employee counts disclosed; charge is a CTA reclassification, not severance.
2022-12-31othercompleted2022-12-31Legal entity rationalizationUSD 21 (millions)MD&A
f5-10k / GLM-5.3-flash-HTML		Loss of $21M recognized on deconsolidation of a foreign subsidiary (including derecognition of related noncontrolling interest) upon its liquidation in December 2022, completed in connection with legal entity rationalization activities. No employee counts or location disclosed.
2022-12-31restructuringin_progressGlobalEnterprise-wide; includes Hillrom integration activitiesUSD 225 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2022 charges of $225M comprise $163M restructuring charges and $62M implementation costs; $85M of the restructuring charges related to Hillrom integration. Program commenced 2H 2015 with cumulative pre-tax costs of ~$1.4B through 2022-12-31; ~$46M of additional pre-tax costs expected to complete initiatives underway. Employee headcount affected not disclosed.
2022-12-31restructuringannounced2023-012023-12-31GlobalEnterprise-wide; new operating model and manufacturing footprintsubsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		New simplified operating model announced January 2023; organizational designs expected finalized 2Q23 with broader operational changes, including updated management reporting, implemented in 2H23. Additional restructuring charges expected during 2023; no employee count or charge amount disclosed.
2022-12-31divestiture_reductionannounced2023-012024-06-30GlobalRenal Care and Acute Therapies product categories (proposed spinoff)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Proposed spinoff into an independent publicly traded kidney care company, announced January 2023; targeted for completion in 1H 2024 (12-18 months from announcement). Categories generated $4.4B of 2022 net sales (~29% of consolidated). Headcount to be separated not disclosed; separation and transaction-related costs expected in 2023 and 1Q24.
2022-12-31otherannounced2023-01GlobalBioPharma Solutions product category (strategic alternatives review, including potential sale)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Strategic alternatives review announced January 2023; BPS generated $644M of 2022 net sales (~4% of consolidated). No completion timeline or workforce impact disclosed.
2022-12-31divestiture_reductioncompleted2022-12-31ArgentinaLegal entity rationalization; operations wound down since early 2021USD 21 (millions)other
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Subsidiary liquidation completed December 2022 with a $21M loss and $65M cumulative translation loss reclassified to earnings; associated headcount not disclosed.
2022-12-31restructuringin_progress2022-01-01GlobalVariousUSD 225 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Total business optimization charges of $225 million in 2022, including $163 million in restructuring charges (employee termination, contract termination, asset impairments) and $62 million in implementation costs. Specific employee count not disclosed.
2022-12-31restructuringin_progress2022-01-01GlobalVariousUSD 225 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Total business optimization charges of $225 million in 2022, including $163 million in restructuring charges. Employee termination costs were $129 million. Includes $85 million related to Hillrom integration. No specific headcount affected disclosed.
2022-12-31restructuringin_progressHillrom [Member] / Integration Activities [Member]USD 85,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2022-12-31restructuringin_progressUSD 163,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2022-12-31restructuringin_progressCost of Sales [Member] / Employee Severance [Member]USD 24,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2022-12-31restructuringin_progressSelling, General and Administrative Expenses [Member] / Employee Severance [Member]USD 102,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2022-12-31restructuringin_progressResearch and Development Expense [Member] / Employee Severance [Member]USD 3,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2022-12-31restructuringin_progressEmployee Severance [Member]USD 129,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2022-12-31restructuringin_progressCost of Sales [Member] / Contract Termination And Other Costs [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2022-12-31restructuringin_progressSelling, General and Administrative Expenses [Member] / Contract Termination And Other Costs [Member]USD 22,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2022-12-31restructuringin_progressResearch and Development Expense [Member] / Contract Termination And Other Costs [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2022-12-31restructuringin_progressContract Termination And Other Costs [Member]USD 22,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2022-12-31restructuringin_progressCost of Sales [Member] / Asset Impairment [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2022-12-31restructuringin_progressSelling, General and Administrative Expenses [Member] / Asset Impairment [Member]USD 10,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2022-12-31restructuringin_progressResearch and Development Expense [Member] / Asset Impairment [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2022-12-31restructuringin_progressAsset Impairment [Member]USD 12,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2022-12-31restructuringin_progressCost of Sales [Member]USD 26,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2022-12-31restructuringin_progressSelling, General and Administrative Expenses [Member]USD 134,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2022-12-31restructuringin_progressResearch and Development Expense [Member]USD 3,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2022-12-31restructuringin_progressHillrom [Member] / Employee Severance [Member]USD 55,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2022-12-31restructuringin_progressHillrom [Member] / Contract Termination And Other Costs [Member]USD 22,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2022-12-31restructuringin_progressHillrom [Member] / Asset Impairment [Member]USD 8,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2022-12-31restructuringin_progressSeverance And Other Employee Related Costs [Member]USD 172,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2022-09-30restructuringin_progressGlobalCorporate-wide; includes Hillrom integration actionsUSD 150 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Nine-month 2022 restructuring charges; $196M total business optimization charges YTD including implementation costs. Severance-type liability balance was $128M at 2022-09-30. No employee counts disclosed; additional pre-tax costs of ~$14M expected for underway initiatives.
2022-09-30restructuringin_progress2023-12-31GlobalVarious (COGS, SG&A, R&D)USD 57 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Q3 2022 restructuring charges of $57M, primarily employee termination costs ($53M). Substantially all cash payments expected by end of 2023.
2022-09-30restructuringin_progress2023-12-31GlobalVarious (COGS, SG&A, R&D)USD 150 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		YTD 2022 restructuring charges of $150M, primarily employee termination costs ($122M). Includes actions related to Hillrom integration.
2022-09-30restructuringin_progressBusiness Optimization Programs [Member]USD 57,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-09-30restructuringin_progressCost of Sales [Member] / Employee Severance [Member]USD 13,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-09-30restructuringin_progressSelling, General and Administrative Expenses [Member] / Employee Severance [Member]USD 36,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-09-30restructuringin_progressResearch and Development Expense [Member] / Employee Severance [Member]USD 4,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-09-30restructuringin_progressEmployee Severance [Member]USD 53,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-09-30restructuringin_progressCost of Sales [Member] / Contract Termination And Other Costs [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-09-30restructuringin_progressSelling, General and Administrative Expenses [Member] / Contract Termination And Other Costs [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-09-30restructuringin_progressResearch and Development Expense [Member] / Contract Termination And Other Costs [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-09-30restructuringin_progressContract Termination And Other Costs [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-09-30restructuringin_progressCost of Sales [Member] / Asset Impairment [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-09-30restructuringin_progressSelling, General and Administrative Expenses [Member] / Asset Impairment [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-09-30restructuringin_progressResearch and Development Expense [Member] / Asset Impairment [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-09-30restructuringin_progressAsset Impairment [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-09-30restructuringin_progressCost of Sales [Member]USD 14,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-09-30restructuringin_progressSelling, General and Administrative Expenses [Member]USD 39,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-09-30restructuringin_progressResearch and Development Expense [Member]USD 4,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-09-30restructuringin_progressUSD 57,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-09-30restructuringin_progressSeverance And Other Employee Related Costs [Member]USD 147,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-06-30restructuringin_progressGlobalCorporate / enterprise-wide (includes Hillrom integration actions)USD 93 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		H1 2022 restructuring charges of $93M (Q2: $26M), primarily employee termination costs; no employee counts disclosed. Restructuring liability $116M at 2022-06-30; substantially all cash payments expected by end of 2023. Cumulative program costs $1.3B since 2015; ~$29M additional costs expected.
2022-06-30acquisition_additioncompleted2021-12-13GlobalHillrom segmentbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Hillrom acquisition closed 2021-12-13 for $10.5B; goodwill includes assembled workforce value. No headcount added disclosed. Measurement period adjustments in H1 2022 increased goodwill by $35M.
2022-06-30otherin_progress2022-05-012022-12-31United StatesHillrom — U.S. Hillrom pension plan (active non-bargaining participants)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Announced May 2022: pay and service accruals freeze for active non-bargaining U.S. Hillrom pension participants effective 2022-12-31; $11M decline in PBO with offsetting curtailment gain. No participant counts disclosed.
2022-06-30restructuringin_progress2023-12-31GlobalVarious (COGS, SG&A)USD 26 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Q2 2022 charges include $20M employee termination costs, $5M contract termination, and $1M asset impairments. Substantially all cash payments expected by end of 2023.
2022-06-30restructuringin_progress2023-12-31GlobalVarious (COGS, SG&A)USD 93 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		YTD 2022 charges include $69M employee termination costs, $17M contract termination, and $7M asset impairments. Includes actions related to Hillrom integration.
2022-06-30othercompleted2022-05-012022-12-31United StatesHillrom Pension Plan ParticipantsUSD -11 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Announced freeze on pay and service amounts for active non-bargaining participants in U.S. Hillrom pension plan effective Dec 31, 2022. Resulted in $11M curtailment gain.
2022-06-30restructuringin_progressBusiness Optimization Programs [Member]USD 26,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-06-30restructuringin_progressCost of Sales [Member] / Employee Severance [Member]USD 4,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-06-30restructuringin_progressSelling, General and Administrative Expenses [Member] / Employee Severance [Member]USD 16,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-06-30restructuringin_progressEmployee Severance [Member]USD 20,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-06-30restructuringin_progressCost of Sales [Member] / Contract Termination And Other Costs [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-06-30restructuringin_progressSelling, General and Administrative Expenses [Member] / Contract Termination And Other Costs [Member]USD 5,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-06-30restructuringin_progressContract Termination And Other Costs [Member]USD 5,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-06-30restructuringin_progressCost of Sales [Member] / Asset Impairment [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-06-30restructuringin_progressSelling, General and Administrative Expenses [Member] / Asset Impairment [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-06-30restructuringin_progressAsset Impairment [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-06-30restructuringin_progressCost of Sales [Member]USD 4,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-06-30restructuringin_progressSelling, General and Administrative Expenses [Member]USD 22,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-06-30restructuringin_progressUSD 26,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-06-30restructuringin_progressSeverance And Other Employee Related Costs [Member]USD 92,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-03-31restructuringin_progressGlobalCorporate; includes Hillrom integration actionsUSD 81 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 2022 charges of $81M ($67M restructuring, $14M implementation costs); no employee counts disclosed. Restructuring liability rose from $109M to $137M; substantially all relates to employee termination costs, cash payments expected by end of 2023. Cumulative program costs of $1.3B since 2015; ~$25M additional expected.
2022-03-31acquisition_additioncompleted2021-12-13GlobalHillrom segmentbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Hillrom acquisition closed 2021-12-13 for $10.5B; first full quarter of Hillrom results in Q1 2022. Headcount added not disclosed; measurement period adjustments recorded in Q1 2022.
2022-03-31restructuringin_progress2023-12-31GlobalVarious (COGS, SG&A)USD 67 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Includes employee termination costs of $49M, contract termination of $12M, and asset impairments of $6M. Substantially all cash payments expected by end of 2023. Employee count not disclosed.
2022-03-31restructuringin_progressBusiness Optimization Programs [Member]USD 67,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-03-31restructuringin_progressCost of Sales [Member] / Employee Severance [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-03-31restructuringin_progressSelling, General and Administrative Expenses [Member] / Employee Severance [Member]USD 47,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-03-31restructuringin_progressResearch and Development Expense [Member] / Employee Severance [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-03-31restructuringin_progressEmployee Severance [Member]USD 49,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-03-31restructuringin_progressCost of Sales [Member] / Contract Termination And Other Costs [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-03-31restructuringin_progressSelling, General and Administrative Expenses [Member] / Contract Termination And Other Costs [Member]USD 12,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-03-31restructuringin_progressResearch and Development Expense [Member] / Contract Termination And Other Costs [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-03-31restructuringin_progressContract Termination And Other Costs [Member]USD 12,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-03-31restructuringin_progressCost of Sales [Member] / Asset Impairment [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-03-31restructuringin_progressSelling, General and Administrative Expenses [Member] / Asset Impairment [Member]USD 6,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-03-31restructuringin_progressResearch and Development Expense [Member] / Asset Impairment [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-03-31restructuringin_progressAsset Impairment [Member]USD 6,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-03-31restructuringin_progressCost of Sales [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-03-31restructuringin_progressSelling, General and Administrative Expenses [Member]USD 65,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-03-31restructuringin_progressResearch and Development Expense [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-03-31restructuringin_progressUSD 67,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-03-31restructuringin_progressSeverance And Other Employee Related Costs [Member]USD 61,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-12-31acquisition_additioncompleted10,0002021-12-13GlobalHillromItem_1_Business
f5-10k / GLM-5.3-flash-HTML		Approximately 10,000 employees joined Baxter in December 2021 through the Hill-Rom Holdings acquisition, completed December 13, 2021 (purchase price $10.5 billion; enterprise value approximately $12.8 billion).
2021-12-31restructuringin_progress2015GlobalMultiple (manufacturing footprint, distribution, G&A infrastructure, R&D)USD 114 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Multi-year program commenced in the second half of 2015; ongoing initiatives not yet complete (additional ~$30 million pre-tax costs expected). Fiscal 2021 charges of $114 million consist of restructuring charges of $91 million (employee termination costs $73 million, contract termination and other $2 million, asset impairments $16 million) plus $23 million implementation costs. Headcount affected not quantified. Cumulative pre-tax program costs ~$1.2 billion; restructuring liability $109 million at December 31, 2021.
2021-12-31plant_closurein_progress2021ArgentinaAmericasMD&A
f5-10k / GLM-5.3-flash-HTML		Wind-down of Argentina operations began in the first quarter of 2021; substantial liquidation still pending at year-end. Upon liquidation a non-cash currency translation adjustment charge in excess of $60 million is expected. No workforce impact quantified in the filing.
2021-12-31acquisition_additioncompleted10,0002021-12-132021-12-13GlobalHillrom segmentItem_1_Business
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Purchase price $10.5 billion; enterprise value ~$12.8 billion. Headcount figure is approximate and stated in Item 1 rather than the business combinations footnote.
2021-12-31restructuringin_progress2022-12-31GlobalEnterprise-wide business optimization programUSD 114 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2021 charges comprise $91M restructuring (including $73M employee termination costs) plus $23M implementation costs. Program began 2H 2015 with cumulative pre-tax costs of ~$1.2 billion through 2021-12-31; ~99% of expected annual pre-tax savings realized, remainder expected by end of 2022. No employee headcount affected is disclosed for 2021.
2021-12-31plant_closurein_progress2021-01-01ArgentinaLegacy Baxter operationsMD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Wind-down expected to reclassify CTA of over $60 million from AOCI to other expense, net upon substantial liquidation. No headcount or charge quantified; announcement date shown as period start because only the quarter of commencement (Q1 2021) is disclosed.
2021-12-31acquisition_additioncompleted10,0002021-12-132021-12-13GlobalHillromItem_1_Business
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Approximately 10,000 employees joined in December 2021 in connection with the acquisition of Hillrom.
2021-12-31restructuringin_progress2022-12-31GlobalVariousUSD 114 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Pre-tax costs of $114 million incurred in 2021 related to business optimization programs including employee termination costs, implementation costs, contract termination costs, asset impairments, and accelerated depreciation. Cumulative pre-tax costs since 2015 are $1.2 billion.
2021-12-31restructuringin_progress2022-12-31GlobalVariousUSD 114 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Cumulative pre-tax costs of $1.2 billion incurred since 2015. $114 million charged in 2021. Remaining actions expected to be realized by end of 2022. Employee count not explicitly disclosed for 2021 charges.
2021-12-31acquisition_additioncompleted10,0002021-12-132021-12-13GlobalHillromItem_1_Business
f5-10k / Qwen3.6-27B-Q8_0		Approximately 10,000 employees joined in connection with the acquisition of Hillrom.
2021-12-31restructuringin_progressUSD 91,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2021-12-31restructuringin_progressCost of Sales [Member] / Employee Severance [Member]USD 37,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2021-12-31restructuringin_progressSelling, General and Administrative Expenses [Member] / Employee Severance [Member]USD 35,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2021-12-31restructuringin_progressResearch and Development Expense [Member] / Employee Severance [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2021-12-31restructuringin_progressEmployee Severance [Member]USD 73,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2021-12-31restructuringin_progressCost of Sales [Member] / Contract Termination And Other Costs [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2021-12-31restructuringin_progressSelling, General and Administrative Expenses [Member] / Contract Termination And Other Costs [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2021-12-31restructuringin_progressResearch and Development Expense [Member] / Contract Termination And Other Costs [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2021-12-31restructuringin_progressContract Termination And Other Costs [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2021-12-31restructuringin_progressCost of Sales [Member] / Asset Impairment [Member]USD 16,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2021-12-31restructuringin_progressSelling, General and Administrative Expenses [Member] / Asset Impairment [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2021-12-31restructuringin_progressResearch and Development Expense [Member] / Asset Impairment [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2021-12-31restructuringin_progressAsset Impairment [Member]USD 16,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2021-12-31restructuringin_progressCost of Sales [Member]USD 53,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2021-12-31restructuringin_progressSelling, General and Administrative Expenses [Member]USD 37,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2021-12-31restructuringin_progressResearch and Development Expense [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2021-12-31restructuringin_progressSeverance And Other Employee Related Costs [Member]USD 94,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2021-09-30restructuringin_progressGlobalCorporate-wide business optimization programUSD 36 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q3 2021 charges of $36M ($32M restructuring, $4M implementation); no employee count disclosed. Program ongoing since H2 2015 with cumulative $1.2B pre-tax costs; ~$35M additional expected.
2021-09-30restructuringin_progressGlobalCorporate-wide business optimization programUSD 81 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		YTD 2021 charges of $81M ($67M restructuring, $14M implementation); no employee count disclosed. Restructuring liability balance $96M at 2021-09-30, substantially all employee termination costs payable by end of 2022.
2021-09-30acquisition_additionannounced2021-09-02GlobalEnterprise (Hill-Rom Holdings, Inc.)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to acquire Hillrom for ~$10.5B cash (~$12.4B enterprise value); expected close early 2022. No headcount added disclosed.
2021-09-30restructuringin_progressGlobalVarious (COGS, SG&A, R&D)USD 32 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Q3 2021 restructuring charges of $32M included $19M employee termination costs, $11M asset impairments, and $2M contract termination/other costs. No specific headcount affected disclosed.
2021-09-30restructuringin_progressGlobalVarious (COGS, SG&A, R&D)USD 67 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		YTD 2021 restructuring charges of $67M included $49M employee termination costs, $16M asset impairments, and $2M contract termination/other costs. No specific headcount affected disclosed.
2021-09-30restructuringin_progressBusiness Optimization Programs [Member]USD 32,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-09-30restructuringin_progressCost of Sales [Member] / Employee Severance [Member]USD 11,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-09-30restructuringin_progressSelling, General and Administrative Expenses [Member] / Employee Severance [Member]USD 8,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-09-30restructuringin_progressResearch and Development Expense [Member] / Employee Severance [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-09-30restructuringin_progressEmployee Severance [Member]USD 19,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-09-30restructuringin_progressCost of Sales [Member] / Contract Termination And Other Costs [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-09-30restructuringin_progressSelling, General and Administrative Expenses [Member] / Contract Termination And Other Costs [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-09-30restructuringin_progressResearch and Development Expense [Member] / Contract Termination And Other Costs [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-09-30restructuringin_progressContract Termination And Other Costs [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-09-30restructuringin_progressCost of Sales [Member] / Asset Impairment [Member]USD 11,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-09-30restructuringin_progressSelling, General and Administrative Expenses [Member] / Asset Impairment [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-09-30restructuringin_progressResearch and Development Expense [Member] / Asset Impairment [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-09-30restructuringin_progressAsset Impairment [Member]USD 11,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-09-30restructuringin_progressCost of Sales [Member]USD 22,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-09-30restructuringin_progressSelling, General and Administrative Expenses [Member]USD 10,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-09-30restructuringin_progressResearch and Development Expense [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-09-30restructuringin_progressUSD 32,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-09-30restructuringin_progressSeverance And Other Employee Related Costs [Member]USD 54,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-06-30restructuringin_progressUSD 45 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Business optimization program ongoing since 2H 2015; $45M total charges in Q2 2021 ($18M) and YTD 2021 ($45M), comprising restructuring charges and implementation costs. No employee counts disclosed. Cumulative pre-tax costs of $1.2B since program inception; approximately $16M of additional pre-tax costs expected to complete current initiatives.
2021-06-30acquisition_additioncompleted2021-03-01United States and specified territories outside the U.S.Americas; EMEAUSD 84 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Transderm Scop rights from GlaxoSmithKline subsidiaries; total consideration $84M ($60M cash plus $24M contingent). No headcount added disclosed.
2021-06-30acquisition_additioncompleted2021-02-01Specified territories outside the U.S.PharmaceuticalsUSD 325 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Caelyx and Doxil rights from a Johnson & Johnson subsidiary; $325M purchase price allocated to intangible assets. No headcount added disclosed.
2021-06-30acquisition_additionannounced2021-07-01United States and specified territories outside the U.S.Advanced SurgeryUSD 25 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Subsequent-event acquisition of PerClot assets from CryoLife, Inc.; $25M upfront plus up to $36M in milestone-based contingent consideration. No headcount added disclosed.
2021-06-30restructuringin_progress2022-12-31GlobalVarious (COGS, SG&A)USD 10 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Q2 2021 charges of $10M ($9M employee termination, $1M asset impairments). Substantially all cash payments for liabilities expected by end of 2022. Employee count not disclosed.
2021-06-30restructuringin_progress2022-12-31GlobalVarious (COGS, SG&A)USD 35 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		YTD 2021 charges of $35M ($30M employee termination, $5M asset impairments). Substantially all cash payments for liabilities expected by end of 2022. Employee count not disclosed.
2021-06-30restructuringin_progressBusiness Optimization Programs [Member]USD 10,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-06-30restructuringin_progressCost of Sales [Member] / Employee Severance [Member]USD 8,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-06-30restructuringin_progressSelling, General and Administrative Expenses [Member] / Employee Severance [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-06-30restructuringin_progressResearch and Development Expense [Member] / Employee Severance [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-06-30restructuringin_progressEmployee Severance [Member]USD 9,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-06-30restructuringin_progressCost of Sales [Member] / Asset Impairment [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-06-30restructuringin_progressSelling, General and Administrative Expenses [Member] / Asset Impairment [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-06-30restructuringin_progressResearch and Development Expense [Member] / Asset Impairment [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-06-30restructuringin_progressAsset Impairment [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-06-30restructuringin_progressCost of Sales [Member]USD 9,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-06-30restructuringin_progressSelling, General and Administrative Expenses [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-06-30restructuringin_progressResearch and Development Expense [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-06-30restructuringin_progressUSD 10,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-06-30restructuringin_progressSeverance And Other Employee Related Costs [Member]USD 33,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-03-31restructuringin_progressGlobalCorporate-wide (organization, manufacturing footprint, R&D, supply chain, support functions)USD 27 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 2021 charges: $25M restructuring + $2M implementation costs. Cumulative $1.1B since 2015; ~$12M additional expected. No employee count disclosed.
2021-03-31acquisition_additioncompleted2021-03-012021-03-31United States and specified territories outside the U.S.Americas and EMEA segments (Pharmaceuticals)USD 84 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquired TDS rights from GlaxoSmithKline subsidiaries; $60M cash + $24M contingent consideration. Asset purchase, no headcount disclosed.
2021-03-31acquisition_additioncompleted2021-02-012021-02-28Specified territories outside the U.S.EMEA segment (Pharmaceuticals)USD 325 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Asset acquisition of liposomal doxorubicin rights from Johnson & Johnson subsidiary; $314M developed technology + $11M customer relationships intangibles. No headcount disclosed.
2021-03-31restructuringin_progress2022-12-31GlobalVarious (COGS, SG&A)USD 25 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Q1 2021 restructuring charges of $25M included $21M employee termination costs and $4M asset impairments. Liability balance of $107M expected to be disbursed by end of 2022. Employee count not disclosed.
2021-03-31restructuringin_progressBusiness Optimization Programs [Member]USD 25,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-03-31restructuringin_progressCost of Sales [Member] / Employee Severance [Member]USD 16,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-03-31restructuringin_progressSelling, General and Administrative Expenses [Member] / Employee Severance [Member]USD 5,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-03-31restructuringin_progressResearch and Development Expense [Member] / Employee Severance [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-03-31restructuringin_progressEmployee Severance [Member]USD 21,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-03-31restructuringin_progressCost of Sales [Member] / Asset Impairment [Member]USD 4,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-03-31restructuringin_progressSelling, General and Administrative Expenses [Member] / Asset Impairment [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-03-31restructuringin_progressResearch and Development Expense [Member] / Asset Impairment [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-03-31restructuringin_progressAsset Impairment [Member]USD 4,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-03-31restructuringin_progressCost of Sales [Member]USD 20,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-03-31restructuringin_progressSelling, General and Administrative Expenses [Member]USD 5,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-03-31restructuringin_progressResearch and Development Expense [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-03-31restructuringin_progressUSD 25,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-03-31restructuringin_progressSeverance And Other Employee Related Costs [Member]USD 21,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-12-31restructuringin_progress2023-12-31GlobalEnterprise-wide (organization, manufacturing footprint, R&D and supply chain optimization)USD 134 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2020 charges: $111M restructuring charges plus $23M implementation costs; cumulative pre-tax program costs of $1.1B since H2 2015; approximately 95% of expected annual pre-tax savings realized through 2020-12-31, remainder by end of 2023; employee headcount affected not disclosed
2020-12-31acquisition_additioncompleted2020-02-14GlobalAdvanced SurgeryUSD 342 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Product-rights acquisition from Sanofi completed 2020-02-14 for approximately $342M cash; contributed $94M net sales in 2020; acquired headcount not disclosed
2020-12-31restructuringin_progress2023-12-31GlobalMultipleUSD 134 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Cumulative pre-tax costs of $1.1 billion incurred through Dec 31, 2020. $134 million charged in 2020. Expected to incur additional $14 million. Savings expected by end of 2023.
2020-12-31restructuringin_progress2023-12-31GlobalVariousUSD 134 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Cumulative pre-tax costs of $1.1 billion incurred through Dec 31, 2020. $134 million charged in 2020. Remaining actions expected to be realized by end of 2023.
2020-12-31restructuringin_progressUSD 111,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2020-12-31restructuringin_progressCost of Sales [Member] / Employee Severance [Member]USD 36,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2020-12-31restructuringin_progressSelling, General and Administrative Expenses [Member] / Employee Severance [Member]USD 54,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2020-12-31restructuringin_progressResearch and Development Expense [Member] / Employee Severance [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2020-12-31restructuringin_progressEmployee Severance [Member]USD 92,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2020-12-31restructuringin_progressCost of Sales [Member] / Contract Termination And Other Costs [Member]USD 4,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2020-12-31restructuringin_progressSelling, General and Administrative Expenses [Member] / Contract Termination And Other Costs [Member]USD 4,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2020-12-31restructuringin_progressResearch and Development Expense [Member] / Contract Termination And Other Costs [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2020-12-31restructuringin_progressContract Termination And Other Costs [Member]USD 8,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2020-12-31restructuringin_progressCost of Sales [Member] / Asset Impairment [Member]USD 8,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2020-12-31restructuringin_progressSelling, General and Administrative Expenses [Member] / Asset Impairment [Member]USD 3,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2020-12-31restructuringin_progressResearch and Development Expense [Member] / Asset Impairment [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2020-12-31restructuringin_progressAsset Impairment [Member]USD 11,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2020-12-31restructuringin_progressCost of Sales [Member]USD 48,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2020-12-31restructuringin_progressSelling, General and Administrative Expenses [Member]USD 61,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2020-12-31restructuringin_progressResearch and Development Expense [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2020-12-31restructuringin_progressSeverance And Other Employee Related Costs [Member]USD 116,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2020-09-30restructuringin_progressGlobalCorporate-wide (organization, manufacturing footprint, R&D, supply chain)USD 77 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Cumulative pre-tax costs of $1.1B since H2 2015; $77M charged YTD 2020 ($32M in Q3). Restructuring liability $81M at 2020-09-30. No employee counts disclosed; ~$15M additional costs expected to complete current initiatives.
2020-09-30acquisition_additioncompletedGlobalAdvanced Surgery (Americas and APAC segments)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Seprafilm product rights from Sanofi completed February 2020 for ~$342M cash; treated as business combination. No headcount added disclosed.
2020-09-30acquisition_additioncompleted2019-10-25GlobalAcute Therapies / Critical Carebusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		100% acquisition of Cheetah Medical completed 2019-10-25 for $208M total consideration; measurement period adjustments recorded in Q3 2020. No headcount added disclosed.
2020-09-30restructuringin_progress2021-12-31GlobalVariousUSD 26 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Q3 2020 restructuring charges of $26M included $20M employee termination costs. Substantially all cash payments for liabilities expected by end of 2021.
2020-09-30restructuringin_progress2021-12-31GlobalVariousUSD 58 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		YTD 2020 restructuring charges of $58M included $42M employee termination costs. Substantially all cash payments for liabilities expected by end of 2021.
2020-09-30restructuringin_progressBusiness Optimization Programs [Member]USD 26,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-09-30restructuringin_progressCost of Sales [Member] / Employee Severance [Member]USD 4,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-09-30restructuringin_progressSelling, General and Administrative Expenses [Member] / Employee Severance [Member]USD 15,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-09-30restructuringin_progressResearch and Development Expense [Member] / Employee Severance [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-09-30restructuringin_progressEmployee Severance [Member]USD 20,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-09-30restructuringin_progressCost of Sales [Member] / Contract Termination And Other Costs [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-09-30restructuringin_progressSelling, General and Administrative Expenses [Member] / Contract Termination And Other Costs [Member]USD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-09-30restructuringin_progressResearch and Development Expense [Member] / Contract Termination And Other Costs [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-09-30restructuringin_progressContract Termination And Other Costs [Member]USD 4,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-09-30restructuringin_progressCost of Sales [Member] / Asset Impairment [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-09-30restructuringin_progressSelling, General and Administrative Expenses [Member] / Asset Impairment [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-09-30restructuringin_progressResearch and Development Expense [Member] / Asset Impairment [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-09-30restructuringin_progressAsset Impairment [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-09-30restructuringin_progressCost of Sales [Member]USD 5,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-09-30restructuringin_progressSelling, General and Administrative Expenses [Member]USD 20,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-09-30restructuringin_progressResearch and Development Expense [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-09-30restructuringin_progressUSD 26,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-09-30restructuringin_progressSeverance And Other Employee Related Costs [Member]USD 53,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-06-30restructuringin_progressGlobalMultiple (organization, manufacturing footprint, R&D, supply chain, support functions)USD 13 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Ongoing business optimization program since H2 2015; cumulative pre-tax costs of $1.0B through June 30, 2020. Q2 2020 charges: $7M restructuring, $6M implementation costs. Additional ~$15M expected. No employee headcount affected disclosed.
2020-06-30acquisition_additioncompleted2020-02-012020-02-01GlobalAdvanced Surgery (Americas and APAC segments)USD 342 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquired product rights to Seprafilm Adhesion Barrier from Sanofi for ~$342M cash. No headcount added disclosed.
2020-06-30acquisition_additioncompletedGlobalMultipleUSD 13 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Other individually immaterial acquisitions in H1 2020 for $13M cash plus up to $12M contingent consideration. No headcount added disclosed.
2020-06-30restructuringin_progressGlobalVarious (COGS, SG&A, R&D)USD 7 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Q2 2020 restructuring charges of $7 million included $3 million employee termination costs, $2 million contract termination/other, and $2 million asset impairments. No specific headcount affected disclosed.
2020-06-30restructuringin_progressGlobalVarious (COGS, SG&A, R&D)USD 32 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		YTD 2020 restructuring charges of $32 million included $22 million employee termination costs, $2 million contract termination/other, and $8 million asset impairments. No specific headcount affected disclosed.
2020-06-30acquisition_additioncompleted2020-02-01Americas and APACAdvanced SurgeryUSD 342 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquired Seprafilm Adhesion Barrier from Sanofi in Feb 2020 for $342 million. Headcount not disclosed.
2020-06-30restructuringin_progressBusiness Optimization Programs [Member]USD 7,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-06-30restructuringin_progressCost of Sales [Member] / Employee Severance [Member]USD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-06-30restructuringin_progressSelling, General and Administrative Expenses [Member] / Employee Severance [Member]USD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-06-30restructuringin_progressResearch and Development Expense [Member] / Employee Severance [Member]USD -3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-06-30restructuringin_progressEmployee Severance [Member]USD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-06-30restructuringin_progressCost of Sales [Member] / Contract Termination And Other Costs [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-06-30restructuringin_progressSelling, General and Administrative Expenses [Member] / Contract Termination And Other Costs [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-06-30restructuringin_progressResearch and Development Expense [Member] / Contract Termination And Other Costs [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-06-30restructuringin_progressContract Termination And Other Costs [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-06-30restructuringin_progressCost of Sales [Member] / Asset Impairment [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-06-30restructuringin_progressSelling, General and Administrative Expenses [Member] / Asset Impairment [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-06-30restructuringin_progressResearch and Development Expense [Member] / Asset Impairment [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-06-30restructuringin_progressAsset Impairment [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-06-30restructuringin_progressCost of Sales [Member]USD 7,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-06-30restructuringin_progressSelling, General and Administrative Expenses [Member]USD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-06-30restructuringin_progressResearch and Development Expense [Member]USD -3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-06-30restructuringin_progressUSD 7,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-06-30restructuringin_progressSeverance And Other Employee Related Costs [Member]USD 29,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-03-31restructuringin_progressGlobalVarious (COGS, SG&A, R&D)USD 25 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Includes $19M employee termination costs and $6M asset impairments. Part of ongoing business optimization programs.
2020-03-31acquisition_additioncompleted2020-02-01GlobalAdvanced SurgeryUSD 342 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquired Seprafilm Adhesion Barrier product rights from Sanofi. Headcount not explicitly disclosed.
2020-03-31restructuringin_progressBusiness Optimization Programs [Member]USD 25,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-03-31restructuringin_progressCost of Sales [Member] / Employee Severance [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-03-31restructuringin_progressSelling, General and Administrative Expenses [Member] / Employee Severance [Member]USD 16,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-03-31restructuringin_progressResearch and Development Expense [Member] / Employee Severance [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-03-31restructuringin_progressEmployee Severance [Member]USD 19,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-03-31restructuringin_progressCost of Sales [Member] / Asset Impairment [Member]USD 6,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-03-31restructuringin_progressSelling, General and Administrative Expenses [Member] / Asset Impairment [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-03-31restructuringin_progressResearch and Development Expense [Member] / Asset Impairment [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-03-31restructuringin_progressAsset Impairment [Member]USD 6,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-03-31restructuringin_progressCost of Sales [Member]USD 8,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-03-31restructuringin_progressSelling, General and Administrative Expenses [Member]USD 16,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-03-31restructuringin_progressResearch and Development Expense [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-03-31restructuringin_progressUSD 25,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-03-31restructuringin_progressSeverance And Other Employee Related Costs [Member]USD 19,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-12-31restructuringin_progress20152020-12-31GlobalEnterprise-wide — organization restructuring, manufacturing footprint optimization, R&D operations, supply chain network, centralized/streamlined support functionsUSD 134 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Ongoing multi-year business optimization program commenced in H2 2015. Filer discloses charges but not employee counts affected. 2019 charges: $134M restructuring (including $75M employee termination costs, $11M contract termination, $48M asset impairments); total business optimization charges of $184M including $45M implementation and $5M accelerated depreciation. Cumulative pre-tax program cost of $980M through December 31, 2019, with approximately $50M additional cash costs expected; restructuring liability of $92M at year-end substantially to be paid by end of 2020, and remaining expected annual pre-tax savings (~$1.2B, ~95% realized through 2019) to be fully realized by end of 2023.
2019-12-31restructuringin_progress2023-12-31GlobalEnterprise-wide (manufacturing, R&D, G&A, supply chain)USD 184 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Multi-year business optimization program; $184M charged in FY2019. Cumulative pre-tax costs of approximately $980M from program commencement in H2 2015 through 2019-12-31, with about $50M additional expected. Approximately 95% of expected annual pre-tax savings of ~$1.2B realized through 2019-12-31; remainder expected by end of 2023. Employees affected not quantified.
2019-12-31acquisition_additioncompleted2019-10-252019-10-25Global (Cheetah Medical, Inc.; operations in US and Israel)Acute Therapies / hemodynamic monitoringbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquired 100% of Cheetah Medical for $195M upfront cash plus $18M acquisition-date fair value of contingent consideration. Headcount added not disclosed.
2019-12-31acquisition_additionannounced2019-12-312020-02-29GlobalAdvanced Surgerysubsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement entered December 2019 to acquire Seprafilm from Sanofi; transaction closed February 2020 for approximately $345M. Excluded from FY2019 financial statements. Headcount added not disclosed.
2019-12-31acquisition_additioncompleted2020-01-312020-01-31United StatesPharmaceuticalssubsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		January 2020 acquisition of U.S. rights to an additional product for $60M; capitalized as developed-technology intangible. Asset purchase rather than business combination; headcount impact not disclosed.
2019-12-31restructuringin_progress2023-12-31GlobalAll segmentsUSD 184 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Cumulative pre-tax costs of $980 million incurred from second half of 2015 through 2019. 2019 charges of $184 million included employee termination costs, implementation costs, asset impairments, and accelerated depreciation. Approximately 95% of expected annual pre-tax savings realized by year-end 2019.
2019-12-31restructuringin_progress2023-12-31GlobalVariousUSD 184 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Cumulative pre-tax costs of $980 million incurred from 2015 through 2019. $184 million charged in 2019. Program expected to complete by end of 2023.
2019-12-31restructuringin_progressUSD 134,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2019-12-31restructuringin_progressCost of Sales [Member] / Employee Severance [Member]USD 13,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2019-12-31restructuringin_progressSelling, General and Administrative Expenses [Member] / Employee Severance [Member]USD 37,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2019-12-31restructuringin_progressResearch and Development Expense [Member] / Employee Severance [Member]USD 25,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2019-12-31restructuringin_progressEmployee Severance [Member]USD 75,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2019-12-31restructuringin_progressCost of Sales [Member] / Contract Termination And Other Costs [Member]USD 10,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2019-12-31restructuringin_progressSelling, General and Administrative Expenses [Member] / Contract Termination And Other Costs [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2019-12-31restructuringin_progressResearch and Development Expense [Member] / Contract Termination And Other Costs [Member]USD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2019-12-31restructuringin_progressContract Termination And Other Costs [Member]USD 11,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2019-12-31restructuringin_progressCost of Sales [Member] / Asset Impairment [Member]USD 37,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2019-12-31restructuringin_progressSelling, General and Administrative Expenses [Member] / Asset Impairment [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2019-12-31restructuringin_progressResearch and Development Expense [Member] / Asset Impairment [Member]USD 9,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2019-12-31restructuringin_progressAsset Impairment [Member]USD 48,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2019-12-31restructuringin_progressCost of Sales [Member]USD 60,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2019-12-31restructuringin_progressSelling, General and Administrative Expenses [Member]USD 40,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2019-12-31restructuringin_progressResearch and Development Expense [Member]USD 34,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2019-12-31restructuringin_progressSeverance And Other Employee Related Costs [Member]USD 113,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2019-09-30restructuringin_progressGlobalCorporate-wide (manufacturing footprint, R&D, supply chain, support functions)USD 131 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Ongoing business optimization program begun H2 2015; $927M cumulative pre-tax costs through 2019-09-30 with ~$100M expected additional. No employee-affected counts disclosed.
2019-09-30restructuringin_progressGlobalCorporate-wideUSD 94 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Restructuring charges of $94M for 9M 2019 (employee termination $62M, contract termination $9M, asset impairments $23M); no headcount affected disclosed.
2019-09-30restructuringin_progressGlobalVarious (COGS, SG&A, R&D)USD 28 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Q3 2019 charges include $5M employee termination, $1M contract termination, and $11M asset impairments. Part of ongoing business optimization programs.
2019-09-30restructuringin_progressGlobalVarious (COGS, SG&A, R&D)USD 131 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		YTD 2019 charges include $62M employee termination, $9M contract termination, and $23M asset impairments. Cumulative pre-tax costs through Sept 30, 2019 are $927M.
2019-09-30restructuringin_progressBusiness Optimization Programs [Member]USD 17,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-09-30restructuringin_progressCost of Sales [Member] / Employee Severance [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-09-30restructuringin_progressSelling, General and Administrative Expenses [Member] / Employee Severance [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-09-30restructuringin_progressResearch and Development Expense [Member] / Employee Severance [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-09-30restructuringin_progressEmployee Severance [Member]USD 5,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-09-30restructuringin_progressCost of Sales [Member] / Contract Termination And Other Costs [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-09-30restructuringin_progressSelling, General and Administrative Expenses [Member] / Contract Termination And Other Costs [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-09-30restructuringin_progressResearch and Development Expense [Member] / Contract Termination And Other Costs [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-09-30restructuringin_progressContract Termination And Other Costs [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-09-30restructuringin_progressCost of Sales [Member] / Asset Impairment [Member]USD 7,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-09-30restructuringin_progressSelling, General and Administrative Expenses [Member] / Asset Impairment [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-09-30restructuringin_progressResearch and Development Expense [Member] / Asset Impairment [Member]USD 4,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-09-30restructuringin_progressAsset Impairment [Member]USD 11,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-09-30restructuringin_progressCost of Sales [Member]USD 9,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-09-30restructuringin_progressSelling, General and Administrative Expenses [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-09-30restructuringin_progressResearch and Development Expense [Member]USD 6,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-09-30restructuringin_progressUSD 17,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-09-30restructuringin_progressSeverance And Other Employee Related Costs [Member]USD 84,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-06-30restructuringin_progressGlobalCorporate-wide (organization, manufacturing footprint, R&D, supply chain)USD 103 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Six months ended 2019 charges: $77M restructuring, $22M implementation, $4M accelerated depreciation. Program began H2 2015; cumulative pre-tax costs $899M through 2019-06-30; ~$70M additional expected. No employee counts disclosed.
2019-06-30acquisition_additioncompletedUnited StatesPharmaceuticalsUSD 94 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 2019 acquisition of U.S. rights to multiple products for $94M; headcount impact not disclosed. Separate July 2019 acquisition of U.S. rights for $62M (subsequent event).
2019-06-30restructuringin_progress2020-12-31GlobalVarious (COGS, SG&A, R&D)USD 52 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Q2 2019 charges include $49M employee termination, $1M contract termination, $2M asset impairments. Reserves expected substantially utilized by end of 2020.
2019-06-30restructuringin_progress2020-12-31GlobalVarious (COGS, SG&A, R&D)USD 77 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		YTD 2019 charges include $57M employee termination, $8M contract termination, $12M asset impairments. Reserves expected substantially utilized by end of 2020.
2019-06-30restructuringin_progressUSD 77,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-06-30restructuringin_progressCost Of Sales [Member] / Employee Severance [Member]USD 6,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-06-30restructuringin_progressSelling General And Administrative Expenses [Member] / Employee Severance [Member]USD 26,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-06-30restructuringin_progressResearch And Development Expense [Member] / Employee Severance [Member]USD 17,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-06-30restructuringin_progressEmployee Severance [Member]USD 49,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-06-30restructuringin_progressCost Of Sales [Member] / Contract Termination And Other Costs [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-06-30restructuringin_progressContract Termination And Other Costs [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-06-30restructuringin_progressCost Of Sales [Member] / Asset Impairment [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-06-30restructuringin_progressResearch And Development Expense [Member] / Asset Impairment [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-06-30restructuringin_progressAsset Impairment [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-06-30restructuringin_progressCost Of Sales [Member]USD 8,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-06-30restructuringin_progressSelling General And Administrative Expenses [Member]USD 26,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-06-30restructuringin_progressResearch And Development Expense [Member]USD 18,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-06-30restructuringin_progressSelling General And Administrative Expenses [Member] / Asset Impairment [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-06-30restructuringin_progressSeverance And Other Employee Related Costs [Member]USD 78,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-03-31restructuringin_progress2023-12-31GlobalEnterprise-wide (organization, manufacturing footprint, R&D, supply chain, support functions)USD 38 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program initiated in the second half of 2015; exact announcement date not disclosed. Q1 2019 charges of $38M comprise $25M restructuring, $10M implementation costs and $3M accelerated depreciation. Cumulative pre-tax costs of $834M through 2019-03-31; approximately $35M of additional costs expected. No employee-affected count disclosed. Completion date inferred from disclosure that remaining savings are expected by end of 2023.
2019-03-31restructuringin_progressGlobalVarious (COGS, SG&A, R&D)USD 25 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Part of ongoing business optimization programs initiated in 2015. Q1 2019 charges include $16M employee termination costs, $7M contract termination/other, and $10M asset impairments. Cumulative pre-tax costs through Q1 2019 are $834M. No specific headcount affected is disclosed for the quarter.
2019-03-31restructuringin_progressUSD 25,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-03-31restructuringin_progressEmployee Severance [Member] / Cost Of Sales [Member]USD 6,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-03-31restructuringin_progressEmployee Severance [Member] / Selling General And Administrative Expenses [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-03-31restructuringin_progressEmployee Severance [Member] / Research And Development Expense [Member]USD 9,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-03-31restructuringin_progressEmployee Severance [Member]USD 16,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-03-31restructuringin_progressContract Termination And Other Costs [Member] / Cost Of Sales [Member]USD 7,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-03-31restructuringin_progressContract Termination And Other Costs [Member]USD 7,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-03-31restructuringin_progressAsset Impairment [Member] / Cost Of Sales [Member]USD 9,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-03-31restructuringin_progressAsset Impairment [Member] / Selling General And Administrative Expenses [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-03-31restructuringin_progressAsset Impairment [Member]USD 10,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-03-31restructuringin_progressCost Of Sales [Member]USD 16,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-03-31restructuringin_progressResearch And Development Expense [Member]USD 9,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-03-31restructuringin_progressSeverance And Other Employee Related Costs [Member]USD 23,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-12-31restructuringin_progress20152020-12-31GlobalCorporate-wide (business optimization charges unallocated to segments)USD 117 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Multi-year program initiated in H2 2015; only FY2018 activity captured. FY2018 total business optimization charges of $220M comprised $117M restructuring charges (including $100M employee termination costs, primarily a global workforce reduction program; $7M facility-closure asset impairments; $10M other exit costs), $94M program implementation costs, and $9M accelerated depreciation. Headcount affected not disclosed. Additional ~$75M pretax costs expected through 2020; cumulative pretax costs of $796M through FY2018, with ~90% of targeted ~$1.2B annual savings expected realized by end of 2019. Restructuring reserve of $101M at 2018-12-31, substantially to be utilized by end of 2019.
2018-12-31restructuringin_progress2020-12-31GlobalGlobal (all segments and corporate)USD 220 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2018 charges of $220M: $117M restructuring (incl. $100M employee termination costs under a global workforce reduction program, $7M facility-closure impairments, $10M other exit costs), $94M implementation costs, $9M accelerated depreciation. Multi-year program begun in 2H 2015; cumulative pre-tax costs of $796M through 2018-12-31. Company expects ~$75M additional pre-tax costs and $50M capex through completion by end of 2020; ~90% of expected $1.2B annual pre-tax savings to be realized by end of 2019. Reserve of $101M at year-end, substantially to be utilized by end of 2019. No headcount affected disclosed.
2018-12-31acquisition_additioncompleted2018-03-16United StatesAdvanced SurgeryUSD 184 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of two hemostat and sealant products from Mallinckrodt for $184M total consideration ($163M cash plus $21M contingent). Asset/product acquisition; no headcount added disclosed.
2018-12-31acquisition_additioncompleted2018-11-18Saudi ArabiaEMEAUSD 80 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquired additional equity for 51% controlling financial interest in the Saudi Arabia joint venture; consolidated beginning Q4 2018. Total consideration transferred $80M. Results of operations not significant; no headcount disclosed.
2018-12-31divestiture_reductioncompleted2018VenezuelaAmericasother
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Company liquidated its Venezuelan subsidiary during 2018 and now sells to distributors through legal entities outside Venezuela. Deconsolidation and related $33M charge occurred in 2017 (prior year); no 2018 headcount impact disclosed.
2018-12-31restructuringin_progress2015-07-012020-12-31GlobalAll segmentsUSD 220 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Ongoing business optimization program initiated in second half of 2015. 2018 charges included $117M restructuring costs ($100M employee termination, $7M asset impairment, $10M other exit) and $94M implementation costs. Cumulative pre-tax costs through Dec 31, 2018 were $796M. Program expected to complete by end of 2020.
2018-12-31restructuringin_progress2015-07-012020-12-31GlobalGlobalUSD 220 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Multi-year business optimization program initiated in H2 2015. 2018 charges include $100M employee termination costs, $7M asset impairments, and $10M other exit costs. Program expected to complete by end of 2020.
2018-12-31restructuringin_progressUSD 117,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-12-31restructuringin_progressEmployee Severance [Member] / Global Workforce Reduction Program [Member]USD 100,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-12-31restructuringin_progressAsset Impairment Related To Facility Closing [Member]USD 7,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-12-31restructuringin_progressOther Restructuring [Member]USD 10,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-12-31restructuringin_progressCost Of Sales [Member] / Employee Severance [Member]USD 38,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-12-31restructuringin_progressSelling General And Administrative Expenses [Member] / Employee Severance [Member]USD 57,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-12-31restructuringin_progressResearch And Development Expense [Member] / Employee Severance [Member]USD 21,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-12-31restructuringin_progressEmployee Severance [Member]USD 116,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-12-31restructuringin_progressCost Of Sales [Member] / Contract Termination And Other Costs [Member]USD 4,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-12-31restructuringin_progressSelling General And Administrative Expenses [Member] / Contract Termination And Other Costs [Member]USD 6,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-12-31restructuringin_progressContract Termination And Other Costs [Member]USD 10,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-12-31restructuringin_progressCost Of Sales [Member] / Asset Impairment [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-12-31restructuringin_progressSelling General And Administrative Expenses [Member] / Asset Impairment [Member]USD 6,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-12-31restructuringin_progressAsset Impairment [Member]USD 7,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-12-31restructuringin_progressCost Of Sales [Member]USD 35,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-12-31restructuringin_progressSelling General And Administrative Expenses [Member]USD 63,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-12-31restructuringin_progressResearch And Development Expense [Member]USD 19,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-12-31restructuringin_progressSeverance And Other Employee Related Costs [Member]USD 126,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-09-30restructuringin_progress2020-12-31GlobalEnterprise-wideUSD 90 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q3 2018 charge of $90M: $63M restructuring (incl. $58M employee termination), $24M implementation, $3M accelerated depreciation. Employee counts not disclosed.
2018-09-30restructuringin_progress2020-12-31GlobalEnterprise-wideUSD 175 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		YTD 2018 charge of $175M: $96M restructuring (incl. $86M employee termination), $74M implementation, $5M accelerated depreciation. Cumulative program cost $751M since 2015; ~$130M additional expected. Employee counts not disclosed.
2018-09-30restructuringin_progress2019-12-31GlobalCorporate and otherUSD 90 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Q3 2018 charges of $90M ($63M restructuring, $24M implementation, $3M accelerated depreciation). Reserves expected to be substantially utilized by end of 2019.
2018-09-30restructuringin_progress2019-12-31GlobalCorporate and otherUSD 175 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		YTD 2018 charges of $175M ($96M restructuring, $74M implementation, $5M accelerated depreciation). Reserves expected to be substantially utilized by end of 2019.
2018-09-30restructuringin_progressUSD 63,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-09-30restructuringin_progressCost Of Sales [Member] / Employee Severance [Member]USD 16,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-09-30restructuringin_progressSelling General And Administrative Expenses [Member] / Employee Severance [Member]USD 33,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-09-30restructuringin_progressResearch And Development Expense [Member] / Employee Severance [Member]USD 9,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-09-30restructuringin_progressEmployee Severance [Member]USD 58,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-09-30restructuringin_progressSelling General And Administrative Expenses [Member] / Contract Termination And Other Costs [Member]USD 4,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-09-30restructuringin_progressContract Termination And Other Costs [Member]USD 4,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-09-30restructuringin_progressSelling General And Administrative Expenses [Member] / Asset Impairment [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-09-30restructuringin_progressAsset Impairment [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-09-30restructuringin_progressCost Of Sales [Member]USD 16,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-09-30restructuringin_progressSelling General And Administrative Expenses [Member]USD 38,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-09-30restructuringin_progressResearch And Development Expense [Member]USD 9,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-09-30restructuringin_progressCost Of Sales [Member] / Asset Impairment [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-09-30restructuringin_progressSeverance And Other Employee Related Costs [Member]USD 92,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-06-30restructuringin_progress2015-07-012020-12-31GlobalEnterprise-wide (organization, manufacturing footprint, R&D, supply chain, support functions)USD 47 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Business optimization program initiated in 2H 2015; Q2 2018 charges of $47M (incl. $21M restructuring with $18M employee termination costs). Cumulative pretax costs $661M through 2018-06-30; ~$170M additional costs and $70M capex expected. No employee counts disclosed.
2018-06-30acquisition_additioncompleted2017-07-272017-07-27India (acquired operations)Americas segment — Pharmaceuticals / generic injectablesbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Claris for ~$629M cash; contributed $33M net sales in Q2 2018. No headcount added disclosed.
2018-06-30acquisition_additioncompleted2018-03-162018-03-16United StatesAmericas segment — Advanced Surgery (hemostats and sealants)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquired two products from Mallinckrodt for $160M cash plus $14M contingent consideration; $17M net sales in Q2 2018. No headcount added disclosed.
2018-06-30restructuringin_progress2018-12-31GlobalVarious (COGS, SGA, R&D)USD 21 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Q2 2018 restructuring charges of $21M included $18M employee termination costs. Reserves expected to be substantially utilized by end of 2018.
2018-06-30restructuringin_progress2018-12-31GlobalVarious (COGS, SGA, R&D)USD 33 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		YTD 2018 restructuring charges of $33M included $28M employee termination costs. Reserves expected to be substantially utilized by end of 2018.
2018-06-30restructuringin_progressUSD 21,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-06-30restructuringin_progressCost Of Sales [Member] / Employee Severance [Member]USD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-06-30restructuringin_progressSelling General And Administrative Expenses [Member] / Employee Severance [Member]USD 8,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-06-30restructuringin_progressResearch And Development Expense [Member] / Employee Severance [Member]USD 7,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-06-30restructuringin_progressEmployee Severance [Member]USD 18,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-06-30restructuringin_progressSelling General And Administrative Expenses [Member] / Contract Termination [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-06-30restructuringin_progressContract Termination [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-06-30restructuringin_progressSelling General And Administrative Expenses [Member] / Asset Impairment [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-06-30restructuringin_progressAsset Impairment [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-06-30restructuringin_progressCost Of Sales [Member]USD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-06-30restructuringin_progressSelling General And Administrative Expenses [Member]USD 11,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-06-30restructuringin_progressResearch And Development Expense [Member]USD 7,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-06-30restructuringin_progressEmployee Severance [Member] / Cost Of Sales [Member]USD 4,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-06-30restructuringin_progressEmployee Severance [Member] / Selling General And Administrative Expenses [Member]USD 14,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-06-30restructuringin_progressEmployee Severance [Member] / Research And Development Expense [Member]USD 10,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-06-30restructuringin_progressContract Termination [Member] / Selling General And Administrative Expenses [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-06-30restructuringin_progressAsset Impairment [Member] / Cost Of Sales [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-06-30restructuringin_progressAsset Impairment [Member] / Selling General And Administrative Expenses [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-06-30restructuringin_progressSeverance And Other Employee Related Costs [Member]USD 30,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-03-31restructuringin_progress2015-07-012018-12-31GlobalCorporate-wide (manufacturing footprint, R&D, supply chain, support functions)USD 12 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Ongoing program initiated H2 2015; Q1 2018 charges comprised $10M employee termination costs and $2M asset impairments. Cumulative pretax costs of $614M through 2018-03-31; ~$200M additional expected. No employee headcount affected disclosed.
2018-03-31acquisition_additioncompleted2018-03-162018-03-16GlobalAdvanced Surgery (hemostats and sealants)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of two products from Mallinckrodt treated as a business combination; no headcount added disclosed.
2018-03-31acquisition_additioncompleted2018-01-012018-03-31United StatesPharmaceuticalsUSD 72 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 2018 payments of ~$37M and ~$35M for rights to Bivalirudin and Dexmedetomidine; asset purchases, no headcount disclosed.
2018-03-31restructuringin_progressUSD 12 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Part of ongoing business optimization initiatives initiated in 2015. Q1 2018 charges included $10M employee termination costs and $2M asset impairments. Total program costs incurred to date are $614M.
2018-03-31restructuringin_progressUSD 25 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Costs to implement business optimization programs, primarily external consulting and transition costs as well as employee salary and related costs.
2018-03-31restructuringin_progressUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Accelerated depreciation primarily associated with facilities to be closed.
2018-03-31restructuringin_progressUSD 12,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-03-31restructuringin_progressCost Of Sales [Member] / Employee Severance [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-03-31restructuringin_progressSelling General And Administrative Expenses [Member] / Employee Severance [Member]USD 6,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-03-31restructuringin_progressResearch And Development Expense [Member] / Employee Severance [Member]USD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-03-31restructuringin_progressEmployee Severance [Member]USD 10,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-03-31restructuringin_progressCost Of Sales [Member] / Asset Impairment [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-03-31restructuringin_progressSelling General And Administrative Expenses [Member] / Asset Impairment [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-03-31restructuringin_progressAsset Impairment [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-03-31restructuringin_progressCost Of Sales [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-03-31restructuringin_progressSelling General And Administrative Expenses [Member]USD 7,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-03-31restructuringin_progressResearch And Development Expense [Member]USD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-03-31restructuringin_progressSeverance And Other Employee Related Costs [Member]USD 10,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-12-31restructuringin_progress20152018-12-31GlobalCompany-wide; charges recorded in cost of sales, marketing and administrative, and R&DUSD 169 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Multi-year program begun in second half of 2015. FY2017 charges of $169M comprise $70M net restructuring (including $59M net employee termination costs from a global workforce reduction program, $6M facility-closure asset impairments, $5M other exit costs), $89M implementation costs and $10M accelerated depreciation. Additional ~$240M pre-tax costs plus $50M capex expected by end of 2018; $112M reserve at year-end 2017 to be substantially utilized by end of 2020; targeted future annual pretax savings ~$975M (~$730M realized in 2017). Number of employees affected not disclosed.
2017-12-31acquisition_additioncompleted2017-07-272017-07-27India (headquarters of acquired business); global operationsGeneric injectable medicines (goodwill allocated to Americas segment)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquired 100% of Claris Injectables Limited on 2017-07-27 for ~$629 million cash, net of cash acquired, adding generic injectable production capabilities; $28M of acquisition and integration costs recorded in 2017. Number of employees added to consolidated workforce not disclosed.
2017-12-31restructuringin_progress2015-07-012018-12-31GlobalCompany-wide (international operations, manufacturing footprint, R&D, supply chain, support functions)USD 169 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Multi-year business optimization program initiated in 2H 2015 (exact announcement date not disclosed). 2017 charges of $169M comprise $70M net restructuring charges (including $59M net employee termination costs from a global workforce reduction program, $6M asset impairments, $5M other exit costs), $89M implementation costs and $10M accelerated depreciation. Cumulative pre-tax costs of $576M through 2017-12-31; approximately $240M additional pre-tax cash costs and $50M capital expenditures expected through completion. Employees affected not quantified.
2017-12-31acquisition_additioncompleted2017-07-272017-07-27IndiaPharmaceuticals (generic injectable medicines)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of 100% of Claris Injectables Limited for approximately $629M cash, net of cash acquired; headcount added through the acquisition not disclosed. Claris represented approximately 2% of total assets and 1% of total revenues excluded from management's ICFR assessment.
2017-12-31divestiture_reductioncompleted2017-06-302017-06-30VenezuelaVenezuelan operationsUSD 33 (millions)other
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Deconsolidation of Venezuelan operations effective 2017-06-30 after concluding control criteria were no longer met; $33M pre-tax charge recorded in other income, net. Headcount removed from consolidated reporting not disclosed.
2017-12-31restructuringin_progress2015-07-012020-12-31GlobalAll segmentsUSD 169 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Part of multi-year business optimization program initiated in H2 2015. 2017 charges included $59M employee termination costs, $6M asset impairments, and $5M other exit costs. Program expected to provide $975M annual pre-tax savings by end of 2020.
2017-12-31acquisition_additioncompleted2017-07-272017-07-27IndiaPharmaceuticalsUSD 629 (millions)business_combinations_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Acquisition of Claris Injectables Limited. Headcount not explicitly disclosed in filing.
2017-12-31restructuringin_progress2015-07-012020-12-31GlobalGlobalUSD 70 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Part of multi-year business optimization program initiated in H2 2015. 2017 charges included $59M employee termination costs, $6M asset impairments, and $5M other exit costs. Program expected to be substantially utilized by end of 2020.
2017-12-31acquisition_additioncompleted2017-07-272017-07-27GlobalAmericasbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of Claris Injectables Limited on July 27, 2017. Headcount not explicitly disclosed in filing.
2017-12-31restructuringin_progressUSD 70,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-12-31restructuringin_progressEmployee Severance [Member] / Global Workforce Reduction Program [Member]USD 59,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-12-31restructuringin_progressAsset Impairment Related To Facility Closing [Member]USD 6,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-12-31restructuringin_progressOther Restructuring [Member]USD 5,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-12-31restructuringin_progressCost Of Sales [Member] / Employee Severance [Member]USD 31,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-12-31restructuringin_progressSelling General And Administrative Expenses [Member] / Employee Severance [Member]USD 47,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-12-31restructuringin_progressEmployee Severance [Member]USD 78,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-12-31restructuringin_progressSelling General And Administrative Expenses [Member] / Contract Termination [Member]USD 5,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-12-31restructuringin_progressContract Termination [Member]USD 5,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-12-31restructuringin_progressCost Of Sales [Member] / Asset Impairment [Member]USD 5,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-12-31restructuringin_progressSelling General And Administrative Expenses [Member] / Asset Impairment [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-12-31restructuringin_progressAsset Impairment [Member]USD 6,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-12-31restructuringin_progressCost Of Sales [Member]USD 27,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-12-31restructuringin_progressSelling General And Administrative Expenses [Member]USD 45,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-12-31restructuringin_progressResearch And Development Expense [Member]USD -2,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-12-31restructuringin_progressSeverance And Other Employee Related Costs [Member]USD 83,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-09-30restructuringin_progress2015-07-012018-12-31GlobalEnterprise-wideUSD 116 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Cumulative pretax costs of $526M through 2017-09-30; expects ~$285M additional charges and $90M capex through end of 2018. No employee headcount disclosed. YTD 2017 charges include $50M restructuring, $58M implementation costs, $8M accelerated depreciation.
2017-09-30acquisition_additioncompleted2017-07-272017-07-27IndiaHospital Productsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquired 100% of Claris Injectables for ~$629M cash. No headcount added disclosed.
2017-09-30divestiture_reductioncompleted2017-06-302017-06-30VenezuelaCorporate / OtherUSD 33 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Deconsolidated Venezuelan operations effective 2017-06-30; $33M pre-tax charge recorded. No employee count disclosed.
2017-09-30plant_closurein_progress2018-12-31GlobalManufacturingrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Accelerated depreciation associated with facilities to be closed ($8M YTD 2017). Part of broader business optimization program; no specific facility closures or employee counts disclosed.
2017-09-30restructuringin_progress2018-12-31GlobalCorporate / UnallocatedUSD 52 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Q3 2017 charges of $52M related to business optimization initiatives, including $31M in employee termination costs and $21M in implementation costs. Program expected to complete by end of 2018.
2017-09-30restructuringin_progress2018-12-31GlobalCorporate / UnallocatedUSD 116 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		YTD 2017 charges of $116M related to business optimization initiatives, including $50M in net restructuring charges (primarily employee terminations) and $58M in implementation costs. Program expected to complete by end of 2018.
2017-09-30acquisition_additioncompleted2017-07-27GlobalHospital ProductsUSD 629 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Claris Injectables Limited completed July 27, 2017. Headcount not disclosed.
2017-09-30restructuringin_progressUSD 31,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-09-30restructuringin_progressCost Of Sales [Member] / Employee Severance [Member]USD 7,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-09-30restructuringin_progressSelling General And Administrative Expenses [Member] / Employee Severance [Member]USD 24,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-09-30restructuringin_progressEmployee Severance [Member]USD 31,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-09-30restructuringin_progressCost Of Sales [Member]USD 7,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-09-30restructuringin_progressSelling General And Administrative Expenses [Member]USD 24,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-09-30restructuringin_progressEmployee Severance [Member] / Cost Of Sales [Member]USD 21,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-09-30restructuringin_progressEmployee Severance [Member] / Selling General And Administrative Expenses [Member]USD 33,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-09-30restructuringin_progressContract Termination [Member] / Selling General And Administrative Expenses [Member]USD 5,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-09-30restructuringin_progressContract Termination [Member]USD 5,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-09-30restructuringin_progressAsset Impairment [Member] / Cost Of Sales [Member]USD 5,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-09-30restructuringin_progressAsset Impairment [Member]USD 5,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-09-30restructuringin_progressResearch And Development Expense [Member]USD -2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-09-30restructuringin_progressSeverance And Other Employee Related Costs [Member]USD 59,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-06-30restructuringin_progress2015-07-012018-12-31Company-wideUSD 35 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q2 2017 charges: $16M restructuring, $16M implementation, $3M accelerated depreciation. Program began H2 2015; $474M cumulative pretax costs through 2017-06-30, ~$335M additional expected through 2018. No employee counts disclosed.
2017-06-30acquisition_additioncompleted2017-07-27IndiaHospital ProductsUSD 625 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Claris Injectables Limited completed 2017-07-27 for ~$625M total consideration; headcount added not disclosed.
2017-06-30restructuringin_progress2018-12-31GlobalCorporate / All SegmentsUSD 35 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Q2 2017 charges included $16M restructuring (employee termination, contract termination, asset impairments), $16M implementation costs, and $3M accelerated depreciation. Program expected to complete by end of 2018.
2017-06-30restructuringin_progress2018-12-31GlobalCorporate / All SegmentsUSD 64 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		YTD 2017 charges included $19M net restructuring, $37M implementation costs, and $8M accelerated depreciation. Program expected to complete by end of 2018.
2017-06-30restructuringin_progressUSD 16,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-06-30restructuringin_progressCost Of Sales [Member] / Employee Severance [Member]USD 4,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-06-30restructuringin_progressSelling General And Administrative Expenses [Member] / Employee Severance [Member]USD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-06-30restructuringin_progressEmployee Severance [Member]USD 7,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-06-30restructuringin_progressSelling General And Administrative Expenses [Member] / Contract Termination [Member]USD 4,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-06-30restructuringin_progressContract Termination [Member]USD 4,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-06-30restructuringin_progressCost Of Sales [Member] / Asset Impairment [Member]USD 5,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-06-30restructuringin_progressAsset Impairment [Member]USD 5,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-06-30restructuringin_progressCost Of Sales [Member]USD 9,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-06-30restructuringin_progressSelling General And Administrative Expenses [Member]USD 7,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-06-30restructuringin_progressResearch And Development Expense [Member]USD -2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-06-30restructuringin_progressSeverance And Other Employee Related Costs [Member]USD 28,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-03-31restructuringin_progress2018-12-31GlobalCompany-wide (organization, manufacturing footprint, R&D, supply chain, support functions)USD 360 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Cumulative pretax costs of $439M incurred through 2017-03-31; additional ~$360M pretax costs and $90M capex expected through end of 2018, ~5% non-cash. Expected annual pretax savings ~$860M. No employee headcount affected disclosed.
2017-03-31divestiture_reductionin_progress2018-12-31Global (two remaining countries pending legal transfer)Baxalta separation — remaining operations not yet legally transferredother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Legal transfer of remaining two countries' operations expected by 2018; no headcount figures disclosed.
2017-03-31restructuringin_progress2018-12-31GlobalCorporate / All SegmentsUSD 29 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Part of ongoing business optimization initiatives initiated in H2 2015. Q1 2017 charges include $3M restructuring, $21M implementation costs, and $5M accelerated depreciation. Total expected additional pretax costs ~$360M through end of 2018.
2017-03-31restructuringin_progressUSD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-03-31restructuringin_progressCost Of Sales [Member] / Employee Severance [Member]USD 10,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-03-31restructuringin_progressSelling General And Administrative Expenses [Member] / Employee Severance [Member]USD 6,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-03-31restructuringin_progressEmployee Severance [Member]USD 16,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-03-31restructuringin_progressSelling General And Administrative Expenses [Member] / Contract Termination [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-03-31restructuringin_progressContract Termination [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-03-31restructuringin_progressCost Of Sales [Member]USD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-03-31restructuringin_progressSelling General And Administrative Expenses [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-03-31restructuringin_progressResearch And Development Expense [Member]USD -2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-03-31restructuringin_progressSeverance And Other Employee Related Costs [Member]USD 17,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-12-31restructuringin_progress20152018-12-31GlobalCompany-wide (cost of sales, marketing and administrative, R&D)USD 285 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Global cost-structure transformation program initiated in the second half of 2015; no employee headcount disclosed. FY2016 restructuring charges of $285M included net employee termination costs of $180M, primarily a global workforce reduction program, plus contract terminations and asset impairments. Total 2016 business optimization charges were $409M (also $65M implementation costs, $33M accelerated depreciation for facilities to be closed under manufacturing footprint rationalization, $26M Gambro integration). Cumulative program costs of $407M through December 31, 2016; roughly $390M additional costs and $90M capital expenditures expected by end of 2018; expected annual pretax savings approximately $860M. Restructuring reserves of $164M at year-end 2016 ($146M employee termination costs) to be substantially utilized by end of 2018. Figures reflect FY2016 activity within a multi-year program.
2016-12-31restructuringcompleted2016VIVIA home hemodialysis development program (Renal)USD 54 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Discontinuation of the VIVIA home hemodialysis development program recorded within FY2016 restructuring charges; comprises $21M contract termination costs, $31M asset impairments, and $2M other exit costs. The $54M is a component of the $285M FY2016 restructuring charges disclosed separately in the primary restructuring record.
2016-12-31restructuringin_progress20162017-12-31USD 125 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Additional business optimization programs recorded in 2016 beyond the transformational program; charges primarily employee termination costs, contract termination costs, asset impairments, and Gambro integration costs, approximately 40% non-cash. No additional costs expected; expected annual pretax savings of approximately $19M; programs substantially complete by end of 2017. No employee headcount disclosed.
2016-12-31restructuringin_progress2018-12-31GlobalCompany-wide (organization, manufacturing footprint, R&D and supply chain)USD 409 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Program initiated in second half of 2015; specific announcement date not disclosed. 2016 total business optimization charges of $409M comprised $285M restructuring (including $180M net employee termination costs under a global workforce reduction program), $65M implementation costs, $26M Gambro integration costs and $33M accelerated depreciation. Cumulative pretax costs of $407M for the transformation actions through 2016-12-31, with approximately $390M of additional pretax costs and $90M capital expenditures expected by end of 2018; expected annual pretax savings of approximately $860M. Restructuring reserves of $164M at 2016-12-31 ($146M employee termination), expected to be substantially utilized by end of 2018. Employees affected count not disclosed.
2016-12-31othercompletedRenal — VIVIA home hemodialysis development programUSD 54 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2016 restructuring charges for discontinuing the VIVIA home hemodialysis development program: $21M contract termination, $31M asset impairments, $2M other exit costs. Workforce impact not separately quantified.
2016-12-31divestiture_reductioncompleted2015-07-012016-06-03GlobalBaxalta Incorporated (biopharmaceuticals) — reported as discontinued operationsdiscontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Approximately 80.5% of Baxalta distributed to shareholders on 2015-07-01; remaining 19.5% interest disposed during 2016 through debt-for-equity exchanges, an equity-for-equity exchange and a pension-plan contribution; Baxalta became a Shire plc subsidiary on 2016-06-03. Associated headcount not disclosed in the filing.
2016-12-31acquisition_additionannounced2017-12-31Hospital Products — generic injectable medicines (anesthesia, analgesics, renal, anti-infectives, critical care)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement entered in December 2016 to acquire Claris Injectables Limited for total consideration of approximately $625M; expected to close in the second half of 2017 subject to regulatory approvals and achievement of a specified revenue target. Exact announcement date and headcount added not disclosed.
2016-12-31restructuringin_progress2015-07-012018-12-31GlobalAll segmentsUSD 409 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Initiated in second half of 2015. Cumulative pretax costs of $407 million incurred through Dec 31, 2016. Additional pretax costs of approx $390 million expected by end of 2018. Includes employee termination costs, implementation costs, and accelerated depreciation. No specific headcount disclosed.
2016-12-31restructuringin_progress2015-07-012018-12-31GlobalCorporate and Support FunctionsUSD 407 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Cumulative pretax costs of $407 million incurred through Dec 31, 2016 related to business optimization actions initiated in H2 2015. Includes employee termination, implementation, and accelerated depreciation. Expected to incur additional $390 million by end of 2018. Employee count not explicitly disclosed.
2016-12-31restructuringcompleted2016-01-012017-12-31GlobalVariousUSD 125 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Additional net business optimization charges of $125 million in 2016. Includes employee termination, contract termination, asset impairments, and Gambro integration costs. No additional costs anticipated.
2016-12-31restructuringin_progressUSD 285,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-12-31restructuringin_progressEmployee Severance [Member] / Global Workforce Reduction Program [Member]USD 180,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-12-31restructuringin_progressAsset Impairment [Member] / Renal [Member] / In Process Research And Development [Member]USD 27,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-12-31restructuringin_progressV I V I A Home Hemodialysis Development Program [Member]USD 54,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-12-31restructuringin_progressContract Termination [Member] / V I V I A Home Hemodialysis Development Program [Member]USD 21,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-12-31restructuringin_progressAsset Impairment [Member] / V I V I A Home Hemodialysis Development Program [Member]USD 31,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-12-31restructuringin_progressOther Restructuring [Member] / V I V I A Home Hemodialysis Development Program [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-12-31restructuringin_progressEmployee Severance [Member] / Cost Of Sales [Member]USD 72,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-12-31restructuringin_progressEmployee Severance [Member] / Selling General And Administrative Expenses [Member]USD 109,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-12-31restructuringin_progressEmployee Severance [Member] / Research And Development Expense [Member]USD 13,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-12-31restructuringin_progressEmployee Severance [Member]USD 194,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-12-31restructuringin_progressContract Termination [Member] / Cost Of Sales [Member]USD 9,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-12-31restructuringin_progressContract Termination [Member] / Selling General And Administrative Expenses [Member]USD 5,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-12-31restructuringin_progressContract Termination [Member] / Research And Development Expense [Member]USD 13,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-12-31restructuringin_progressContract Termination [Member]USD 27,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-12-31restructuringin_progressAsset Impairment [Member] / Cost Of Sales [Member]USD 38,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-12-31restructuringin_progressAsset Impairment [Member] / Research And Development Expense [Member]USD 40,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-12-31restructuringin_progressAsset Impairment [Member]USD 78,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-12-31restructuringin_progressCost Of Sales [Member]USD 118,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-12-31restructuringin_progressSelling General And Administrative Expenses [Member]USD 103,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-12-31restructuringin_progressResearch And Development Expense [Member]USD 64,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-12-31restructuringin_progressSeverance And Other Employee Related Costs [Member]USD 221,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-09-30restructuringin_progress2017-12-31GlobalCompany-wideUSD 101 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q3 2016 net employee termination costs of $101M, primarily a global workforce reduction program; no headcount disclosed. Restructuring reserves of $196M at 2016-09-30 include $171M employee termination costs, expected substantially utilized by end of 2017.
2016-09-30restructuringin_progress2017-12-31GlobalRenal — VIVIA home hemodialysis programUSD 54 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		YTD 2016 costs to discontinue VIVIA home hemodialysis development program: $21M contract termination, $31M asset impairments, $2M other exit costs; no employee count disclosed.
2016-09-30divestiture_reductionin_progress2015-07-012016-12-31GlobalBaxalta (biopharmaceuticals) — discontinued operationsother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Baxalta spin-off completed 2015-07-01; remaining operations expected to transfer to Baxalta in Q4 2016. No headcount figures disclosed.
2016-09-30restructuringin_progress2017-12-31GlobalGlobal workforce reductionUSD 101 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Q3 2016 net employee termination costs of $101 million primarily consisted of a global workforce reduction program. Expected to provide annual savings of $0.12 per diluted share when fully implemented by end of 2017.
2016-09-30restructuringcompletedRenalUSD 27 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Impairment of acquired in-process R&D intangible asset in Renal segment and in-center hemodialysis program.
2016-09-30restructuringcompletedRenalUSD 54 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Costs associated with discontinuance of VIVIA home hemodialysis development program (YTD 2016). Includes contract termination, asset impairments, and other exit costs.
2016-09-30restructuringin_progressUSD 237,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-09-30restructuringin_progressSelling, General and Administrative Expenses [Member]USD 85,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-09-30restructuringin_progressSelling, General and Administrative Expenses [Member] / Contract Termination [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-09-30restructuringin_progressSelling, General and Administrative Expenses [Member] / Employee Severance [Member]USD 94,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-09-30restructuringin_progressCost of Sales [Member]USD 88,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-09-30restructuringin_progressCost of Sales [Member] / Other Restructuring [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-09-30restructuringin_progressCost of Sales [Member] / Contract Termination [Member]USD 8,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-09-30restructuringin_progressCost of Sales [Member] / Employee Severance [Member]USD 51,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-09-30restructuringin_progressCost of Sales [Member] / Asset Impairment [Member]USD 28,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-09-30restructuringin_progressResearch and Development Expense [Member]USD 64,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-09-30restructuringin_progressResearch and Development Expense [Member] / Contract Termination [Member]USD 13,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-09-30restructuringin_progressResearch and Development Expense [Member] / Employee Severance [Member]USD 13,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-09-30restructuringin_progressResearch and Development Expense [Member] / Asset Impairment [Member]USD 40,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-09-30restructuringin_progressOther Restructuring [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-09-30restructuringin_progressOther Restructuring [Member] / VIVIA Home Hemodialysis Development Program [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-09-30restructuringin_progressContract Termination [Member]USD 23,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-09-30restructuringin_progressContract Termination [Member] / VIVIA Home Hemodialysis Development Program [Member]USD 21,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-09-30restructuringin_progressEmployee Severance [Member]USD 158,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-09-30restructuringin_progressAsset Impairment [Member]USD 68,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-09-30restructuringin_progressAsset Impairment [Member] / VIVIA Home Hemodialysis Development Program [Member]USD 31,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-09-30restructuringin_progressSeverance And Other Employee Related Costs [Member]USD 183,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-09-30restructuringin_progressVIVIA Home Hemodialysis Development Program [Member]USD 54,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-09-30restructuringin_progressIn Process Research and Development [Member] / Asset Impairment [Member] / Renal [Member]USD 27,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-09-30restructuringin_progressEmployee Severance [Member] / Global Workforce Reduction Program [Member]USD 101,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-06-30restructuringin_progress2016-12-31GlobalCorporate-wideUSD 103 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q2 2016 restructuring charges of $103M (employee termination, contract termination, asset impairment, other exit costs); no employee counts disclosed. Reserves expected substantially utilized by end of 2016.
2016-06-30restructuringin_progress2016-12-31GlobalRenalUSD 58 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Discontinuance of VIVIA home hemodialysis development program: $25M contract termination, $31M asset impairments, $2M other exit costs; no employee counts disclosed.
2016-06-30divestiture_reductionin_progress2015-07-012016-12-31GlobalBaxalta (discontinued operations)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Spin-off of Baxalta completed 2015-07-01; legal transfer of remaining net assets expected during 2016. No headcount figures disclosed.
2016-06-30restructuringin_progress2016-12-31GlobalVarious (Manufacturing, G&A, R&D)USD 103 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Includes $58M for discontinuance of VIVIA home hemodialysis program. Reserves expected to be substantially utilized by end of 2016.
2016-06-30restructuringin_progress2016-12-31GlobalVariousUSD 107 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		YTD restructuring charges for six months ended June 30, 2016. Includes employee termination costs of $54M.
2016-06-30restructuringin_progressUSD 107,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-06-30restructuringin_progressSelling, General and Administrative Expenses [Member]USD 4,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-06-30restructuringin_progressSelling, General and Administrative Expenses [Member] / Contract Termination [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-06-30restructuringin_progressSelling, General and Administrative Expenses [Member] / Employee Severance [Member]USD 10,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-06-30restructuringin_progressSelling, General and Administrative Expenses [Member] / Reserve Adjustments [Member]USD -8,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-06-30restructuringin_progressCost of Sales [Member]USD 64,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-06-30restructuringin_progressCost of Sales [Member] / Other Restructuring [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-06-30restructuringin_progressCost of Sales [Member] / Contract Termination [Member]USD 11,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-06-30restructuringin_progressCost of Sales [Member] / Employee Severance [Member]USD 30,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-06-30restructuringin_progressCost of Sales [Member] / Reserve Adjustments [Member]USD -1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-06-30restructuringin_progressCost of Sales [Member] / Asset Impairment [Member]USD 22,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-06-30restructuringin_progressResearch and Development Expense [Member]USD 39,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-06-30restructuringin_progressResearch and Development Expense [Member] / Contract Termination [Member]USD 14,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-06-30restructuringin_progressResearch and Development Expense [Member] / Employee Severance [Member]USD 14,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-06-30restructuringin_progressResearch and Development Expense [Member] / Reserve Adjustments [Member]USD -2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-06-30restructuringin_progressResearch and Development Expense [Member] / Asset Impairment [Member]USD 13,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-06-30restructuringin_progressOther Restructuring [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-06-30restructuringin_progressOther Restructuring [Member] / VIVIA Home Hemodialysis Development Program [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-06-30restructuringin_progressContract Termination [Member]USD 27,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-06-30restructuringin_progressContract Termination [Member] / VIVIA Home Hemodialysis Development Program [Member]USD 25,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-06-30restructuringin_progressEmployee Severance [Member]USD 54,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-06-30restructuringin_progressReserve Adjustments [Member]USD -11,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-06-30restructuringin_progressAsset Impairment [Member]USD 35,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-06-30restructuringin_progressAsset Impairment [Member] / VIVIA Home Hemodialysis Development Program [Member]USD 31,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-06-30restructuringin_progressSeverance And Other Employee Related Costs [Member]USD 83,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-06-30restructuringin_progressVIVIA Home Hemodialysis Development Program [Member]USD 58,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-03-31restructuringin_progress2016-12-31GlobalCorporate / Multiple segmentsUSD 15 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 2016 total business optimization charges of $15M, comprising $4M restructuring charges (net) and $11M implementation costs. Reserves of $111M at quarter-end, expected substantially utilized by end of 2016. No employee headcount disclosed.
2016-03-31restructuringin_progress2017-12-31GlobalCorporate / Multiple segmentsUSD 15 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Additional restructuring charges of $15M recorded in Q1 2016 for certain manufacturing efficiency programs; future savings of approximately $0.03 per diluted share expected through 2017. No employee headcount disclosed.
2016-03-31restructuringin_progress2016-12-31GlobalVarious (Manufacturing, G&A, R&D)USD 15 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Business optimization initiatives including employee termination costs ($15M gross charges, $11M reserve adjustments, net $4M charge) and implementation costs ($11M). Reserves expected to be substantially utilized by end of 2016.
2016-03-31restructuringin_progressUSD 4,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-03-31restructuringin_progressEmployee Severance [Member]USD 15,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-03-31restructuringin_progressResearch and Development Expense [Member] / Employee Severance [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-03-31restructuringin_progressSelling, General and Administrative Expenses [Member] / Employee Severance [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-03-31restructuringin_progressCost of Sales [Member] / Employee Severance [Member]USD 13,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-03-31restructuringin_progressSeverance And Other Employee Related Costs [Member]USD 15,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-03-31restructuringin_progressReserve Adjustments [Member]USD -11,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-03-31restructuringin_progressResearch and Development Expense [Member] / Reserve Adjustments [Member]USD -2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-03-31restructuringin_progressSelling, General and Administrative Expenses [Member] / Reserve Adjustments [Member]USD -8,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-03-31restructuringin_progressCost of Sales [Member] / Reserve Adjustments [Member]USD -1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-03-31restructuringin_progressResearch and Development Expense [Member]USD -1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-03-31restructuringin_progressSelling, General and Administrative Expenses [Member]USD -7,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-03-31restructuringin_progressCost of Sales [Member]USD 12,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-12-31divestiture_reductioncompleted2015-07-01GlobalBioPharmaceuticals (Baxalta Incorporated)discontinued_operations_footnote
f5-10k / GLM-5.3-flash-HTML		Spin-off completed July 1, 2015 via distribution of ~80.5% of Baxalta common stock. Note 2 provides the assets ($11.8B) and liabilities ($7.7B) distributed but discloses no headcount transferred to the spun-off business. Post-separation, Baxter reports ~50,000 employees.
2015-12-31restructuringin_progress2017GlobalMultiple: international operations, manufacturing facilities, G&A infrastructure, R&DUSD 130 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		2015 continuing-operations charges of $130M composed of $120M cash expenses and $42M non-cash expenses, less $32M reserve adjustments. Optimization reserves of $116M remain at year-end, expected to be substantially utilized by end of 2016, with full implementation through 2017 and anticipated savings of ~$0.16 per diluted share. Number of employees affected is not disclosed. A separate earlier 2012–2014 optimization tranche (with residual savings through 2016) is described but its 2015-specific activity is not separately quantified.
2015-12-31divestiture_reductioncompleted2015-07-012015-07-01GlobalBiopharmaceuticals (Baxalta)Item_1_Business
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Distribution of ~80.5% of Baxalta common stock to Baxter stockholders; Baxalta results reported as discontinued operations. No employee headcount transferred is quantified in the filing; local legal separation of Baxalta operations in certain countries remained incomplete at year-end under the ICOA.
2015-12-31restructuringin_progress2016-12-31GlobalCompany-wide (international operations, manufacturing, G&A, R&D)USD 130 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2015 charges of $130 million ($120M cash, $42M non-cash, $(32)M reserve adjustments) for streamlining international operations, rationalizing manufacturing facilities, reducing G&A infrastructure and re-aligning R&D. Employee counts affected are not disclosed; reserves expected to be substantially utilized by end of 2016, with savings of ~$0.16 per diluted share through 2017.
2015-12-31restructuringin_progressGlobalVariousUSD 130 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		In 2015, the company recorded charges of $130 million related to business optimization initiatives to streamline operations, rationalize manufacturing facilities, and enhance infrastructure. No specific employee count was disclosed for this action in the 10-K.
2015-12-31restructuringin_progress2017-12-31GlobalVariousUSD 130 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Company recorded charges of $130 million in 2015 for business optimization initiatives. Programs expected to be fully implemented through 2017. Specific employee count not disclosed.
2015-12-31restructuringin_progressUSD 130,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-12-31restructuringin_progressSeverance And Other Employee Related Costs [Member]USD 120,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-12-31restructuringin_progressResearch and Development Expense [Member]USD 13,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-12-31restructuringin_progressSelling, General and Administrative Expenses [Member]USD 79,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-12-31restructuringin_progressCost of Sales [Member]USD 38,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-09-30restructuringin_progress2016-12-31GlobalCorporate-wideUSD 74 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q3 2015 gross business optimization charges of $105M, of which $74M was severance and employee-related costs from a global workforce reduction program. No employee count disclosed. Reserves of $136M expected substantially utilized by end of 2016.
2015-09-30divestiture_reductioncompleted2015-07-012015-07-01GlobalBiopharmaceuticals (Baxalta)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Spin-off of Baxalta distributed ~80.5% of biopharmaceuticals business to Baxter shareholders. Baxalta operations reclassified to discontinued operations. No headcount figures disclosed for transferred employees.
2015-09-30restructuringin_progress2016-12-31GlobalGlobal workforce reductionUSD 74 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Q3 2015 gross business optimization charges of $105M, including $74M for severance/employee-related costs from global workforce reduction. Expected savings of $0.10 per diluted share through 2016.
2015-09-30restructuringin_progressUSD 102,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-09-30restructuringin_progressResearch and Development Expense [Member]USD 11,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-09-30restructuringin_progressSelling, General and Administrative Expenses [Member]USD 63,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-09-30restructuringin_progressCost of Sales [Member]USD 28,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-06-30restructuringin_progress2016-12-31GlobalBoth segments (BioScience and Medical Products); primarily severance and employee-related costsUSD 32 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Gross business optimization charges of $32M in first half of 2015; reserve balance of $122M at June 30, 2015, expected substantially utilized by end of 2016. No employee counts disclosed.
2015-06-30divestiture_reductioncompleted2015-07-01GlobalBiopharmaceuticals business (Baxalta Incorporated)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Distribution of approximately 80.5% of Baxalta common stock completed July 1, 2015; Baxalta results will be presented as discontinued operations starting Q3 2015. No headcount impact disclosed.
2015-06-30acquisition_additioncompleted2015-032015-03GermanyBioSciencebusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of SuppreMol GmbH for $228M cash net of cash acquired; no employee headcount added disclosed.
2015-06-30restructuringin_progress2016-12-31GlobalVarious (International operations, manufacturing, G&A, R&D)USD 3 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Business optimization initiatives recorded $3 million in charges for the six months ended June 30, 2015, primarily related to severance and employee-related costs. Expected savings of $0.02 per diluted share through 2016.
2015-06-30acquisition_additioncompleted2015-03-01GermanyBioScienceUSD 228 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of SuppreMol GmbH completed in March 2015. Headcount not explicitly disclosed.
2015-06-30restructuringin_progressUSD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-06-30restructuringin_progressResearch and Development Expense [Member]USD -3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-06-30restructuringin_progressSelling, General and Administrative Expenses [Member]USD 10,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-06-30restructuringin_progressCost of Sales [Member]USD -4,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-03-31restructuringin_progress2016-12-31GlobalCorporate / multiple segmentsUSD 18 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 2015 charges of $18M, primarily severance and employee-related costs, partly offset by a $29M downward revision of prior estimates; reserves of $127M expected substantially utilized by end of 2016. No employee count disclosed.
2015-03-31acquisition_additioncompletedGermanyBioSciencebusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of SuppreMol GmbH completed March 2015 for $228M cash; operations in Munich, Germany acquired. No headcount added disclosed.
2015-03-31restructuringin_progress2016-12-31GlobalCorporate / All SegmentsUSD 18 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Additional business optimization charges of $18 million primarily related to severance and employee-related costs. Reserves expected to be substantially utilized by end of 2016.
2015-03-31acquisition_additioncompleted2015-03-31GermanyBioScienceUSD 228 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of SuppreMol GmbH. Headcount not explicitly disclosed.
2015-03-31restructuringin_progressUSD 16,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-03-31restructuringin_progressResearch and Development Expense [Member]USD -6,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-03-31restructuringin_progressCost of Sales [Member]USD -7,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-03-31restructuringin_progressSelling, General and Administrative Expenses [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-03-31restructuringin_progressEmployee Severance [Member]USD 18,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-12-31restructuringin_progress2016-12-31GlobalCorporate / multiple segmentsUSD 83 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2014 business optimization charges of $83M gross ($27M net of $64M reserve releases), covering severance for the new Cambridge, Massachusetts R&D center and Gambro post-acquisition restructuring; programs expected substantially complete by end of 2016. No employee counts disclosed.
2014-12-31divestiture_reductioncompleted2014-07-012014-12-31GlobalBioScience — Vaccines franchisediscontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Sale of commercial vaccines business to Pfizer completed December 2014 ($639M proceeds, $417M after-tax gain); remainder of Vaccines franchise sale expected to close in Q1 2015. No headcount disclosed.
2014-12-31acquisition_additioncompleted2014-04-012014-04-30United StatesBioScience — gene therapybusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of all membership interests in Chatham Therapeutics, LLC; $70M initial payment plus contingent milestones. No headcount disclosed.
2014-12-31acquisition_additioncompleted2014-06-012014-06-30United StatesBioScience — sickle cell disease programbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of all membership interests in AesRx, LLC; $15M initial payment plus contingent milestones. No headcount disclosed.
2014-12-31otherannounced2014-03-012015-06-30GlobalCorporate — planned separation into two independent healthcare companiesUSD 167 (millions)Item_1_Business
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Tax-free distribution of >80% of biopharmaceuticals company stock announced March 2014, expected completion mid-2015; $167M separation-related costs recorded in FY2014. No workforce reduction quantified.
2014-12-31restructuringcompleted2014-01-012016-12-31GlobalVariousUSD 83 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Business optimization charges of $83 million recorded in 2014. Program expected to be fully implemented through 2016. Employee count not explicitly disclosed for this specific charge.
2014-12-31restructuringcompleted2014-01-012014-12-31GlobalVariousUSD 64 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Benefit of $64 million for business optimization reserves no longer probable of being utilized. Represents reversal of prior accruals.
2014-12-31restructuringin_progress2014-01-012016-12-31GlobalVariousUSD 83 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Business optimization charges of $83 million recorded in 2014. Program expected to be fully implemented through 2016. Employee count not disclosed.
2014-12-31acquisition_additioncompleted2013-09-062013-09-06GlobalMedical Productsbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of Gambro completed September 6, 2013. Employee count added not explicitly disclosed in filing.
2014-12-31restructuringin_progressUSD 19,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-12-31restructuringin_progressCash [Member]USD 87,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-12-31restructuringin_progressResearch and Development Expense [Member]USD 25,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-12-31restructuringin_progressCost of Sales [Member]USD -8,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-12-31restructuringin_progressSelling, General and Administrative Expenses [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-09-30restructuringin_progress2015-12-31GlobalCorporate / R&D (Cambridge, MA center) / Medical Products (Gambro integration)USD 61 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Nine-month 2014 charges of $61M (incl. $8M in discontinued operations) for severance and employee-related costs tied to forming a Cambridge, MA R&D center and Gambro post-acquisition restructuring; Q3 portion was $28M. No employee counts disclosed. Reserve of $221M at 2014-09-30, expected substantially utilized by end of 2015.
2014-09-30divestiture_reductionin_progress2014-07-012014-12-31GlobalBioScience — Vaccines franchiseother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Agreement to sell commercial vaccines business (NeisVac-C, FSME-IMMUN) entered July 2014, expected to close Q4 2014, plus plan to divest remainder of Vaccines franchise incl. R&D programs. No headcount impact disclosed; assets of $157M and liabilities of $15M classified held for sale at 2014-09-30.
2014-09-30otherin_progress2014-04-012016-03-31United StatesMedical Products — Fluid Systems (SIGMA Spectrum Infusion Pump)USD 93 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		FDA Class 1 recall field corrective action for SIGMA Spectrum Infusion Pump; $93M charge in first nine months of 2014 for remediation (software corrections, limited pump replacements), completion expected by March 2016. No workforce reduction quantified; remediation is product-focused rather than headcount-focused.
2014-09-30restructuringin_progress2015-12-31GlobalR&D, Manufacturing, G&AUSD 28 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges primarily include severance and employee-related costs associated with the formation of a new R&D center in Cambridge, Massachusetts and Gambro post-acquisition restructuring activities. Reserves expected to be substantially utilized by end of 2015.
2014-09-30restructuringin_progress2015-12-31GlobalR&D, Manufacturing, G&AUSD 61 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Nine months ended Sept 30, 2014 charges. Includes $8 million related to discontinued operations. Includes $37 million adjustment to previous charges no longer probable of being utilized.
2014-09-30restructuringin_progressCash [Member]USD 60,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-09-30restructuringin_progressEmployee Severance [Member]USD 61,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-09-30restructuringin_progressEmployee Severance [Member] / Discontinued Operations [Member]USD 8,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-06-30restructuringin_progress2015-12-31GlobalEnterprise-wideUSD 33 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Ongoing cost-structure optimization program; no employee counts disclosed. First-half 2014 charges of $33M per MD&A, offset by $37M of reserve adjustments no longer probable; reserve rollforward table shows $32M charges. Cash reserves of $215M at quarter-end, expected substantially utilized by end of 2015.
2014-06-30divestiture_reductionannounced2014-03-272015-06-30GlobalBioScience (biopharmaceuticals business)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Tax-free spin-off announced 2014-03-27, expected completion by mid-year 2015 subject to conditions; no workforce reduction figures disclosed. $22M of separation-related costs recorded in Q2 2014 within marketing and administrative expenses.
2014-06-30restructuringin_progress2015-12-31GlobalCorporate / Global OperationsUSD 4 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Business optimization initiatives resulted in a net benefit of $4 million for the six months ended June 30, 2014, primarily related to adjustments to previous reserves. Programs expected to be fully implemented in 2015.
2014-06-30otherin_progress2016-03-31United StatesMedical ProductsUSD 93 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Class 1 recall of SIGMA Spectrum Infusion Pump. Remediation includes software corrections and limited pump replacements. Charge of $93 million recorded for cash costs associated with remediation.
2014-06-30restructuringin_progressGlobalCorporateUSD 22 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Separation-related costs incurred for the planned spin-off of the biopharmaceuticals business.
2014-06-30restructuringin_progressCash [Member]USD -32,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-06-30restructuringin_progressEmployee Severance [Member]USD 33,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-03-31restructuringin_progress2015-12-31GlobalCompany-wide (includes Gambro post-acquisition restructuring)USD 28 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 2014 business optimization charge of $28M, primarily severance and employee-related costs, including Gambro post-acquisition restructuring. No employee count disclosed. Reserves expected substantially utilized by end of 2015.
2014-03-31acquisition_additioncompleted2013-09-062013-09-06Sweden (global operations)Medical Products — Renalbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Gambro acquisition closed September 6, 2013; Q1 2014 reflects measurement period adjustments. No headcount added through the acquisition is disclosed in this filing.
2014-03-31divestiture_reductioncompletedMedical Products — Renal (legacy CRRT business)USD 17 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 2014 loss of $17M on divestiture of Baxter's legacy Continuous Renal Replacement Therapy (CRRT) business, part of $34M total Gambro integration charges. No workforce impact quantified.
2014-03-31otherannounced2014-03-272015-06-30GlobalBiopharmaceuticals business (planned spin-off)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Announced March 27, 2014: tax-free spin-off creating two independent healthcare companies, expected completion by mid-year 2015. No workforce impact quantified; subsequent to separation, biopharmaceuticals results will be presented as discontinued operations.
2014-03-31restructuringin_progress2014-01-012015-12-31GlobalVariousUSD 28 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges primarily related to severance and employee-related costs, inclusive of Gambro post-acquisition restructuring activities. Reserves expected to be substantially utilized by end of 2015.
2013-12-31acquisition_additioncompleted2013-09-06Global (Gambro headquartered in Lund, Sweden)Medical Products — Renal franchisebusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquired Indap Holding AB, holding company for Gambro AB, on 2013-09-06 for $3.7 billion cash consideration (net of assumed debt of $221 million). Filing does not disclose Gambro employee headcount. 2013 Gambro acquisition and integration charges of $192 million pre-tax (including $101 million acquisition-related costs) were recorded; Gambro post-acquisition restructuring activities were folded into the company's business optimization program.
2013-12-31restructuringin_progress2015-12-31Global; severance-related cash costs principally in Europe and the United StatesCompany-wide; benefits both BioScience and Medical Products segmentsUSD 314 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		2013 business optimization charges of $314 million pre-tax include Gambro post-acquisition restructuring activities and severance plus non-cash impairment losses from discontinuing certain Vaccines R&D programs; components recorded were $145 million in cost of sales, $96 million in marketing and administrative expenses, and $73 million in R&D. Cash costs of $182 million were principally severance and other employee-related costs in Europe and the United States. The MD&A special-items table separately identifies $280 million of business optimization charges (excluding the Gambro post-acquisition restructuring component). Program expected fully implemented in 2015 with estimated annualized savings of about $0.17 per diluted share; reserves expected substantially utilized by end of 2015. Number of employees affected is not disclosed.
2013-12-31restructuringin_progress2015-12-31International operations, including Europe and the United StatesCompany-wide (BioScience and Medical Products); includes discontinued Vaccines R&D programs and Gambro post-acquisition restructuringUSD 314 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Multi-year business optimization program; only FY2013 activity captured. Note 6 reports total 2013 charges of $314M (incl. $182M cash severance costs and $132M asset impairments); MD&A special-items table cites a $280M pre-tax business optimization charge. Employees affected not disclosed. Reserves expected substantially utilized by end of 2015.
2013-12-31acquisition_additioncompleted2013-09-062013-09-06Sweden (global operations)Medical Products — Renal franchiseUSD 3,700 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Total cash consideration of $3.7B for Gambro AB; acquired headcount not disclosed. Gambro represented approximately 18% of consolidated total assets at year-end.
2013-12-31acquisition_additioncompleted2013-03-312013-03-31United StatesBioScience — Hemophilia (OBI-1 compound and manufacturing operations)USD 51 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Upfront cash payment of $51M plus $269M estimated fair value of contingent payments; acquired headcount not disclosed. Exact closing day not stated in filing.
2013-12-31restructuringin_progress2013-01-012015-12-31GlobalBioScience and Medical ProductsUSD 280 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Pre-tax business optimization charges of $280 million recorded in 2013. Includes severance costs, asset impairments, and contract terminations. Program expected to yield annualized savings of approximately $0.17 per diluted share when fully implemented in 2015.
2013-12-31acquisition_additioncompleted2013-09-062013-09-06GlobalMedical ProductsItem 1. Business
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Acquisition of Gambro AB completed in September 2013. Enhanced Medical Products business portfolio. Specific headcount added not disclosed.
2013-12-31restructuringin_progress2013-01-012015-12-31GlobalAll segmentsUSD 280 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Pre-tax business optimization charges of $280 million recorded in 2013. Program expected to yield annualized savings when fully implemented in 2015. Includes severance and asset impairments.
2013-12-31acquisition_additioncompleted2013-09-062013-09-06GlobalMedical Productsbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Acquired 100% of Gambro AB on September 6, 2013. Employee count added not explicitly disclosed in filing.
2013-12-31restructuringin_progressUSD 314,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-09-30acquisition_additioncompleted2013-09-062013-09-06Global (headquartered in Lund, Sweden)Medical Products (Renal franchise)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Baxter acquired 100% of Gambro AB for $3.7B cash. No employee headcount added disclosed.
2013-09-30restructuringin_progress2014-12-31GlobalCorporate-wideUSD 32 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Business optimization program charges of $32M in first nine months 2013; reserves expected substantially utilized by end of 2014. No employee count disclosed.
2013-09-30restructuringcompletedNot specifiedR&D (Alzheimer's disease program)USD 18 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q2 2013 charge for contract termination and exit costs from discontinuing Alzheimer's program. No employee count disclosed.
2013-09-30restructuringin_progress2013-09-06GlobalMedical Products (Gambro integration)USD 14 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q3 2013 post-acquisition restructuring charge related to Gambro integration. No employee count disclosed.
2013-09-30restructuringcompletedUSD 14 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Charge related to post-acquisition restructuring activities in connection with the Gambro acquisition.
2013-09-30restructuringcompletedResearch and DevelopmentUSD 18 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Charge recorded in Q2 2013 related to contract termination and other exit costs associated with the discontinuation of the Alzheimer's disease program.
2013-06-30restructuringin_progress20092014-12-31GlobalCompany-wideUSD 42 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Ongoing global cost-structure program; $42M reserve utilization in H1 2013, $180M reserve remaining at quarter-end. No employee counts disclosed.
2013-06-30restructuringcompleted2013-04-012013-06-30GlobalResearch and DevelopmentUSD 18 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q2 2013 charge for contract termination and exit costs from discontinuing the Alzheimer's program; no employee count disclosed.
2013-06-30acquisition_additionannounced2012-12-312013-09-30Sweden (global operations)Medical Products — Renalother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to acquire Gambro AB for approximately $4 billion; expected to close Q3 2013 subject to regulatory approvals. No headcount disclosed.
2013-03-31restructuringin_progress2014-12-31Global (primarily Europe and United States)Company-wide (cost structure optimization)USD 19 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Ongoing program; $19M reserve utilization in Q1 2013; reserves of $202M at quarter-end expected substantially utilized by end of 2014. No employee count disclosed.
2013-03-31acquisition_additioncompleted2013-03-012013-03-31United StatesBioScienceUSD 51 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of OBI-1 compound and manufacturing operations; $51M upfront plus up to $135M contingent milestones. No headcount added disclosed.
2013-03-31acquisition_additionannounced2012-12-012013-06-30Sweden (global)Medical Products (Renal)USD 4,000 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Planned acquisition of Gambro AB for approximately $4 billion; expected to close end of Q2 2013. No headcount addition disclosed.
2012-12-31restructuringin_progress2014-12-31Global; severance and other employee-related cash costs principally in Europe and the United StatesCorporate level, not allocated to segments; covers streamlining international operations, rationalizing manufacturing facilities, enhancing G&A infrastructure, and re-aligning R&D activitiesUSD 150 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Multi-year global cost-optimization program (pre-tax charges: $257M in 2010, $192M in 2011, $150M in 2012); only FY2012 activity captured per extraction rules. FY2012 charge split: $98M cash costs principally severance and employee-related (Europe/US) and $52M asset impairments/contract terminations; recorded $62M in cost of sales, $60M in marketing and administrative expenses, $28M in R&D. Cash severance reserve rolled from $225M (start of 2012) to $220M (end of 2012) after a $98M charge, $99M utilization, and $4M CTA. Reserves expected to be substantially utilized by end of 2014, used here as the completion timeline; no explicit program completion date and no affected-employee headcount disclosed.
2012-12-31othercompleted16,0002012-08-312012-12-31United StatesU.S. pension plan — terminated-vested participants (former employees)USD 164 (millions)other
f5-10k / GLM-5.3-flash-HTML		Pension de-risking action, not an active-workforce reduction: a voluntary one-time lump-sum offer to settle pension obligations for approximately 16,000 terminated-vested (former employee) participants in the U.S. plan. Acceptance was approximately 50 percent, producing a final payout of $377 million from plan assets in December 2012. A $164 million non-cash settlement charge was recognized in Q4 2012 to expense previously deferred actuarial losses (total 2012 pension settlement charges reported as $168 million in Note 14/cash flow statement). Did not reduce active workforce headcount, hence no percent-of-workforce figure.
2012-12-31restructuringin_progress2014-12-31GlobalCorporateUSD 150 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2012 charge of $150M for global cost-structure optimization, including $98M cash severance costs and $52M asset impairments/contract terminations; covers international streamlining, manufacturing rationalization, G&A infrastructure and R&D re-alignment. Reserves expected substantially utilized by end of 2014. Employees affected not disclosed.
2012-12-31voluntary_separationcompleted16,0002012-08-312012-12-31United StatesCorporateUSD 164 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		One-time lump-sum offer to approximately 16,000 terminated-vested U.S. pension participants to settle plan obligations; final acceptance rate approximately 50%, resulting in a $377M payout from plan assets in December 2012. Charge shown is the non-cash settlement charge recorded in Q4 2012.
2012-12-31acquisition_additioncompleted2012-02-01United StatesBioScienceUSD 304 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Synovis Life Technologies, Inc. completed February 2012; consideration $304M cash net of cash acquired. Headcount added not disclosed.
2012-12-31acquisition_additionannounced2012-12-012013-06-30Sweden / GlobalMedical Products (Renal)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement announced December 2012 to acquire Gambro AB for approximately $4B including pre-acquisition debt; expected to close end of Q2 2013 subject to regulatory approvals. Headcount added not disclosed. Announcement date stated only as month (December 2012).
2012-12-31acquisition_additionannounced2013-01-01United StatesBioScienceUSD 50 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		January 2013 agreement to acquire OBI-1 assets and manufacturing operations; $50M upfront plus up to $20M regulatory milestones and sales-based payments. Subject to FTC review. Headcount added not disclosed. Announcement date stated only as month (January 2013).
2012-12-31restructuringcompletedGlobalVariousUSD 150 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Business optimization charges of $150 million recorded in 2012 related to streamlining international operations, rationalizing manufacturing facilities, improving general and administrative infrastructure, and re-aligning R&D activities. Includes severance costs and asset impairments.
2012-12-31restructuringin_progress2012-01-012014-12-31GlobalGlobalUSD 150 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Pre-tax business optimization charges of $150 million recorded in 2012. Reserves expected to be substantially utilized by end of 2014. Employee count not explicitly disclosed for 2012 actions.
2012-12-31voluntary_separationcompleted2012-08-312012-12-31United StatesPension Plan ParticipantsUSD 164 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Offer of lump-sum payment to terminated-vested participants in U.S. pension plan. Approximately 50% acceptance rate. $164 million non-cash settlement charge recorded.
2012-12-31restructuringin_progressUSD 150,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2012-06-30restructuringin_progress2013-12-31GlobalCorporate / multiplerestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Ongoing cost-structure optimization program since 2009; $47M cash reserve utilization in H1 2012; $170M reserve remaining at quarter-end; no employee count disclosed.
2012-06-30acquisition_additioncompleted2012-02-012012-02-29United StatesBioSciencebusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Synovis completed February 2012 for $304M total consideration; no headcount added disclosed.
2012-06-30acquisition_additioncompleted2012-04-012012-04-30United StatesMedical Productsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Exercise of option to purchase remaining SIGMA equity for $90M cash; treated as equity transaction; no headcount disclosed.
2012-06-30acquisition_additioncompleted2012-04-012012-06-30FranceMedical Productsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of remaining equity of Laboratoire Fasonut (French parenteral nutrition company); $19M goodwill added; no headcount disclosed.
2012-03-31acquisition_additioncompleted2012-02-01United StatesBioScienceUSD 304 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquired Synovis Life Technologies at $28 per share; total consideration net of acquired cash was $304 million. No headcount added disclosed.
2012-03-31restructuringin_progress2013-12-31Global (primarily Europe and United States)Corporate-wide cost structure optimizationUSD 196 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Business optimization program: $409M cash charges 2009-2011 (severance and employee-related costs), $27M reserve utilization in Q1 2012, $196M reserve remaining at 2012-03-31; expected substantially utilized by end of 2013. No employee counts disclosed.
2012-03-31acquisition_additionannounced2012-04-01United StatesMedical Products (Infusion Systems)USD 90 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		April 2012 exercise of option to purchase remaining equity of SIGMA for $90 million cash; SIGMA already consolidated since 2009 40% stake. No headcount disclosed; not expected to materially affect 2012 results.
2012-03-31restructuringin_progress2012-07-31United StatesMedical Productsrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		FDA order requiring recall of approx. 200,000 COLLEAGUE infusion pumps; company offering replacement pumps or monetary consideration. Completion expected by July 2012. No specific employee count disclosed for this recall execution.
2012-03-31restructuringin_progress2013-12-31GlobalCorporaterestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Ongoing business optimization initiatives including severance and employee-related costs. Reserves expected to be substantially utilized by end of 2013. No specific employee count disclosed for Q1 2012 activity.
2011-12-31restructuringin_progress2013-12-31Global; severance and employee-related cash costs principally in Europe and the United StatesCorporate-level business optimization — streamlining international operations, rationalizing manufacturing facilities, and enhancing general and administrative infrastructure; charges not allocated to a segmentUSD 192 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		2011 pre-tax charge of $192 million ($95 million in cost of sales, $97 million in marketing and administrative expenses), comprising $156 million cash costs principally for severance and employee-related costs plus $36 million of asset impairments and contract terminations. Multi-year program also generated charges of $79 million in 2009 and $257 million in 2010 (comparatives not extracted). Severance reserves totaled $225 million at December 31, 2011, expected to be substantially utilized by the end of 2013. Employee counts affected were not disclosed.
2011-12-31divestiture_reductioncompleted2011-05United StatesMedical Products — U.S. multi-source generic injectables businessdiscontinued_operations_footnote
f5-10k / GLM-5.3-flash-HTML		Divestiture of the U.S. multi-source generic injectables business to Hikma Pharmaceuticals completed in May 2011 for $104 million of consideration after closing adjustments, covering vial/ampoule generic products, a Cherry Hill, New Jersey manufacturing facility, and a Memphis, Tennessee distribution center. The related $112 million impairment charge was recorded in Q3 2010, prior to this fiscal year. Employee headcount transferred was not disclosed.
2011-12-31acquisition_additioncompleted2011-05United StatesMedical Products — premixed drug solutions (NEXTERONE amiodarone HCl)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquired privately-held Prism Pharmaceuticals in May 2011 for a $170 million upfront cash payment plus contingent sales-milestone payments of up to $168 million through 2017; total consideration valued at $237 million. Employee headcount added through the acquisition was not disclosed.
2011-12-31acquisition_additioncompleted2011-11United StatesMedical Products — fluid medication preparation, handling, packaging and administration devices (Baxa)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquired privately-held Baxa Corporation in November 2011 for a $360 million cash purchase price (adjusted for closing-date cash); complements Baxter's nutrition and drug delivery systems portfolio. Employee headcount added through the acquisition was not disclosed.
2011-12-31acquisition_additioncompleted2011-122012-02United StatesBioScience — regenerative medicine (soft tissue repair products)subsequent_events
f5-10k / GLM-5.3-flash-HTML		Definitive agreement signed December 2011 to acquire publicly-traded Synovis Life Technologies at $28 per share, approximately $325 million ($260 million net of cash acquired); acquisition completed in February 2012, after fiscal year-end but before the filing date. Employee headcount added through the acquisition was not disclosed.
2011-12-31restructuringin_progress2013-12-31Global (charges principally related to Europe and United States severance)Corporate-level; streamlining international operations, manufacturing rationalization, G&A infrastructureUSD 192 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2011 charge under multi-year business optimization program; $156M of the 2011 charge was cash costs (severance and other employee-related costs), $36M was asset impairments/contract terminations. Reserve of $225M at 2011-12-31, expected substantially utilized by end of 2013. Employees affected not disclosed.
2011-12-31divestiture_reductioncompleted2011-05-31United States (Cherry Hill, New Jersey manufacturing facility; Memphis, Tennessee warehouse/distribution center)Medical Products — Global Injectables (U.S. multi-source generic injectables business)discontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Divestiture to Hikma Pharmaceuticals completed May 2011 for $104M consideration; a $112M impairment charge had been recorded in Q3 2010. Headcount associated with the divested business not disclosed.
2011-12-31acquisition_additioncompleted2011-05-31United StatesMedical Products — Global Injectables (premixed drugs, NEXTERONE)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of privately-held Prism Pharmaceuticals completed May 2011; total consideration valued at $237M. Employees added not disclosed.
2011-12-31acquisition_additioncompleted2011-11-30United StatesMedical Products — IV Therapies / pharmacy automation devicesbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of privately-held Baxa Corporation completed November 2011; cash payment of $360M. Employees added not disclosed.
2011-12-31acquisition_additioncompleted2011-06-30United StatesMedical Products — home hemodialysis (HHD/DEKA collaboration)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Exercise of $25M option (purchased 2007) to acquire assets of HHD, LLC in June 2011; payment recorded to goodwill. Employees added not disclosed.
2011-12-31acquisition_additioncompleted2011-12-312012-02-29United StatesBioScience — Regenerative Medicine / soft tissue repairsubsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement entered December 2011; acquisition of Synovis Life Technologies completed February 2012 at $28 per share (~$325M, ~$260M net of cash). Employees added not disclosed.
2011-12-31restructuringin_progressGlobalGlobalUSD 192 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Pre-tax business optimization charges of $192 million recorded in 2011. Includes severance costs, asset impairments, and contract terminations. Employee count not explicitly disclosed.
2011-12-31restructuringin_progress2011-01-012013-12-31GlobalCorporate / All SegmentsUSD 192 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Pre-tax business optimization charges of $192 million recorded in 2011. Includes $156 million in cash costs (severance) and $36 million in asset impairments. Reserves expected to be substantially utilized by end of 2013. Employee count not explicitly disclosed for 2011 action.
2011-09-30restructuringin_progress2012-12-31Global (primarily Europe and United States)Corporate-wide cost structure optimizationrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Ongoing business optimization program; original charges of $257M (2010) and $79M (2009) covering severance, asset impairments and contract terminations. Reserve utilization of $83M during the first nine months of 2011 left $97M reserves at 2011-09-30; company expects reserves substantially utilized by end of 2012. Number of employees affected is not disclosed in this filing.
2011-09-30restructuringin_progress2012-12-31GlobalGlobalUSD 253 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Reserves of $97 million remain as of Sept 30, 2011, expected to be substantially utilized by end of 2012. Original charges in 2009/2010 included $253 million in cash costs principally pertaining to severance.
2011-09-30acquisition_additioncompleted2011-05-01United StatesMedical ProductsUSD 170 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Prism Pharmaceuticals, Inc. completed in May 2011. Upfront cash payment of $170 million. Employee count not disclosed.
2011-09-30divestiture_reductioncompletedUnited StatesMedical ProductsUSD 104 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Divestiture of U.S. multi-source generic injectables business to Hikma Pharmaceuticals PLC completed in May 2011. Consideration totaled $104 million. Employee count not disclosed.
2011-06-30restructuringin_progress20102011-12-31GlobalCorporate-wide (cost structure optimization)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Ongoing global cost-structure program; charges of $257M (2010) and $79M (2009) included severance and asset impairments. Reserve utilization of $57M in the six months ended 2011-06-30 left $128M remaining; company expects reserves substantially utilized by end of 2011. Number of employees affected not disclosed.
2011-06-30acquisition_additioncompleted2011-052011-05-31Medical Productsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of privately held Prism Pharmaceuticals completed May 2011; total consideration up to $338M ($170M upfront cash plus up to $168M contingent). Headcount added through the acquisition not disclosed.
2011-06-30divestiture_reductioncompleted2011-052011-05-31United StatesMedical Products — U.S. generic injectablesother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Divestiture of U.S. generic injectables business to Hikma completed May 2011 for $104M, including a Cherry Hill, NJ manufacturing facility and a Memphis, TN warehouse/distribution center. Employees removed not disclosed.
2011-06-30restructuringin_progress2011-12-31GlobalGlobalUSD 128 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Reserves as of June 30, 2011 were $128 million. Company expects reserves to be substantially utilized by end of 2011. Charges relate to optimizing cost structure, streamlining international operations, and rationalizing manufacturing facilities.
2011-06-30divestiture_reductioncompleted2011-05-31United StatesMedical Productsbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Completed divestiture of U.S. generic injectables business to Hikma Pharmaceuticals PLC in May 2011. Consideration totaled $104 million. Employee count not disclosed.
2011-03-31restructuringin_progressGlobalCorporate / Global Operationsrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Company recorded charges in 2010 and 2009 primarily related to optimizing global cost structure, streamlining international operations, and rationalizing manufacturing facilities. Charges included severance costs. No specific employee count disclosed for current quarter activity.
2011-03-31divestiture_reductioncompleted2011-05-31United StatesMedical Productssubsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Completed divestiture of U.S. generic injectables business to Hikma Pharmaceuticals PLC in May 2011. Consideration approx $112 million. Includes manufacturing facility in Cherry Hill, NJ and warehouse in Memphis, TN. Employee count not disclosed.
2010-12-31restructuringin_progress20102011-12-31Global (cash severance and employee-related costs principally in Europe and the United States)Corporate (not allocated to reportable segments)USD 257 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Global business optimization: streamlining international operations, rationalizing manufacturing facilities and enhancing G&A infrastructure. Pre-tax charge of $257M recorded in 2010 (of which $132M in cost of sales and $125M in marketing and administrative expenses), including cash costs of $184M principally severance and other employee-related costs; reserve of $180M at December 31, 2010 expected to be substantially utilized by end of 2011. Number of employees affected not disclosed. Follows a separate $79M charge under the same initiative in 2009; only 2010 activity captured here.
2010-12-31divestiture_reductionannounced7502010-10United StatesMedication Delivery — U.S. generic injectables businessUSD 112 (millions)discontinued_operations_footnote
f5-10k / GLM-5.3-flash-HTML		October 2010 definitive agreement to divest the U.S. generic injectables business to Hikma Pharmaceuticals PLC (vials/ampoule products, Cherry Hill NJ manufacturing facility and Memphis TN distribution center); approximately 750 employees will transfer with the transaction. Pre-tax impairment charge of $112M (principally PP&E and intangibles) recorded on the divestiture agreement; consideration also approximately $112M subject to closing adjustments. Transaction subject to customary closing conditions including regulatory approvals; business had net sales of $198M in 2010.
2010-12-31restructuringin_progress20102011-12-31Global (charges principally in Europe and the United States)Corporate — international operations streamlining, manufacturing rationalization, G&A infrastructureUSD 257 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2010 charge of $257M, including $184M cash costs (severance and other employee-related costs) and $73M asset impairments; $132M in cost of sales and $125M in marketing and administrative expenses. Reserve of $180M expected to be substantially utilized by end of 2011. Employees affected not disclosed; charges recorded at corporate level, not allocated to a segment.
2010-12-31divestiture_reductionannounced7502010-10United States (Cherry Hill, New Jersey; Memphis, Tennessee)Medication Delivery — U.S. generic injectables businessUSD 112 (millions)discontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to divest U.S. generic injectables to Hikma Pharmaceuticals; approximately 750 employees to transfer with the transaction. Subject to customary closing conditions including regulatory approvals. Associated $112M charge is an impairment of PP&E and intangibles, not severance.
2010-12-31acquisition_additioncompleted2010-03United Kingdom (with facilities in the United States and Germany)BioScience — regenerative medicine / orthobiologicsbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of ApaTech Limited; total purchase price up to $337M ($247M up-front plus up to $90M contingent). Headcount added not disclosed.
2010-12-31acquisition_additioncompleted2010-12United States / United KingdomBioScience — hemophilia program (Archemix assets, ARC19499)USD 34 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of hemophilia-related assets and exclusive license; $30M up-front recognized as IPR&D expense (IPR&D charge of $34M in 2010), with contingent payments of up to $285M. Asset/technology deal; headcount added not disclosed.
2010-12-31divestiture_reductioncompleted2010AustraliaRenal — Renal Therapy Services centersMD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2010 investing cash inflows principally from divestiture of certain Renal Therapy Services centers in Australia; employees affected not disclosed.
2010-12-31restructuringin_progress2010GlobalCorporate / All SegmentsUSD 257 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Business optimization charge of $257 million recorded in 2010 related to streamlining international operations, rationalizing manufacturing facilities, and enhancing general and administrative infrastructure. Includes severance costs, asset impairments, and contract terminations. Employee count not explicitly disclosed in aggregate for this specific charge, though divestiture below mentions 750 employees.
2010-12-31divestiture_reductionannounced7502010-10United StatesMedication DeliveryUSD 112 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Agreement to divest U.S. generic injectables business to Hikma Pharmaceuticals PLC announced in October 2010. Approximately 750 employees to transfer as part of the transaction. $112 million impairment charge recorded.
2010-12-31restructuringin_progress20102011-12-31GlobalCorporateUSD 257 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		2010 business optimization charge of $257 million. Reserves expected to be substantially utilized by end of 2011. Employee count not explicitly disclosed in footnote.
2010-12-31divestiture_reductionannounced7502010-10United StatesMedication DeliveryUSD 112 (millions)discontinued_operations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Agreement to divest U.S. generic injectables business. Approximately 750 employees to transfer as part of the transaction. $112 million impairment charge recorded.
2010-09-30divestiture_reductionannounced7502010-10-29United StatesMedication Delivery — U.S. generic injectables businessUSD 112 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Post-quarter definitive agreement (Oct 29, 2010) to sell the U.S. generic injectables business to Hikma Pharmaceuticals; approximately 750 employees transfer with the Cherry Hill, NJ manufacturing facility and Memphis, TN distribution center. The $112M charge is an asset impairment (PP&E and intangibles), not a severance charge. Closing expected within a few months of the announcement; no exact completion date disclosed.
2010-09-30divestiture_reductionannounced7502010-10-29United StatesMedication DeliveryUSD 112 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Agreement to divest U.S. generic injectables business to Hikma; 750 employees to transfer.
2010-09-30restructuringin_progress2009-12-312010-12-31GlobalCorporateUSD 69 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2009 Cost Optimization Charge; $69M cash costs principally pertaining to severance. Reserves expected substantially utilized by end of 2010.
2010-06-30acquisition_additioncompleted2010-03United Kingdom (targets in UK, US, Germany)BioSciencebusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Baxter acquired ApaTech Limited in March 2010; total purchase price up to $337 million ($247 million up-front plus up to $90 million contingent). No headcount added disclosed.
2010-06-30restructuringin_progress20092010-12-31GlobalCorporate (global cost structure optimization)USD 69 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Charge of $79 million recorded in Q4 2009 ($30M cost of sales, $49M marketing and administrative), including $69 million of cash costs principally severance and employee-related costs; $29 million of the cash reserve utilized through 2010-06-30. No employee count disclosed; reserves expected substantially utilized by end of 2010.
2010-06-30restructuringin_progress2009-10-012010-12-31GlobalCorporate / GlobalUSD 79 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2009 Cost Optimization Charge recorded in Q4 2009. Includes $10M asset impairments and $69M cash costs (principally severance). Reserves expected to be substantially utilized by end of 2010.
2010-06-30restructuringin_progress2007-03-012010-12-31GlobalTransfusion TherapiesUSD 35 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charge recorded in Q1 2007 in connection with divestiture of Transfusion Therapies business. Principally associated with severance and other employee-related costs. Reserves expected to be substantially utilized by end of 2010.
2010-03-31acquisition_additioncompleted2010-03-31United KingdomBioScienceUSD 335 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Baxter acquired ApaTech Limited in March 2010; total purchase price up to $335M. No employee headcount for the acquired workforce was disclosed.
2010-03-31restructuringin_progress2009-12-312010-12-31GlobalCorporateUSD 79 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Charge recorded in Q4 2009 for global cost optimization; includes $69M cash costs principally for severance. Cash reserve utilization of $16M through March 31, 2010. No employee count disclosed. Company expects reserves substantially utilized by end of 2010.
2010-03-31restructuringin_progress2009-10-012010-12-31GlobalCorporate / Global OperationsUSD 79 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2009 Cost Optimization Charge recorded in Q4 2009. Includes $69M cash costs principally pertaining to severance and other employee-related costs. Company expects reserves substantially utilized by end of 2010.
2010-03-31restructuringin_progress2007-03-012010-12-31GlobalTransfusion TherapiesUSD 35 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charge recorded in connection with divestiture of Transfusion Therapies business in Q1 2007. Principally associated with severance and other employee-related costs. Company expects reserves substantially utilized by end of 2010.
2009-12-31restructuringin_progress2%2009-122010-12-31GlobalCorporate (not allocated to segments)USD 79 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Percent shown is an upper bound only: severance-related costs covered elimination of less than 2% of the workforce. Charge comprised $69 million of cash costs (principally severance and other employee-related costs) and $10 million of asset impairments tied to discontinued insignificant products and projects; $30 million recorded in cost of sales and $49 million in marketing and administrative expenses. Reserve utilization was $5 million through year-end 2009, with substantial utilization expected by end of 2010. Charge recognized in Q4 2009; exact announcement date not disclosed.
2009-12-31acquisition_additioncompleted2009-04Medication Deliverybusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Exclusive three-year distribution agreement with Sigma International General Medical Apparatus, LLC (SIGMA), a 40% equity stake and a purchase option for the remainder, with a $100 million up-front payment; Baxter consolidated SIGMA from April 2009. Employee headcount added through the consolidation was not disclosed.
2009-12-31acquisition_additioncompleted2009-08Renalbusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		August 2009 purchase of certain Edwards Lifesciences Corporation assets (hemofiltration / Continuous Renal Replacement Therapy business) for $56 million. Employee headcount added was not disclosed.
2009-12-31restructuringin_progress2009-10-012010-12-31GlobalCorporate (not allocated to a segment)USD 79 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Charge recognized in Q4 2009; $69M cash severance covering elimination of less than 2% of workforce plus $10M asset impairments. Reserve utilization of $5M through 2009-12-31; expected substantially utilized by end of 2010. Headcount affected not quantified.
2009-12-31acquisition_additioncompleted2009-04-012009-04-30United States and international marketsMedication Deliverybusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Consolidation of SIGMA (40% equity stake, exclusive distribution agreement, purchase option) beginning April 2009; noncontrolling interest of $159M recognized. Headcount added not disclosed.
2009-12-31acquisition_additioncompleted2009-08-012009-08-31United StatesRenalbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Edwards Lifesciences hemofiltration (CRRT) assets for $56M plus up to $9M contingent. Headcount added not disclosed.
2009-12-31restructuringcompleted2007-01-012009-12-31Primarily outside the United StatesMedication Delivery (principally)USD 22 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Multi-year program announced in 2007 ($70M total charge, approximately 1% of total workforce); only FY2009 activity captured here — $22M of reserve utilization during 2009. Reserve substantially utilized by end of 2009. Employees affected during 2009 not disclosed.
2009-12-31restructuringcompleted2009-10-012010-12-31GlobalCorporateUSD 79 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Cost optimization charge recognized in Q4 2009. Included $69 million cash costs for severance and other employee-related costs associated with the elimination of less than 2% of the company's workforce. Reserve expected to be substantially utilized by end of 2010.
2009-12-31restructuringcompleted2007-01-012009-12-31InternationalMedication DeliveryUSD 70 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		2007 restructuring charge principally associated with consolidation of commercial and manufacturing operations outside the US. Included $53 million cash costs for severance and other employee-related costs associated with the elimination of approximately 1% of the company's total workforce. Reserve substantially utilized by end of 2009.
2009-12-31restructuringcompleted2%2009-12-312010-12-31GlobalCorporateUSD 79 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		2009 Cost Optimization Charge. Elimination of less than 2% of workforce. Reserve expected to be substantially utilized by end of 2010.
2009-09-30acquisition_additioncompleted2009-04-01United States and international marketsMedication Deliverybusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Baxter consolidated SIGMA (40% equity stake plus purchase option) beginning April 2009; no employee count for the acquired workforce is disclosed. Noncontrolling interest of $159 million recorded.
2009-09-30acquisition_additioncompleted2009-08-01Renalbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Edwards Lifesciences hemofiltration (CRRT) product line assets for $56 million; asset purchase with no headcount disclosed.
2009-09-30restructuringin_progress20072009-12-31InternationalCommercial and ManufacturingUSD 70 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2007 charge principally associated with consolidation of commercial and manufacturing operations outside the US. Reserves expected to be substantially utilized by end of 2009.
2009-09-30restructuringin_progress20042009-12-31GlobalCorporateUSD 543 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2004 charge associated with actions to reduce overall cost structure. Reserves expected to be substantially utilized by end of 2009.
2009-09-30divestiture_reductionin_progress20072009-12-31GlobalTransfusion TherapiesUSD 35 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charge associated with divestiture of Transfusion Therapies business, principally severance and other employee-related costs.
2009-06-30restructuringin_progress2007-01-012009-12-31USD 22 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Ongoing 2007 and 2004 restructuring programs; $22M reserve utilization in H1 2009, $17M reserve remaining at quarter-end; no employee counts disclosed this period.
2009-06-30acquisition_additioncompleted2009-04-012009-04-30United StatesMedication Deliverybusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Consolidation of SIGMA as a VIE beginning April 2009; $100M upfront paid for 40% equity stake plus purchase option; no headcount disclosed.
2009-06-30restructuringin_progress20072009-12-31InternationalCommercial and manufacturing operationsUSD 70 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2007 charge principally associated with consolidation of commercial and manufacturing operations outside the US. Reserves expected to be substantially utilized by end of 2009.
2009-06-30restructuringin_progress20042009-12-31GlobalCorporateUSD 543 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2004 charge principally associated with actions to reduce overall cost structure. Reserves expected to be substantially utilized by end of 2009.
2009-06-30divestiture_reductionin_progress20072009-12-31GlobalTransfusion TherapiesUSD 35 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charge associated with divestiture of Transfusion Therapies business, principally severance and other employee-related costs. Reserve expected to be substantially utilized by end of 2009.
2009-03-31restructuringin_progress20072009-12-31Outside of the United StatesCommercial and manufacturing operationsUSD 70 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2007 charge principally associated with consolidation of certain commercial and manufacturing operations outside of the United States. Reserves expected to be substantially utilized by end of 2009.
2009-03-31restructuringin_progress20042009-12-31GlobalCorporateUSD 543 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2004 charge principally associated with actions to reduce overall cost structure and drive sustainable improvements in financial performance. Reserves expected to be substantially utilized by end of 2009.
2009-03-31divestiture_reductionin_progress20072009-12-31GlobalTransfusion TherapiesUSD 35 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charge principally associated with severance and other employee-related costs in connection with the divestiture of substantially all assets and liabilities of the Transfusion Therapies business. Reserve expected to be substantially utilized by end of 2009.
2008-12-31restructuringin_progress5501%20072009-12-31Outside the United StatesPrincipally Medication DeliveryUSD 70 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Multi-year program: charge and elimination of roughly 550 positions (about 1% of workforce) were recorded in Q2 2007; current-year (FY2008) activity was $14 million of severance-reserve utilization (total 2008 utilization across programs was $42 million). $53 million of the $70 million charge was cash severance/employee-related costs, $17 million asset impairments; reserves expected substantially utilized by end of 2009, with roughly $0.02 of diluted-share savings once fully implemented. Position count attributed to the original 2007 charge, carried in this filing as an open program at December 31, 2008.
2008-12-31restructuringin_progress5502009-12-31Primarily outside the United StatesMedication Deliveryrestructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Multi-year program: the 550 positions (approx. 1% of workforce) were eliminated under the $70M 2007 charge; 2008 activity was limited to reserve utilization of $42M ($14M under the 2007 program, $28M under the 2004 program), with reserves expected to be substantially utilized by end of 2009. No new restructuring charge was recorded in 2008.
2008-12-31restructuringcompleted5501%2007-01-012009-12-31InternationalMedication DeliveryUSD 70 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		2007 restructuring program affecting approximately 550 positions (1% of workforce). Reserve expected to be substantially utilized by end of 2009.
2008-12-31restructuringin_progress5501%20072009-12-31Outside the United StatesMedication DeliveryUSD 53 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		2007 restructuring program involving consolidation of commercial and manufacturing operations. Elimination of approximately 550 positions (1% of total workforce). Reserve expected to be substantially utilized by end of 2009.
2008-12-31divestiture_reductioncompleted2007-02-282007-02-28GlobalBioScience (Transfusion Therapies)USD 35 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Divestiture of Transfusion Therapies business to Fenwal Inc. on February 28, 2007. Recorded $35 million charge principally associated with severance and other employee-related costs. Specific headcount reduction not disclosed.
2008-09-30restructuringin_progress5501%2009-12-31Primarily outside the United StatesPrimarily Medication Delivery; commercial and manufacturing operationsUSD 53 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2007 program: consolidation of commercial and manufacturing operations; $53M cash costs for severance covering ~550 positions (~1% of workforce), plus $17M asset impairments. Reserve utilization of $6M in Q3 2008 ($3M from 2007 program, $3M from 2004 program); reserve at 2008-09-30 was $52M total across 2007 and 2004 programs. Program announced in 2007; no new positions disclosed as eliminated during Q3 2008.
2008-09-30restructuringin_progress2009-12-31GlobalCorporate-wide cost structure reductionUSD 347 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2004 restructuring program ($543M total charge, of which $347M cash costs); reserve still active with $3M utilization in Q3 2008. Employee count for this program not disclosed in this filing. Expected substantially utilized by end of 2009.
2008-09-30divestiture_reductioncompleted2007-02-282007-02-28GlobalBioScience — Transfusion Therapies businessUSD 35 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale of TT business to TPG Capital affiliate (Fenwal) for $540M on 2007-02-28; $35M pre-tax charge for severance and employee-related costs, $10M utilized through 2008-09-30, reserve expected substantially utilized by end of 2009. Headcount transferred not disclosed.
2008-09-30restructuringin_progress5501%20072009-12-31Outside of the United StatesMedication DeliveryUSD 70 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2007 program: consolidation of commercial and manufacturing operations. Elimination of approx. 550 positions (1% of total workforce). Reserve expected to be substantially utilized by end of 2009.
2008-09-30restructuringin_progress20042009-12-31GlobalCorporateUSD 543 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2004 program: actions to reduce overall cost structure. Reserve expected to be substantially utilized by end of 2009. Specific headcount not disclosed in this filing.
2008-06-30restructuringin_progress5501%20072009-12-31Primarily outside the United StatesPrimarily Medication Delivery; commercial and manufacturing operationsUSD 70 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2007 program consolidating commercial and manufacturing facilities; $53M cash costs and $17M asset impairments. Reserve of $58M remaining at 2008-06-30; positions eliminated in 2007, program cash utilization ongoing through 2009.
2008-06-30restructuringin_progress20042009-12-31GlobalEnterprise-wide cost structure reductionUSD 543 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2004 restructuring program; $347M cash costs and $196M asset impairments. Reserve of $58M total remaining at 2008-06-30 across 2004 and 2007 programs; expected utilization by end of 2009. No employee count disclosed for this program in this filing.
2008-06-30restructuringin_progress5501%2007-01-012009-12-31Outside of the United StatesMedication DeliveryUSD 53 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2007 program: Consolidation of commercial and manufacturing operations. Charge includes $53M for cash costs (severance/employee-related) associated with elimination of ~550 positions (~1% of total workforce). Reserve expected to be utilized by end of 2009.
2008-03-31restructuringin_progress5501%20072009-12-31Primarily outside the United StatesPrimarily Medication Delivery; commercial and manufacturing operationsUSD 70 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2007 program: $70M total charge ($17M asset impairments, $53M cash costs) for consolidating commercial and manufacturing operations outside the US, eliminating ~550 positions (~1% of workforce). Positions eliminated in 2007; Q1 2008 reserve utilization was $12M ($3M from 2007 program, $9M from 2004 program). Reserve at 2008-03-31 was $69M across both programs, expected to be utilized by end of 2009.
2008-03-31restructuringin_progress1%2007-01-012009-12-31Outside of the United StatesMedication DeliveryUSD 53 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2007 restructuring program. Charge included $53 million for cash costs, principally severance, associated with elimination of approx. 550 positions (approx. 1% of total workforce). Reserve utilization of $3 million occurred in Q1 2008.
2008-03-31restructuringin_progress2004-01-012009-12-31GlobalCorporateUSD 347 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2004 restructuring program. Original charge included $347 million for cash costs, principally severance. Reserve utilization of $9 million occurred in Q1 2008.
2007-12-31restructuringin_progress5501%2007-062009-12-31Outside the United States (principal)Principally Medication Delivery; savings affect cost of goods sold, general and administrative expenses and R&DUSD 70 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Charge recorded in Q2 2007 (per quarterly data note) for consolidation of commercial and manufacturing operations outside the US; comprised $17M asset impairments and $53M cash costs, mainly severance and other employee-related costs, tied to elimination of approximately 550 positions (approximately 1% of workforce; ~1.2% implied against the disclosed ~46,000 total, consistent with the filing's rounding). Severance/other reserve expected to be utilized by end of 2009 with majority of payments in 2008; reserve utilization in 2007 totaled $27M ($5M for this program).
2007-12-31divestiture_reductioncompleted2007-02-28Global — divested business operated five manufacturing facilities in Dominican Republic, France, Puerto Rico (two sites) and TunisiaBioScience — Transfusion Therapies (TT) businessUSD 35 (millions)other
f5-10k / GLM-5.3-flash-HTML		Substantially all TT assets and liabilities sold to an affiliate of TPG Capital, L.P. on February 28, 2007 for $540 million; a $35M charge (after-tax $24M) was recorded principally for severance and other employee-related costs, with $4M of reserve utilization in 2007 and the reserve expected to be substantially utilized by end of 2009. Number of employees transferred with the business is not disclosed; the original sale-announcement date is not disclosed in this filing.
2007-12-31acquisition_additioncompleted2007-062007-06Medication Delivery — R&D (infusion systems technology)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		In June 2007 the company acquired substantially all assets of MAAS Medical, LLC, a specialist in infusion systems technology; the acquired talent and technology were incorporated into Baxter's R&D organization. Headcount added is not disclosed. The $11 million purchase price was principally allocated to acquired in-process R&D and expensed (an $11M IPR&D charge); it is not a workforce-related charge.
2007-12-31restructuringin_progress5502007-12-312009-12-31Outside the United StatesMedication DeliveryUSD 70 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Consolidation of certain commercial and manufacturing operations outside the U.S., principally in Medication Delivery. Charge comprised $17M asset impairments and $53M cash severance/employee costs; approximately 550 positions, or about 1% of total workforce. Reserve expected to be utilized by end of 2009. Announcement date not separately disclosed; fiscal year-end used as placeholder.
2007-12-31divestiture_reductioncompleted2007-02-282007-02-28Dominican Republic; France; Puerto Rico; TunisiaBioScience — Transfusion TherapiesUSD 35 (millions)discontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Substantially all TT assets and liabilities sold to a TPG Capital affiliate (Fenwal Inc.) for $540M; five manufacturing facilities transferred. Headcount transferred not disclosed. A $35M charge ($24M after tax) was recorded principally for severance and employee-related costs, with reserve utilization of $4M in 2007 and expected substantial utilization by end of 2009.
2007-12-31restructuringin_progress5501%2007-01-012009-12-31Outside the United StatesMedication DeliveryUSD 70 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Consolidation of commercial and manufacturing operations. Charge includes $17M asset impairments and $53M cash costs for severance/employee-related costs. Reserve expected to be utilized by end of 2009.
2007-12-31divestiture_reductioncompleted2007-02-282007-02-28GlobalBioScience (Transfusion Therapies)USD 35 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Sale of Transfusion Therapies business to TPG Capital affiliate. Charge associated with severance and other employee-related costs.
2007-12-31restructuringin_progress5501%20072009-12-31Outside of the United StatesMedication DeliveryUSD 53 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Consolidation of commercial and manufacturing operations. Charge includes $17M asset impairments and $53M cash costs for severance. Total charge $70M.
2007-12-31divestiture_reductioncompleted2007-02-282007-02-28GlobalBioScienceUSD 35 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Sale of Transfusion Therapies business to Fenwal Inc. Charge principally associated with severance and other employee-related costs.
2007-09-30restructuringin_progress5501%2007-062009-12-31Outside the United StatesPrincipally Medication Delivery; commercial and manufacturing operationsUSD 70 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Charge comprises $17M asset impairments and $53M cash severance costs; reserve utilization not significant through 2007-09-30; percentage is filer-stated share of total workforce
2007-09-30divestiture_reductioncompleted2007-02-282007-02-28Global (facilities in Dominican Republic, France, Puerto Rico, Tunisia)BioScience — Transfusion Therapies businessUSD 35 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale of TT business to TPG Capital/Fenwal completed 2007-02-28; $35M pre-tax charge principally for severance and employee-related costs; headcount transferred not disclosed
2007-09-30restructuringin_progress5501%2007-06-302009-12-31Outside of the United StatesMedication DeliveryUSD 70 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Consolidation of commercial and manufacturing operations; charge includes $17M asset impairments and $53M cash costs for severance.
2007-09-30divestiture_reductioncompleted2007-02-282007-02-28GlobalBioScienceUSD 35 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Sale of Transfusion Therapies business to Fenwal Inc.; charge principally associated with severance and other employee-related costs.
2007-06-30restructuringin_progress5501%2009-12-31Primarily outside the United StatesPrincipally Medication Delivery; commercial and manufacturing operationsUSD 70 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Pre-tax charge of $70M ($46M after tax, $0.07 per diluted share), comprising $17M asset impairments and $53M cash severance costs. Elimination of approximately 550 positions, about 1% of total workforce. Reserve utilization in Q2 2007 was not material; majority of payments expected in 2007-2008. Estimated savings of about $0.02 per diluted share when fully implemented in 2009. Filer does not state an announcement date; charge recorded during the quarter.
2007-06-30acquisition_additioncompletedMedication Delivery — infusion systems R&DUSD 11 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		June 2007 acquisition of certain assets of MAAS Medical, LLC. Purchase price of $11M principally allocated to in-process R&D and expensed. Headcount added not disclosed; contingent payments of up to $14M may follow based on regulatory approvals and retention of key employees.
2007-06-30restructuringin_progress5501%2007-06-302009-12-31Outside of the United StatesMedication DeliveryUSD 70 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Consolidation of commercial and manufacturing operations. Charge includes $17M asset impairments and $53M cash costs for severance. Majority of payments expected in 2007 and 2008.
2007-06-30divestiture_reductioncompleted2007-02-282007-02-28GlobalBioScienceUSD 35 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Sale of Transfusion Therapies business to TPG Capital. Charge principally associated with severance and other employee-related costs. Reserve expected to be utilized by end of 2008.
2007-03-31divestiture_reductioncompleted2007-02-282007-02-28International (Haina, Dominican Republic; La Chatre, France; Maricao and San German, Puerto Rico; Nabeul, Tunisia)BioScience — Transfusion TherapiesUSD 35 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale of substantially all TT assets/liabilities to TPG Capital for $540M; $35M pre-tax charge ($24M after-tax) mainly for severance and employee-related costs; reserve expected utilized by end of 2008. No employee headcount disclosed.
2007-03-31restructuringin_progress2004-01-012007-12-31GlobalAll segmentsUSD 543 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2004 restructuring program; $3M reserve utilization in Q1 2007; reserve at 2007-03-31 was $52M; substantially complete with remaining cash outflows for long-term leases and severance. No employee counts disclosed.
2007-03-31plant_closurein_progress2005-07-012007-12-31United StatesMedication Delivery — Infusion Systems (COLLEAGUE/SYNDEO/6060 pumps)USD 108 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sales hold on COLLEAGUE pumps in US since July 2005; $11M reserve utilization in Q1 2007; reserve at 2007-03-31 was $108M. FDA clearance received 2007-02-27; FDA authorization to modify pumps received 2007-05-02 (subsequent event). No employee counts disclosed.
2007-03-31plant_closurein_progress2005-07-012007-12-31GlobalRenal — Hemodialysis Instruments (Meridian)USD 50 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Discontinuation of HD instrument manufacture; $16M of $27M cash reserve utilized through Q1 2007; remainder expected utilized in 2007. No employee counts disclosed.
2007-03-31restructuringin_progress2004-01-012007-12-31GlobalCorporate / All SegmentsUSD 543 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2004 restructuring program. $543M pre-tax charge recorded in 2004. $52M reserve remaining at March 31, 2007. Substantially all remaining reserve expected to be utilized in 2007. Employee-related costs component of original charge was $212M.
2007-03-31restructuringin_progress2007-02-282008-12-31GlobalBioScience (Transfusion Therapies)USD 35 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charge associated with divestiture of Transfusion Therapies business. Principally associated with severance and other employee-related costs. Reserve expected to be utilized by end of 2008.
2006-12-31divestiture_reductionannounced2006-10-022007-03Multi-country: Dominican Republic, France, Puerto Rico, TunisiaBioScience — Transfusion Therapies (TT) businessother
f5-10k / GLM-5.3-flash-HTML		Definitive agreement to sell substantially all TT assets and liabilities to an affiliate of Texas Pacific Group for $540 million; includes five manufacturing facilities. Company projects a modest gain on closing. Headcount not disclosed. TT is not presented as discontinued operations; close expected in Q1 2007 subject to approvals.
2006-12-31divestiture_reductioncompleted20062006United KingdomRenal — Renal Therapy Services (RTS)MD&A
f5-10k / GLM-5.3-flash-HTML		RTS business divested in Q4 2006 consistent with strategy to exit lower-margin services businesses; annual sales of the business were not material. Headcount not disclosed.
2006-12-31restructuringcompleted4,0008%20042007Global (approximately half of eliminated positions in the United States)All three segments plus corporate headquarters and administrative functionsUSD 543 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Cumulative program figures from the 2004 pre-tax charge: over 4,000 positions (8% of workforce) eliminated. No new 2006 charges; 2006 activity was $38 million of reserve utilization, with the remaining $55 million reserve expected to be used in 2007 (residual severance and lease payments). Management considers the program substantially complete.
2006-12-31otherannounced20062007-01-01United StatesU.S. qualified defined benefit pension plan and U.S. qualified defined contribution planother
f5-10k / GLM-5.3-flash-HTML		Benefit plan redesign adopted during 2006: employees hired on or after 2007-01-01 receive higher defined-contribution company contributions and are excluded from the pension plan; non-fully-vested existing employees had until 2007-02-15 to elect continued pension participation. No curtailment gain or loss resulted.
2006-12-31divestiture_reductionannounced2006-10-022007-03-31Global (facilities in Dominican Republic, France, Puerto Rico, Tunisia)BioScience — Transfusion Therapiesother
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Sale of substantially all TT assets and liabilities to a Texas Pacific Group affiliate for $540 million; expected to close in Q1 2007 subject to closing conditions. No headcount disclosed; Baxter will provide manufacturing and support services under transition agreements post-divestiture
2006-12-31divestiture_reductioncompletedUnited KingdomRenal — Renal Therapy ServicesMD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Divested in the fourth quarter of 2006 as part of the strategy to exit lower-margin services businesses; annual sales related to this business were not material. No headcount disclosed
2006-12-31restructuringin_progress2004-01-012007-12-31GlobalAll segments plus corporate and administrative functionsrestructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2004 restructuring program (which eliminated over 4,000 positions, 8% of the global workforce, in 2004 — prior-year activity, not extracted here). FY2006 activity only: $38 million of the cash reserve utilized in 2006; remaining reserve of $55 million expected to be utilized in 2007; no new restructuring charge recorded in 2006. Program described as substantially complete
2006-12-31restructuringcompleted20042007-12-31GlobalAll segments and corporate headquartersUSD 543 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		2004 program eliminated over 4,000 positions (8% of global workforce). Program substantially complete; remaining reserves expected utilized in 2007.
2006-12-31restructuringcompleted4,0008%2004GlobalAll segments and corporate headquartersUSD 543 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		2004 restructuring program substantially complete by 2006. Elimination of over 4,000 positions (8% of global workforce). Remaining reserve of $55 million expected to be utilized in 2007.
2006-09-30restructuringin_progress4,0008%2004GlobalCompany-wideUSD 543 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2004 program eliminated over 4,000 positions (8% of global workforce); substantially all targeted positions eliminated through Q3 2006. Reserve of $62M at 2006-09-30; $9M utilized in Q3 2006 and $34M YTD 2006 (including $3M from a 2003 program). Charge comprises $347M cash costs and $196M asset impairments.
2006-09-30divestiture_reductionannounced2006-10-022007-03-31Global (facilities in Dominican Republic, France, Puerto Rico, Tunisia)BioScience — Transfusion Therapiessubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Agreement to sell substantially all Transfusion Therapies assets/liabilities to an affiliate of Texas Pacific Group for $540 million; expected to close by Q1 2007. No employee headcount associated with the divestiture was disclosed; management projects a modest gain on closing.
2006-09-30restructuringin_progress20042006-12-31GlobalCorporate / All SegmentsUSD 347 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2004 restructuring program. Original charge included elimination of over 4,000 positions (8% of global workforce). Substantially all targeted positions eliminated through Q3 2006. Remaining reserves of $62 million expected to be utilized in remainder of 2006.
2006-09-30restructuringcompleted20032006-09-30GlobalCorporate / All Segmentsrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2003 restructuring program. Substantially complete as of Q3 2006.
2006-06-30restructuringin_progress4,0008%2004GlobalCompany-wideUSD 543 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program announced in 2004; over 4,000 positions (8% of global workforce) eliminated cumulatively. Filing states substantially all targeted positions eliminated through Q2 2006; remaining reserve $71 million at 2006-06-30, mostly expected to be used during remainder of 2006. Charge includes $196M asset impairments and $347M cash costs.
2006-06-30restructuringin_progress20042006-12-31GlobalCorporate / All SegmentsUSD 25 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2004 restructuring program. Substantially all targeted positions eliminated through Q2 2006. YTD 2006 cash utilization of $25 million (includes $22M for 2004 program and $3M for 2003 program). Remaining reserve of $71 million expected to be utilized primarily in remainder of 2006.
2006-03-31restructuringin_progress4,0008%2004GlobalCompany-wideUSD 543 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2004 program eliminated over 4,000 positions (8% of global workforce) via severance, facility closures including additional plasma collection centers, and contract exits; included $196M asset impairments and $347M cash costs. Substantially all targeted positions eliminated through Q1 2006; reserve fell from $93M (2005-12-31) to $75M (2006-03-31) with $18M utilized in the quarter; approximately $60M of remaining reserve expected utilized during remainder of 2006, balance relating to long-term leases and remaining severance. Filer does not state an explicit completion date.
2006-03-31restructuringin_progress2004GlobalCorporate / All SegmentsUSD 18 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Utilization of $18 million from 2004 restructuring reserve during Q1 2006. Original 2004 program eliminated over 4,000 positions (8% of global workforce). Substantially all targeted positions eliminated through Q1 2006.
2006-03-31restructuringcompleted2003GlobalCorporate / All SegmentsUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Utilization of $1 million from 2003 restructuring program during Q1 2006. Program is substantially complete.
2005-12-31restructuringin_progress4,0008%20042006Global — approximately 50% of eliminated positions in the United StatesAll three segments (Medication Delivery, BioScience, Renal) plus corporate headquarters and administrative functionsUSD 543 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Multi-year program announced in 2004; cumulative through FY2005-end approximately 90% of targeted positions eliminated. Headcount disclosed as 'over 4,000 positions, or 8% of the global workforce'. Charge comprised $347M cash costs ($212M employee-related severance, $135M contractual) and $196M asset impairments. FY2005 activity: $101M reserve utilization, $61M of reserve adjustments (income benefit); remaining reserve $93M at Dec 31, 2005, of which ~$70M expected to be utilized in 2006.
2005-12-31restructuringcompleted3,2002003-062005-12-31Global — 26 US plasma collection centers and Rochester, Michigan plasma fractionation facility closed; facility consolidations in Maryland (US), Frankfurt (Germany), Issoire (France), Mirandola (Italy)Company-wide, principally plasma operationsUSD 337 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Multi-year program announced June 2003; substantially complete as of Dec 31, 2005 with substantially all targeted positions eliminated (cumulative program total of ~3,200 positions). Charge included $209M cash costs ($160M employee-related, $49M contractual) and $128M asset impairments; also discontinued recombinant hemoglobin program. FY2005 activity: $16M reserve utilization and $28M reserve adjustments (income benefit); remaining $5M reserve, principally long-term leases, expected substantially paid in 2006.
2005-12-31plant_closurein_progress2005Renal — hemodialysis (HD) instruments manufacturing, including Meridian instrumentUSD 50 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Management decision in 2005 to discontinue manufacture of HD instruments; charge comprises $23M asset impairments (inventory write-down, equipment) and $27M estimated cash payments with spending commencing in 2006. Headcount impact not disclosed. Company simultaneously entered agreement with Gambro Renal Products to distribute HD instruments.
2005-12-31divestiture_reductioncompleted2005-03-312005-03-31TaiwanRenal — Renal Therapy Services (RTS) services businessMD&A
f5-10k / GLM-5.3-flash-HTML		Divestiture of RTS business in Taiwan completed at end of Q1 2005; the business generated approximately $20 million of revenue per quarter in 2004. Headcount removed not disclosed. Goodwill attributable to the divested Taiwanese services business decreased $28 million. Part of company's exit of lower-margin services businesses under its discontinued-operations divestiture plan, substantially complete at Dec 31, 2005.
2005-12-31divestiture_reductionin_progress2005Outside the United StatesMedication Delivery — 'Other' product line (hospital-distributed products in international markets)MD&A
f5-10k / GLM-5.3-flash-HTML		Company continued to exit certain lower-margin distribution businesses outside the United States; declines in 'Other' product-line sales attributed largely to these exits. No employee counts or charges disclosed.
2005-12-31acquisition_additioncompleted2005Renal — distributor of peritoneal dialysis (PD) suppliesMD&A
f5-10k / GLM-5.3-flash-HTML		Acquisition of certain assets of a distributor of PD supplies; headcount added not disclosed. Included within $47M of 2005 net cash outflows for acquisitions and investments, which also covered payments relating to a prior-year BioScience acquisition.
2005-12-31restructuringin_progressGlobalAll segments, corporate headquarters and administrative functionsrestructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Cumulative through fiscal year-end: program targeted elimination of over 4,000 positions (8% of global workforce), approximately 50% in the United States; approximately 90% of targeted positions eliminated as of 2005-12-31. Original $543M charge recorded in FY2004 (prior year); $101M of reserve utilized during 2005, with approximately $70M of remaining reserve expected to be utilized in 2006. Approximately three-quarters of estimated savings impacted general and administrative expenses.
2005-12-31restructuringcompleted2003-06GlobalAll segments; plasma collection centers and fractionation facilitiesrestructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Cumulative through fiscal year-end: program targeted reduction of approximately 3,200 positions globally, including closure of 26 U.S. plasma collection centers and a Rochester, Michigan fractionation facility; substantially all targeted positions eliminated as of 2005-12-31 and program substantially complete. Original $337M charge recorded in FY2003 (prior year); $16M of reserve utilized during 2005.
2005-12-31divestiture_reductioncompleted2005-03-31TaiwanRenal — Renal Therapy Services (RTS)MD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Divestiture of the RTS services business completed at the end of the first quarter of 2005; associated headcount not disclosed. Business generated approximately $20 million per quarter in revenues in 2004.
2005-12-31othercompletedGlobalRenal — hemodialysis instrument manufacturingUSD 50 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Management decision in 2005 to discontinue manufacture of HD instruments (including Meridian); $50M charge comprising $23M asset impairments and $27M estimated cash costs with spending commencing in 2006. Associated headcount impact not disclosed.
2005-12-31othercompleted2005-11-15GlobalMedication Delivery — 6060 multi-therapy infusion pumpUSD 49 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Withdrawal of the 6060 ambulatory infusion pump from the market over 12 months announced 2005-11-15; approximately 34,000 pumps in use worldwide. Charge includes $41M cash costs (customer replacement pumps commencing 2006) plus asset impairments. Associated headcount impact not disclosed.
2005-12-31restructuringin_progress4,0008%20042006GlobalAll segments and corporate headquartersUSD 543 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		2004 restructuring program. Approximately 90% of targeted 4,000 positions eliminated through Dec 2005. Remaining reserve expected to be utilized in 2006.
2005-12-31restructuringcompleted3,20020032005GlobalAll segmentsUSD 337 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		2003 restructuring program. Substantially complete as of Dec 31, 2005.
2005-12-31restructuringin_progress4,0008%20042006GlobalAll segments and corporate headquartersUSD 543 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		2004 restructuring program. Approximately 90% of targeted 4,000 positions eliminated through Dec 2005. Remaining reserve expected to be utilized in 2006.
2005-09-30restructuringin_progress4,0008%2004-06-30Global (approximately 50% United States)All three segments plus corporate headquarters and functionsUSD 543 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Second quarter 2004 program; count stated as over 4,000 positions, 8% of global workforce. Charge includes $196M asset impairments and $347M cash costs. Approximately 87% of targeted positions eliminated as of 2005-09-30; ~$30M of reserve expected utilized in Q4 2005, remainder in 2006+ for long-term leases. Exact announcement date not disclosed; Q2 2004 quarter-end used as placeholder.
2005-09-30restructuringcompleted3,2002003-06-30GlobalAll segments; includes closure of plasma collection centers and a plasma fractionation facilityUSD 337 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Second quarter 2003 program; substantially all targeted positions eliminated as of 2005-09-30 and program substantially complete. Charge includes $128M asset impairments and $209M cash costs. Exact announcement date not disclosed; Q2 2003 quarter-end used as placeholder.
2005-09-30restructuringin_progress2005-07Not specifiedRenal — exit of hemodialysis (HD) instruments manufacturingUSD 28 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q3 2005 charge to discontinue HD instrument manufacturing; includes $24M asset impairments and $4M cash severance costs (no employee count disclosed). Management estimates total exit plan cost of approximately $50M; additional charges expected in future quarters. Company entered distribution agreement with Gambro.
2005-09-30restructuringin_progress2005-06-30Not specifiedMedication Delivery — COLLEAGUE infusion pump design remediationUSD 77 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q2 2005 charge for materials, labor and freight to remediate COLLEAGUE pump design issues; no headcount impact disclosed. No change to estimate in Q3 2005; further charges possible. Included here only for completeness — not a headcount action.
2005-09-30restructuringin_progress8%2004-04-01GlobalAll segments and corporate headquartersUSD 543 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Program initiated in Q2 2004 to eliminate over 4,000 positions (8% of global workforce). As of Sept 30, 2005, 87% of targeted positions eliminated. Q3 2005 recorded $5M benefit due to higher attrition than anticipated.
2005-09-30restructuringin_progress3,2002003-04-01GlobalVariousUSD 337 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Program initiated in Q2 2003. Substantially complete. Q2 2005 recorded $104M benefit related to adjustments of 2004 and 2003 charges.
2005-09-30restructuringin_progress2005-07-01GlobalRenalUSD 28 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Decision to discontinue manufacture of hemodialysis instruments. Charge includes $4M for severance and other employee-related costs. Total expected exit cost approx $50M.
2005-06-30restructuringin_progress4,0008%2004-06-302006-12-31Global (approximately 50% of positions in the United States)All three segments plus corporate headquarters and functionsUSD 543 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Filing states 'over 4,000 positions, or 8% of the global workforce'; announcement date approximated to quarter-end (filing says only 'second quarter of 2004'). Charge comprises $196M asset impairments and $347M cash costs (severance, facility closures including additional plasma collection centers, contract exits). About 80% of targeted positions eliminated as of 2005-06-30; reserve of $137M remains, with roughly $50M expected to be used in H2 2005 and the remainder in 2006. Q2 2005 recorded a $104M pre-tax benefit from reserve adjustments across the 2004 and 2003 programs (higher-than-planned attrition reduced severance needs).
2005-06-30restructuringcompleted3,2002003-06-302005-12-31GlobalPlasma collection centers and a plasma fractionation facility; recombinant hemoglobin program discontinued; other workforce reductionsUSD 337 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Approximately 3,200 positions worldwide; announcement date approximated to quarter-end (filing says only 'second quarter of 2003'). Charge comprises $128M asset impairments and $209M cash costs. Substantially all targeted positions eliminated as of 2005-06-30 and program substantially complete; remaining reserve of $10M expected to be utilized during 2005. Included in the $104M Q2 2005 restructuring benefit adjustment.
2005-06-30divestiture_reductioncompleted2005-03-31TaiwanRenal — Renal Therapy Services (RTS) businessMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Divestiture completed at the end of Q1 2005; announcement date not disclosed. No headcount impact or charge disclosed; the filing notes the business generated roughly $20M of quarterly revenue in 2004.
2005-06-30restructuringannounced2005-07Global (manufacturing); distribution agreement covers Latin America exclusively and the U.S./rest of world non-exclusivelyRenal — cessation of hemodialysis (HD) instrument manufacturing; agreement with Gambro to distribute Gambro HD instrumentssubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		July 2005 decision, after the 2005-06-30 quarter end. Management estimates future pre-tax costs for severance, contract termination and other items will total between $40 million and $50 million (range not representable as a single charge value); exit plans not yet finalized, so no completion date or employee count disclosed. Baxter will continue distributing its HD dialyzers, solutions and concentrates.
2005-06-30restructuringin_progress8%2004-04-012006-12-31GlobalAll segments and corporateUSD -104 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2004 program: Elimination of over 4,000 positions (8% of global workforce). Q2 2005 recorded $104M benefit due to higher attrition than anticipated and lower severance estimates. ~80% of targeted positions eliminated as of June 30, 2005.
2005-06-30restructuringcompleted3,2002003-04-012005-12-31GlobalAll segmentsrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2003 program: Elimination of approximately 3,200 positions. Substantially all targeted positions eliminated as of June 30, 2005. Program substantially complete.
2005-06-30restructuringannounced2005-07-01GlobalRenalUSD 45 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Decision to cease manufacturing HD instruments. Estimated pre-tax cost between $40M and $50M for severance, contract termination, and other costs.
2005-03-31restructuringin_progress4,0008%20042006Global (approximately 50% of positions in the United States)All three segments plus corporate headquarters and functionsUSD 543 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Filer states 'over 4,000 positions' (8% of global workforce); charge comprises $196M asset impairments and $347M cash costs. Approximately three-quarters of targeted positions eliminated as of 2005-03-31; $37M of reserve utilized in Q1 2005, ~$150M expected during full-year 2005 with remainder in 2006. Reserve at 2005-03-31 was $218M.
2005-03-31restructuringin_progress3,20020032005GlobalPlasma collection centers, plasma fractionation facility, consolidated facilities, corporate functionsUSD 337 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Charge comprises $128M asset impairments and $209M cash costs. Virtually all targeted positions eliminated and program substantially complete as of 2005-03-31; remaining reserve of $43M expected to be utilized during 2005.
2005-03-31divestiture_reductioncompleted2005-03-31TaiwanRenal — Renal Therapy Services (RTS)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		RTS business in Taiwan divested at the end of Q1 2005; associated headcount not disclosed.
2005-03-31restructuringin_progress4,0008%2004-04-012006-12-31GlobalAll segments and corporate headquartersUSD 543 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Announced Q2 2004. Includes elimination of over 4,000 positions (8% of global workforce). Approximately 50% of positions in the US. As of March 31, 2005, approximately three-quarters of targeted positions have been eliminated. Program proceeding on plan.
2005-03-31restructuringcompleted3,2002003-04-012005-03-31GlobalAll segmentsUSD 337 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Announced Q2 2003. Included elimination of approximately 3,200 positions worldwide. Virtually all targeted positions eliminated as of March 31, 2005. Program substantially complete.
2004-12-31restructuringin_progress4,0008%20042006Global; approximately 50% of the eliminated positions are in the United StatesAll three segments (Medication Delivery, BioScience, Renal) plus corporate headquarters and functions; roughly three-quarters of targeted savings affect general and administrative expenses, remainder primarily cost of salesUSD 543 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Second-quarter 2004 program to reduce the overall cost structure. Involves elimination of over 4,000 positions (stated as 8% of the global workforce; approximately 60% eliminated as of December 31, 2004, consistent with the disclosed ~48,000 total headcount), further plasma production reductions, closure of additional plasma collection centers, and exits of certain facilities and activities. Charge comprises $347 million of cash costs (principally severance and other employee-related costs) and $196 million of asset impairments (primarily PP&E). $92 million of the cash-cost reserve was utilized in the second half of 2004; approximately $150 million expected to be expended in 2005 and approximately $105 million in 2006, funded from operating cash flows.
2004-12-31restructuringcompleted3,20020032005Global; 26 plasma collection centers closed in the United States; plasma fractionation facility closed in Rochester, Michigan; facilities consolidated in Maryland (US), Frankfurt (Germany), Issoire (France), and Mirandola (Italy)Plasma operations (BioScience) and global workforce reductions; recombinant hemoglobin protein program discontinuedUSD 337 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Cumulative through fiscal year-end 2004: $337 million charge recorded in the second quarter of 2003, including $128 million of asset impairments and $209 million of cash costs principally for severance of approximately 3,200 positions worldwide. During 2004, $91 million of the cash-cost reserve was utilized; virtually all targeted positions had been eliminated as of December 31, 2004 and the program is substantially complete, with remaining severance and other costs expected to be paid in 2005.
2004-12-31restructuringcompleted15020022005Research and development programs across all three segmentsUSD 26 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Cumulative: fourth-quarter 2002 charge to prioritize R&D investments across the three segments; approximately 150 R&D positions eliminated ($14 million cash costs, primarily severance, and $12 million asset impairments). Fiscal 2004 activity was limited to $1 million of cash payments; the remaining reserve relates to lease payments continuing through early 2005.
2004-12-31divestiture_reductioncompleted7520022004-12-31RTS dialysis clinics primarily in Latin America and Europe; RMS businesses and offsite pharmacy business (geography not specified)Renal segment services businesses (Renal Therapy Services dialysis clinics, RMS Disease Management, RMS Lifeline) and Medication Delivery offsite pharmacy admixture businessUSD 294 (millions)discontinued_operations_footnote
f5-10k / GLM-5.3-flash-HTML		Fourth-quarter 2002 decision to divest the majority of Renal services businesses, recorded as a $294 million pre-tax exit charge ($229 million after-tax) within discontinued operations, comprising $269 million of non-cash write-downs and $25 million of cash costs tied to elimination of approximately 75 positions plus legal/contractual commitment costs. RTS centers were divested during 2003 and 2004; the RMS businesses and the offsite pharmacy admixture business were sold in 2003. Divestiture plan substantially complete at December 31, 2004; headcount effects of the RTS clinic transfers beyond the ~75 positions were not quantified.
2004-12-31restructuringin_progress4,0008%2004-06-302006-12-31Global (approximately 50% of positions in the United States)All three segments plus corporate headquarters and functionsUSD 543 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Elimination of over 4,000 positions (8% of global workforce); charge comprises $347M cash costs and $196M asset impairments. Approximately 60% of targeted positions eliminated by 2004-12-31; ~$150M cash expected in 2005 and ~$105M in 2006. Announcement date reflects second quarter 2004 as stated (day not specified).
2004-12-31plant_closurein_progress2004-06-302006-12-31GlobalBioScience (plasma collection centers and plasma production reduction)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Component of the 2004 restructuring program: further reduction of plasma production and closure of additional plasma collection centers; no separate headcount or charge disclosed. Included within the consolidated $543M charge.
2004-12-31restructuringin_progress3,2002003-06-302005-12-31GlobalAll segments; included closure of 26 U.S. plasma collection centers and a plasma fractionation facility in Rochester, MichiganUSD 337 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Cumulative through fiscal year-end; program announced Q2 2003. Virtually all 3,200 targeted positions eliminated as of 2004-12-31; $91M of the reserve was utilized during 2004, with remaining severance payable in 2005. Charge amount is the original 2003 program charge.
2004-12-31divestiture_reductionin_progress2002-12-312005-12-31Primarily Latin America and EuropeRenal (Renal Therapy Services dialysis clinics) and related services businessesdiscontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Divestiture plan substantially complete at 2004-12-31; RTS centers divested during 2004 and 2003. No headcount associated with the divestitures is disclosed; $4M of the cash-cost reserve remained at year-end.
2004-12-31restructuringin_progress4,0008%2004-06-302006-12-31GlobalAll segments and corporateUSD 543 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Announced in second quarter 2004. Approximately 60% of targeted positions eliminated as of Dec 31, 2004. Remaining expected to be completed by 2006.
2004-12-31restructuringcompleted3,2002003-06-302004-12-31GlobalAll segmentsUSD 337 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Announced in second quarter 2003. Virtually all targeted positions eliminated as of Dec 31, 2004. Program substantially complete.
2004-12-31restructuringcompleted1502002-12-312005-03-31GlobalResearch and DevelopmentUSD 26 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Announced in fourth quarter 2002. R&D prioritization charge. Remaining reserve pertains to lease payments through early 2005.
2004-12-31restructuringin_progress4,0008%2004-06-302006-12-31GlobalAll segments and corporateUSD 543 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Announced in Q2 2004. Includes elimination of over 4,000 positions (8% of global workforce). Approximately 50% of positions in US. 60% of targeted positions eliminated as of Dec 31, 2004.
2004-12-31restructuringcompleted3,2002003-06-302004-12-31GlobalAll segmentsUSD 337 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Announced in Q2 2003. Virtually all of the 3,200 targeted positions eliminated as of Dec 31, 2004. Program substantially complete.
2004-12-31restructuringcompleted1502002-12-312005-03-31GlobalR&DUSD 26 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Announced in Q4 2002. 150 R&D positions eliminated. Reserve expected to be fully utilized by early 2005.
2004-09-30restructuringin_progress4,0008%2004-012006Global (approximately 50% of positions in the United States)All three segments (Medication Delivery, BioScience, Renal) plus corporate headquarters and functionsUSD 543 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program announced January 2004, finalized in Q2 2004; eliminates over 4,000 positions (8% of global workforce). Charge comprises $347M cash costs (severance, primarily) and $196M asset impairments; after-tax charge $394M. Approximately one third of targeted positions eliminated as of 2004-09-30; about half expected eliminated by year-end 2004. Roughly three quarters of estimated savings affect G&A expenses. Cash reserve payments: ~$50M remainder of 2004, ~$150M in 2005, remainder in 2006. Filer does not present the program broken out by geography or segment counts, so one consolidated record is emitted.
2004-09-30restructuringcompleted3,2002003-062004-09-30Global (United States, Germany, France, Italy)Includes closure of 26 U.S. plasma collection centers, a plasma fractionation facility in Rochester, Michigan, and consolidation of facilities in Maryland, Frankfurt, Issoire and Mirandola; termination of recombinant hemoglobin protein programUSD 337 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Announced during Q2 2003; charge comprises $209M cash costs and $128M asset impairments; after-tax charge $202M. Virtually all targeted positions eliminated as of 2004-09-30 and program substantially complete, with remaining severance cash payments expected mostly by end of 2004. Included because the filing reports current-period reserve utilization ($26M in Q3 2004; $83M YTD 2004).
2004-09-30divestiture_reductionin_progress752002-102004-12-31Not specifiedRenal segment services businesses (discontinued operations)USD 25 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Cash-cost component of the Q4 2002 $294M pre-tax divestiture charge, covering severance and related costs for approximately 75 positions; approximately $2M of the reserve utilized during 2004. Management expects the divestiture plan to be completed by end of 2004.
2004-09-30restructuringin_progress4,0008%2004-01-01GlobalAll segments and corporate headquartersUSD 543 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Announced Jan 2004, finalized Q2 2004. Includes elimination of over 4,000 positions (8% of global workforce). Approximately 50% of positions in the US. Charge of $543 million recorded in Q2 2004 for severance, facility closures, and contract exits. Approximately one-third of targeted positions eliminated as of Sept 30, 2004.
2004-09-30restructuringcompleted3,2002003-04-01GlobalGlobalUSD 337 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Announced Q2 2003. Elimination of approx 3,200 positions worldwide. Virtually all targeted positions eliminated as of Sept 30, 2004. Program substantially complete.
2004-09-30restructuringcompleted752002-10-01GlobalRenal segment services businessesUSD 25 (millions)discontinued_operations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Recorded in Q4 2002. Elimination of approx 75 positions associated with divestiture of majority of services businesses in Renal segment. Remaining reserve insignificant and expected to be substantially utilized in 2004.
2004-06-30restructuringin_progress4,0008%2004-012006-12-31Global (approximately 50% United States)All three segments plus corporate headquarters and functionsUSD 543 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plans announced January 2004 and finalized in Q2 2004; eliminates about 4,000 positions (8% of global workforce). Pre-tax charge $543M, of which $347M cash costs (severance) and $196M asset impairments. About $100M of cash costs expected paid in 2004, $150M in 2005, remainder in 2006; savings fully implemented in 2006. Includes further plasma production reductions and closure of additional plasma collection centers.
2004-06-30restructuringin_progress3,2002003-04-302004-12-31GlobalAll segments; includes closure of 26 U.S. plasma collection centers and a plasma fractionation facility in Rochester, MichiganUSD 337 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Approximately 94% of targeted positions eliminated as of 2004-06-30; majority of remaining costs expected paid and positions eliminated by end of 2004. Charge includes $128M asset impairments and $209M cash costs. Announcement date approximate (charge recorded in Q2 2003).
2004-06-30restructuringin_progress4,0008%2004-01-012006-12-31GlobalAll segments and corporateUSD 543 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Announced Jan 2004, finalized Q2 2004. Includes elimination of ~4,000 positions (8% of global workforce). ~50% in US. Charge of $543M includes $196M asset impairments and $347M cash costs. Costs expected paid in 2004-2006.
2004-06-30restructuringin_progress3,2002003-04-012004-12-31GlobalAll segmentsUSD 337 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Announced Q2 2003. Elimination of ~3,200 positions. 94% of targeted positions eliminated as of June 30, 2004. Majority of costs expected paid by end of 2004.
2004-03-31restructuringin_progress3,2002003-06-302004-12-31WorldwideCompany-wide; includes closure of 26 US plasma collection centers, a plasma fractionation facility in Rochester, Michigan, and consolidations in Maryland, Frankfurt, Issoire and MirandolaUSD 337 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Announced during second quarter 2003 (exact date not disclosed); charge is pre-tax ($209M cash severance costs, $128M non-cash). Approximately 87% of targeted positions eliminated as of 2004-03-31; $37M of cash-cost reserve utilized in Q1 2004, leaving $103M reserve. Expected to yield $0.15-$0.20 per diluted share of annual savings when fully implemented.
2004-03-31restructuringannounced3,5007%2004-01-312006-12-31WorldwideCompany-wide; nearly three quarters of positions affect general and administrative expenses; includes reduction of plasma production and closure of additional plasma collection centersUSD 350 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Announced January 2004 (plans to be finalized during Q2 2004); count is the low end of a disclosed range of 3,500-4,000 positions, approximately 7-8% of global workforce. Charge of $350-$400M is after-tax ($0.55-$0.65 per diluted share), expected to be recorded in Q2 2004. Savings: $0.05 per diluted share in H2 2004, $0.20-$0.25 in 2005, $0.30-$0.35 when fully implemented in 2006.
2004-03-31divestiture_reductionin_progress2004-12-31United StatesRenal segment (Renal Therapy Services centers) and Medication Delivery offsite pharmacy admixture businessother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Divestiture plan of Renal services businesses (originating from a 2002 $294M pre-tax charge that included elimination of approximately 75 positions) continues; majority of transactions closed or under contract during 2003, with plan expected to be completed during 2004. Headcount removed during the current quarter not quantified.
2004-03-31restructuringin_progress3,2002003-04-012004-12-31GlobalGeneral and Administrative; Plasma CollectionUSD 337 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Second quarter 2003 charge. Elimination of approx. 3,200 positions. 87% eliminated as of March 31, 2004. Includes closure of 26 plasma centers and one fractionation facility.
2004-03-31restructuringannounced3,7507.5%2004-01-012006-12-31GlobalGeneral and Administrative; Plasma ProductionUSD 375 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Announced Jan 2004, finalized Q2 2004. Elimination of 3,500-4,000 positions (7-8% of global workforce). Expected after-tax charge $350-400M recorded in Q2 2004.
2004-03-31restructuringcompleted752002-10-012004-12-31GlobalRenal Therapy ServicesUSD 25 (millions)discontinued_operations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Part of 2002 divestiture of Renal services businesses. Elimination of approx. 75 positions. Remaining reserve expected to be utilized in 2004.
2003-12-31restructuringin_progress3,2002003-062004-12-31Global; approximately 40% of position reductions in the United States, 60% outside the United StatesCompany-wide; principally plasma therapies (BioScience) facility actions; about half of reductions manufacturing-related, remainder primarily selling, general and administrativeUSD 337 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Pre-tax charge of $337M ($202M after-tax, $0.33 per diluted share), comprising $209M cash costs (principally severance and other employee-related costs for the ~3,200 eliminated positions) and $128M non-cash impairments of property, plant and equipment, goodwill and other intangibles. Actions included closing 26 US plasma collection centers and the Rochester, Michigan plasma fractionation facility, consolidating facilities in Maryland, Frankfurt (Germany), Issoire (France) and Mirandola (Italy), and discontinuing the recombinant hemoglobin protein program. About 80% of the positions were eliminated during 2003; remaining positions and cash costs expected to be completed by end of 2004, funded by operating cash flow.
2003-12-31divestiture_reductionin_progress2002Renal Therapy Services dialysis centers principally located in Latin America and EuropeRenal segment services businesses (Renal Therapy Services, RMS Disease Management, RMS Lifeline); Medication Delivery offsite pharmacy admixture products and services businessUSD 294 (millions)discontinued_operations_footnote
f5-10k / GLM-5.3-flash-HTML		Multi-year exit program announced in Q4 2002 with a $294M pre-tax charge ($229M after-tax) that included severance for approximately 75 positions. Fiscal 2003 activity: sold RMS Lifeline, RMS Disease Management and the Medication Delivery offsite pharmacy admixture business, and closed or put under contract the majority of RTS center divestiture transactions by year-end. Headcount removed through the 2003 sales is not quantified; ~$9M of the cash-cost reserve was utilized and ~$8M reversed during 2003.
2003-12-31othercompleted12003-12-172004-01-31Executive (corporate)USD 530,000 ()other
f5-10k / GLM-5.3-flash-HTML		Individual executive separation, not a mass workforce action. One-time lump-sum payment of $530,000 less applicable withholdings, in lieu of payments under the addendum to his offer letter and conditioned on execution of a release agreement; earned 2003 Officer Incentive Compensation Plan benefit also payable in Q1 2004. Termination effective January 31, 2004, prior to the 10-K filing date.
2003-12-31otherin_progress12004-01-262004-06-30Senior Vice President and President, BioScience divisionUSD 380,000 ()subsequent_events
f5-10k / GLM-5.3-flash-HTML		Individual executive separation agreed after fiscal year-end (subsequent event), not a mass workforce action. Resignation as Executive Officer on or about February 24, 2004; employment termination June 30, 2004. Consideration includes a $380,000 lump sum, tax preparation costs for 2003-2004, relocation of household goods and family travel from Southern California to a European location of his choice, and up to 12 months of executive outplacement; also eligible for the SIP Limited Loan Extension after resigning as an officer.
2003-12-31restructuringin_progress3,2002003-062004-12-31Worldwide (approximately 40% United States, 60% rest of world)All segments; approximately half manufacturing-related, remainder primarily selling, general and administrativeUSD 337 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Pre-tax charge of $337M ($202M after tax), of which $209M cash costs (severance and employee-related) and $128M non-cash. Approximately 80% of positions eliminated during 2003; $69M of reserve utilized in 2003 with $140M remaining at year-end. Program also included discontinuation of the recombinant hemoglobin protein program.
2003-12-31plant_closurecompleted2003-062003-12-31United StatesBioScience (plasma therapies)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Closed 26 plasma collection centers across the United States to improve plasma therapies economics; headcount not separately disclosed (included in the 3,200-position restructuring total)
2003-12-31plant_closurecompleted2003-062003-12-31United States (Rochester, Michigan)BioScience (plasma fractionation)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Plasma fractionation facility closed; headcount not separately disclosed (included in the 3,200-position restructuring total)
2003-12-31plant_closurein_progress2003-062004-12-31United States (Maryland); Germany (Frankfurt); France (Issoire); Italy (Mirandola)Multiple segmentsrestructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Consolidation and integration of several facilities; headcount not separately disclosed (included in the 3,200-position restructuring total)
2003-12-31divestiture_reductionin_progress2002-102004-12-31International (primarily Latin America and Europe)Renal (Renal Therapy Services, RMS Disease Management, RMS Lifeline) and Medication Delivery (offsite pharmacy admixture)discontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		During 2003 the company sold RMS Lifeline, RMS Disease Management and the offsite pharmacy admixture business, and closed or contracted the majority of RTS center transactions. The $294M pre-tax exit charge and approximately 75 position eliminations were recorded in 2002; no 2003-specific headcount reduction disclosed. $9M of the cash-cost reserve utilized in 2003, $8M remaining.
2003-12-31acquisition_additioncompleted2003-102003-10-31United StatesBioSciencebusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		October 2003 acquisition of certain assets from Alpha Therapeutic Corporation (including Aralast) for $71M net of $36M divestiture proceeds; acquired headcount not disclosed
2003-12-31restructuringin_progress3,2002003-06-302004-12-31GlobalManufacturing, Selling, General and AdministrativeUSD 337 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Second quarter 2003 restructuring charge of $337 million. Included $209 million for cash costs (severance) associated with elimination of approx. 3,200 positions. Approx. 80% of positions eliminated during 2003. Majority of cash costs expected to be paid and remaining positions eliminated by end of 2004.
2003-12-31restructuringcompleted752002-12-312003-12-31GlobalRenal Therapy ServicesUSD 25 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Fourth quarter 2002 charge of $294 million (including $25 million cash costs for severance for approx. 75 positions) related to divestiture of Renal Therapy Services. During 2003, company sold RMS Lifeline, RMS Disease Management, and offsite pharmacy admixture business, and closed or contracted majority of RTS center divestitures.
2003-12-31restructuringcompleted1502002-12-312003-12-31GlobalResearch and DevelopmentUSD 26 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Fourth quarter 2002 R&D prioritization charge of $26 million. Included $14 million cash costs for severance associated with elimination of approx. 150 R&D positions.
2003-12-31restructuringin_progress3,2002003-06-302004-12-31GlobalManufacturing, Selling, General & AdministrativeUSD 337 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Approximately 3,200 positions eliminated worldwide. 80% eliminated by year-end 2003. Remaining expected by end of 2004. Includes closure of 26 plasma collection centers and one fractionation facility.
2003-12-31restructuringcompleted1502002-12-312005-03-31GlobalResearch & DevelopmentUSD 26 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		150 R&D positions eliminated to prioritize R&D investments. Majority of remaining cash costs expected to be paid in 2004.
2003-12-31divestiture_reductioncompleted752002-12-312003-12-31GlobalRenal ServicesUSD 294 (millions)discontinued_operations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Elimination of approximately 75 positions associated with divestiture of Renal Therapy Services and other services businesses.
2003-12-31restructuringin_progress3,2002003-06-302004-12-31Global (approximately 40% United States, 60% rest of world)Cross-segment; principally BioScience plasma operations plus manufacturing and SG&A positionsUSD 337 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Program bundles closure of 26 US plasma collection centers, the Rochester Michigan plasma fractionation facility, and consolidations in Maryland, Frankfurt, Issoire and Mirandola, plus discontinuation of the recombinant hemoglobin program. Charge comprises $128M non-cash and $209M cash costs; $69M of cash reserve utilized in 2003 with $140M remaining at year-end. Approximately 80% of positions eliminated during 2003; remainder expected by end of 2004. Filer presents no sub-component headcounts, so one consolidated record emitted.
2003-12-31plant_closurecompleted2003-06-302003-12-31United StatesBioScience — plasma collection and fractionationrestructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		26 plasma collection centers across the United States and the Rochester, Michigan plasma fractionation facility closed under the 2003 restructuring program; headcount not separately disclosed, so no double-count of the 3,200 program total.
2003-12-31divestiture_reductioncompleted2003-12-31International (principally Latin America and Europe)Renal — Renal Therapy Services, RMS Disease Management, RMS Lifeline; Medication Delivery offsite pharmacy admixturediscontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		During 2003 the company completed sales of RMS Lifeline, RMS Disease Management and the offsite pharmacy admixture business and closed or contracted most RTS center transactions. The associated $294M pre-tax exit charge and the elimination of approximately 75 positions were recorded in 2002 (prior fiscal year) and are not extracted here; no 2003-specific headcount reduction is disclosed.
2003-12-31acquisition_additioncompleted2003-10-31United StatesBioScience — alpha-1 antitrypsin (Aralast)USD 71 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		October 2003 acquisition of certain assets from Alpha Therapeutic Corporation for $71M net of $36M proceeds from immediate divestiture of certain acquired assets; acquired headcount not disclosed.
2003-12-31restructuringin_progress3,2002003-06-302004-12-31Worldwide (approximately 40% United States, 60% rest of world)Primarily manufacturing and selling/general/administrative positions across all three segmentsUSD 337 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Pre-tax charge of $337M ($202M after-tax, $0.33/diluted share). Cash costs $209M, non-cash $128M. Approximately 80% of positions eliminated during 2003; remaining expected by end of 2004. Reserve for cash costs: $140M remaining at 12/31/2003.
2003-12-31plant_closurecompleted2003-06-302004-12-31United StatesBioScience — plasma therapiesrestructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Closure of 26 plasma collection centers across the United States and a plasma fractionation facility in Rochester, Michigan. Part of the $337M restructuring program; headcount not separately disclosed for these closures.
2003-12-31plant_closurein_progress2003-06-302004-12-31Maryland (USA), Frankfurt (Germany), Issoire (France), Mirandola (Italy)Consolidation and integration of facilitiesrestructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Facility consolidations and integrations included in the $337M restructuring program; headcount not separately disclosed by facility.
2003-12-31restructuringcompleted2003-06-302003-12-31WorldwideBioScience — recombinant hemoglobin protein programrestructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Discontinuation of recombinant hemoglobin protein program due to failure to meet clinical milestones; included in the $337M restructuring charge. Headcount not separately disclosed.
2003-09-30restructuringin_progress3,20020032004-12-31Global (approximately 40% United States, 60% rest of world)Company-wide; roughly half manufacturing-related, remainder primarily selling, general and administrativeUSD 337 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Announced during Q2 2003; $209M cash severance and $128M non-cash impairment. Program includes closing 26 U.S. plasma collection centers, the Rochester, Michigan fractionation facility, and consolidations in Maryland, Frankfurt, Issoire and Mirandola; also discontinued the recombinant hemoglobin program. In Q3 2003, $28M of reserve utilized and approximately 1,740 positions eliminated. Geography split disclosed only as percentages, not counts.
2003-09-30plant_closurecompleted2003United StatesBioScience — plasma collection and fractionationrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Facility component of the Q2 2003 restructuring: 26 plasma collection centers across the United States and a plasma fractionation facility in Rochester, Michigan were closed. Headcount attributable to the closures not separately disclosed; included in the 3,200-position program total.
2003-09-30reduction_in_forcein_progress16020022003-12-31Not specifiedResearch and developmentUSD 26 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Charge recorded in Q4 2002 ($15M after tax). Approximately 148 of the planned ~160 R&D positions eliminated through 2003-09-30; management estimates ~152 will ultimately be eliminated. Remaining cash reserve of $2M at quarter end.
2003-09-30divestiture_reductionin_progress7520022003-12-31Primarily international (Renal Therapy Services centers)Renal — services businesses (RTS, RMS Disease Management, RMS Lifeline)USD 294 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q4 2002 pre-tax charge of $294M ($229M after tax) for divesting most Renal services businesses, including elimination of approximately 75 positions. RMS Lifeline and RMS Disease Management sold; majority of remaining RTS centers expected sold or under contract by end of 2003. $11M cash reserve remaining.
2003-09-30reduction_in_forcecompleted3602001Ronneby, Sweden and Miami Lakes, Florida (principal sites)Renal — A, AF and AX series dialyzer product lineUSD 189 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Legacy program disclosed with current-period activity: approximately 360 positions eliminated and the Ronneby and Miami Lakes facilities closed. $32M cash reserve remained at 2003-09-30, of which $29M relates to legal costs; certain legal payments and insurance recoveries expected in 2004.
2003-09-30plant_closurecompleted2003-102003-10United StatesBioScience — plasma collection (assets acquired from Alpha Therapeutic Corporation)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Post-quarter event: Baxter acquired assets from Alpha Therapeutic Corporation (including Aralast) for approximately $80M net of divestiture proceeds, and closed the 38 U.S. plasma collection centers included in the acquired assets. Concurrently sold three plasma collection centers, a central testing laboratory and other assets. Headcount effects not disclosed.
2003-09-30restructuringin_progress3,2002003-06-302004-12-31GlobalManufacturing, Selling, General and AdministrativeUSD 337 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Second quarter 2003 restructuring charge. Includes closure of 26 plasma collection centers and one fractionation facility. 40% of reductions in US, 60% rest of world. Half of reductions manufacturing-related, remainder SG&A. Approximately 1,740 positions eliminated by end of Q3 2003.
2003-09-30restructuringin_progress1602002-12-312005-03-31GlobalResearch and DevelopmentUSD 26 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Fourth quarter 2002 R&D prioritization charge. 148 positions eliminated through September 30, 2003. Total estimated 152 positions to be eliminated. Majority of severance paid by end of 2003, lease payments by early 2005.
2003-09-30restructuringin_progress3602001-12-312004-12-31Sweden, United StatesRenalUSD 189 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Fourth quarter 2001 charge related to discontinuing A, AF and AX series dialyzers. Facilities in Ronneby, Sweden and Miami Lakes, Florida closed. Remaining reserve $32 million at Sept 30, 2003, mostly legal costs.
2003-09-30divestiture_reductionin_progress752002-12-312004-12-31GlobalRenalUSD 294 (millions)discontinued_operations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Fourth quarter 2002 decision to divest majority of Renal segment services businesses (RTS, RMS Disease Management, RMS Lifeline). 75 positions eliminated associated with severance and employee-related costs.
2003-06-30restructuringin_progress3,2002003-06-302004-12-31Worldwide (approximately 40% United States, 60% rest of world)All segments; about half of reductions manufacturing-related, remainder primarily selling, general and administrativeUSD 337 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Charge of $337M pre-tax ($202M after tax, $0.33/diluted share): $128M non-cash (mainly P,P&E and goodwill/intangible impairments) and $209M cash severance. Includes closing 26 U.S. plasma collection centers, the Rochester, Michigan fractionation facility, and consolidations in Maryland, Frankfurt, Issoire and Mirandola; also discontinuation of the recombinant hemoglobin program. Majority of cash costs expected paid by end of 2004; expected annual savings of $0.15-$0.20 per diluted share when fully implemented.
2003-06-30plant_closurein_progress2003-06-302004-12-31United StatesBioScience — plasma collection and fractionationrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Facility-closure component of the Q2 2003 restructuring: 26 plasma collection centers across the United States plus the Rochester, Michigan plasma fractionation facility. Headcount not separately disclosed; included within the 3,200-position program total.
2003-06-30divestiture_reductionin_progress752002-12-312003-12-31International markets (Renal Therapy Services primarily Latin America)Renal — services businesses (RTS, RMS Disease Management, RMS Lifeline)USD 294 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Approximately 75 positions were eliminated in connection with the Q4 2002 decision to divest the Renal services portfolio ($294M pre-tax charge, of which $25M cash). Divestiture plan continues: RMS Lifeline sold and RMS Disease Management sale signed in July 2003; first RTS dialysis center transaction closed; plan expected complete in 2003.
2003-06-30restructuringin_progress3,2002003-06-302004-12-31GlobalManufacturing, Selling, General and AdministrativeUSD 337 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Includes closure of 26 plasma collection centers and one fractionation facility; discontinuation of recombinant hemoglobin protein program. Majority of cash costs expected paid by end of 2004.
2003-06-30restructuringin_progress1602002-12-312003-12-31GlobalResearch and DevelopmentUSD 26 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Fourth quarter 2002 R&D prioritization charge. 147 positions eliminated through June 30, 2003. Remaining cash costs expected paid in 2003.
2003-06-30divestiture_reductionin_progress752002-12-312003-12-31GlobalRenal ServicesUSD 25 (millions)discontinued_operations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Associated with decision to divest majority of Renal segment services businesses. Reserve for cash costs utilized and reversed during period.
2003-06-30restructuringin_progress3602001-12-312004-12-31Sweden, United StatesRenal ManufacturingUSD 73 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Fourth quarter 2001 charge for discontinuing A, AF and AX series dialyzers. Facilities in Ronneby, Sweden and Miami Lakes, Florida closed. Legal payments expected in 2004.
2003-03-31restructuringin_progress1602002-12-312003-12-31Research and development, across all three operating segmentsUSD 26 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Charge recorded in Q4 2002 to prioritize R&D investments; exact announcement date not disclosed. Approximately 142 of the ~160 positions had been eliminated through 2003-03-31, with about $7 million of cash costs paid during Q1 2003; majority of remaining severance expected paid in 2003. Charge comprised $14 million cash (severance) and $12 million non-cash impairment.
2003-03-31divestiture_reductionin_progress752002-12-312003-12-31International markets (Renal services operations, primarily Latin America)Renal segment — services businesses (Renal Therapy Services, RMS Disease Management, RMS Lifeline)USD 25 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Decision to divest majority of Renal services businesses made in Q4 2002; exact announcement date not disclosed. Total pre-tax charge was $294 million, of which $25 million was cash costs principally for severance and employee-related costs tied to elimination of approximately 75 positions. $1 million of the cash reserve was used in Q1 2003 (transaction costs); divestiture expected completed during 2003.
2003-03-31restructuringcompleted3602001-12-31Ronneby, Sweden and Miami Lakes, Florida (manufacturing facilities closed); workforce reductions also in other locationsRenal segment — A, AF and AX series dialyzer product lineUSD 189 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Charge recorded in Q4 2001 to discontinue the dialyzer product line; exact announcement date not disclosed. Elimination of approximately 360 positions, principally at the two closed facilities. Position reductions substantially complete; $2 million of legal costs paid in Q1 2003, leaving $36 million cash reserve at 2003-03-31, with certain legal payments and insurance recoveries expected in 2004.
2003-03-31restructuringin_progress752002-10-012003-12-31GlobalRenalUSD 25 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Divestiture of majority of Renal services businesses; 75 positions eliminated. $25M cash costs for severance and employee-related costs. $1M utilized in Q1 2003.
2003-03-31restructuringin_progress3602001-10-012003-12-31Sweden, United StatesRenalUSD 73 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Discontinuation of A, AF and AX series dialyzers. 360 positions eliminated in Ronneby, Sweden and Miami Lakes, Florida. $73M cash costs including severance. $2M legal costs paid in Q1 2003.
2003-03-31restructuringin_progress1602002-10-012003-12-31GlobalResearch and DevelopmentUSD 14 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		R&D prioritization initiative. 160 positions targeted; 142 eliminated through March 31, 2003. $14M cash costs for severance. $7M paid in Q1 2003.
2002-12-31divestiture_reductionin_progress752002-12-042003Principally Latin America and Europe (RTS dialysis centers); also U.S.-based RMS Disease Management and RMS LifelineRenal — services businesses (Renal Therapy Services, RMS Disease Management, RMS Lifeline)USD 294 (millions)discontinued_operations_footnote
f5-10k / GLM-5.3-flash-HTML		Q4 2002 decision to divest majority of Renal services businesses; intent announced via Form 8-K dated December 4, 2002. Total pre-tax exit charge of $294M comprises $269M non-cash impairments (property/equipment, goodwill, intangibles) and $25M cash costs, principally severance for approximately 75 eliminated positions plus legal and contractual commitments. Charge also includes $16M for exiting the Medication Delivery offsite pharmacy admixture business. Additional severance possible in 2003; divestiture plan expected completed in 2003.
2002-12-31restructuringin_progress1602002-102003Research & Development (across Medication Delivery, BioScience and Renal segments)USD 26 (millions)other
f5-10k / GLM-5.3-flash-HTML		announcement_date reflects start of Q4 2002, when the program was executed. Approximately 160 R&D positions eliminated; charge comprises $14M cash costs primarily employee severance and $12M non-cash write-downs of property, equipment and other assets. $2M of cash costs paid in Q4 2002; remaining cash costs expected paid in 2003. Management deems the reserve adequate to complete the actions.
2002-12-31restructuringcompleted1602002-10-012003-03-31GlobalResearch & DevelopmentUSD 26 (millions)MD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Approximately 160 R&D positions eliminated as part of a $26M pre-tax charge to prioritize R&D investments across three segments; $2M cash costs paid in Q4 2002, remainder expected in early 2003
2002-12-31divestiture_reductionin_progress752002-12-042003-12-31Latin America and Europe (primarily)Renal — Renal Therapy Services (RTS)USD 25 (millions)discontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Cash costs of $25M for severance and other employee-related costs tied to elimination of approximately 75 positions; part of a $294M pre-tax charge ($229M after-tax) for divesting majority of Renal services businesses; additional severance possible in 2003
2002-12-31restructuringcompleted1602002-12-312003-03-31GlobalResearch and DevelopmentUSD 26 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Pre-tax charge of $26 million to prioritize R&D investments. Approximately 160 R&D positions eliminated. Remaining cash costs expected to be paid in early 2003.
2002-12-31restructuringcompleted3602001-10-012004-12-31GlobalRenalUSD 73 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Elimination of approximately 360 positions associated with global recall and cessation of manufacturing A, AF and AX series dialyzers. Charge recorded in 2001; cash costs paid through 2004.
2002-12-31divestiture_reductionin_progress752002-12-312003-12-31GlobalRenalUSD 25 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Decision to divest majority of Renal services businesses. Elimination of approximately 75 positions. Majority of cash costs expected to be paid in 2003.
2002-12-31restructuringcompleted1602002-12-312003-03-31GlobalResearch and DevelopmentUSD 26 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Pre-tax charge of $26 million to prioritize R&D investments; approximately 160 R&D positions eliminated.
2002-12-31restructuringcompleted3602001-10-012004-12-31GlobalRenalUSD 73 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Cash costs principally pertaining to legal costs, recall costs, contractual commitments, and severance associated with elimination of approximately 360 positions due to dialyzer recall.
2002-12-31restructuringin_progress752002-12-312003-12-31Latin America and EuropeRenalUSD 25 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Cash costs principally relating to severance and other employee-related costs associated with elimination of approximately 75 positions in divestiture of Renal services businesses.
2002-09-30plant_closurein_progress3602001-10Sweden (Ronneby); United States (Miami Lakes, Florida)RenalUSD 73 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program announced in Q4 2001; positions eliminated relate to the 2001 charge. This filing reports ongoing reserve utilization and that the Miami Lakes facility closure is still in process; no new headcount reductions were announced in the current quarter.
2002-09-30restructuringin_progress3602001-10-012002-12-31Global (primarily Ronneby, Sweden and Miami Lakes, Florida)RenalUSD 73 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charge relates to discontinuing A, AF and AX series dialyzers. Includes severance for approx 360 positions. Remaining reserve expected substantially utilized by end of year.
2001-12-31plant_closurecompleted3602001-10Global (Ronneby, Sweden and Miami Lakes, Florida, United States)RenalUSD 189 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Global recall of A, AF and AX dialyzers initiated October 2001 after reports of patient deaths; manufacturing permanently ceased, Ronneby facility closure in process and Miami Lakes facility closed. $189M pretax charge ($156M after-tax) includes $12M severance for approximately 360 eliminated positions (substantially all eliminated by 2001-12-31), $21M inventory write-off, $15M PP&E write-down, $80M goodwill/intangible impairment, and $61M other costs (recall, litigation, long-term lease). Approximately $13M of cash costs paid by year-end; facility wind-down and litigation still ongoing at fiscal year-end.
2001-12-31acquisition_additioncompleted2001-102001-10Germany (worldwide oncology operations)Medication Deliverybusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquired oncology business from Degussa AG for a $455 million purchase price (including a $250M IPR&D charge); related to this acquisition Baxter issued 9.7 million common shares for $500 million in December 2001 to rebalance capital structure. Headcount added through the acquisition not disclosed.
2001-12-31acquisition_additioncompleted2001-082001-08United StatesMedication Deliverybusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquired contract filling business for syringes and vials (formerly a unit of Cook Group Incorporated) for a $220 million purchase price, paid with approximately 2.1 million Baxter shares plus $111 million cash. Headcount added through the acquisition not disclosed.
2001-12-31acquisition_additioncompleted2001-022001-02United StatesBioSciencebusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquired plasma-collection business operating 80 plasma centers in 28 states plus a central testing laboratory for a $127 million purchase price paid in approximately 2.8 million Baxter shares. Headcount added through the acquisition not disclosed.
2001-12-31restructuringcompleted3602001-10-012001-12-31Sweden and United StatesRenalUSD 12 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Severance for elimination of ~360 positions following global recall of A, AF and AX dialyzers; substantially all positions eliminated by year-end. Part of $189M pretax charge including facility closures at Ronneby, Sweden and Miami Lakes, Florida.
2001-12-31plant_closurecompleted2001-10-012001-12-31SwedenRenalrestructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Ronneby, Sweden manufacturing facility being closed; Miami Lakes, Florida facility also closed. Headcount not separately disclosed from the 360-position severance figure.
2001-12-31restructuringcompleted3602001-10-012001-12-31Global (primarily Ronneby, Sweden and Miami Lakes, Florida)RenalUSD 12 (millions)Note 4
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Severance costs resulting from the elimination of approximately 360 positions due to the decision to permanently cease manufacturing A, AF and AX series dialyzers. Substantially all positions eliminated by year-end.
2001-12-31restructuringcompleted3602001-102001-12-31Global (primarily manufacturing facilities)RenalUSD 12 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Elimination of approximately 360 positions due to discontinuation of A, AF and AX series dialyzers. Substantially all positions eliminated by year-end.
2001-09-30plant_closureannounced2001-10-31Ronneby, SwedenRenal — A series dialyzer manufacturingUSD 125 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		After-tax charge estimated at $100–150M (midpoint shown); after-tax cash impact estimated no more than $50M. No employee count disclosed.
2001-09-30acquisition_additioncompleted2001-10-302001-10-30Germany (global operations)Medication Delivery — OncologyUSD 470 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquired ASTA Medica Onkologie GmbH & CoKG from Degussa AG for approximately €525M ($470M). No headcount disclosed. Substantial portion of purchase price expected to be expensed as in-process R&D.
2000-12-31restructuringcompleted3751998WorldwidePrincipally BioScience and Medication Delivery segmentsUSD 122 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		1998 decisions to end clinical development of HemAssist (DCLHb), exit non-strategic investments (primarily Asia) and reorganize activities. Total charge included $74 million of asset write-downs and $48 million of other costs, of which $34 million was employee severance for elimination of approximately 375 positions worldwide. Approximately 360 positions eliminated through December 31, 2000 (cumulative through fiscal year-end); program substantially complete as originally planned, with FY2000 reserve utilization of $4 million (employee-related) and $3 million of reserves remaining at year-end.
2000-12-31restructuringin_progress1996-12EuropeBioScience (primarily sales and marketing functions)USD 79 (millions)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Reserves established at the December 1996 acquisition of Immuno International AG for employee severance from European headcount reductions ($38 million employee-related) and contract termination/other costs ($41 million). FY2000 reserve utilization was $16 million ($3 million employee-related); remaining reserve $26 million at December 31, 2000. Number of positions affected not disclosed.
2000-12-31divestiture_reductioncompleted2000-03-31Cardiovascular business (Edwards Lifesciences Corporation)discontinued_operations_footnote
f5-10k / GLM-5.3-flash-HTML		Tax-free spin-off completed March 31, 2000 (announcement date shown is the spin-off completion date); distribution of Edwards stock totaled $961 million. Headcount transferred/removed not disclosed. Edwards employees were required to exercise vested stock options within 90 days of the spin-off and unvested options were canceled; U.S. defined benefit pension and retiree health/life benefits were frozen for Edwards employees at the spin-off date.
2000-12-31acquisition_additioncompleted2000-01United StatesMedication DeliveryMD&A
f5-10k / GLM-5.3-flash-HTML		January 2000 acquisition of a domestic ambulatory and infusion pump business (identified in Item 1 as the ambulatory infusion pump business of Sabratek Corporation). Headcount added not disclosed.
2000-12-31acquisition_additioncompleted2000-03SwedenRenalbusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquisition of Althin Medical A.B., a hemodialysis products manufacturer based in Ronneby, Sweden, completed March 2000; approximately $55 million net cash outflow plus roughly 592,000 Baxter common shares. Headcount added not disclosed.
2000-12-31acquisition_additioncompleted2000-06United StatesBioSciencebusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquisition completed June 2000; $328 million purchase price paid principally in approximately 3,770,000 Baxter common shares, with a $250 million in-process R&D charge. Headcount added not disclosed.
2000-12-31acquisition_additioncompleted2001-02-01United StatesBioScience (plasma collection)Item_1_Business
f5-10k / GLM-5.3-flash-HTML		Completed February 1, 2001, subsequent to fiscal year-end: acquisition of Sera-Tec Biologicals, L.P., which operates approximately 80 plasmapheresis centers in 28 states and a central testing laboratory, bringing Baxter's total plasma collection centers to approximately 110 worldwide. Headcount added not disclosed.
2000-12-31restructuringin_progress3601998-01-01WorldwideBioScience and Medication DeliveryUSD 4 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Cumulative through fiscal year-end; program originated in 1998 with ~375 positions targeted; ~360 eliminated through Dec 31, 2000; FY2000 reserve utilization was $4M; reserves of $3M remain
2000-12-31divestiture_reductioncompleted2000-03-312000-03-31WorldwideCardiovascular (Edwards Lifesciences)discontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Tax-free spin-off of Edwards Lifesciences to shareholders of record March 29, 2000; headcount not disclosed
2000-12-31acquisition_additioncompleted2000-06-012000-06-30United StatesBioScienceUSD 250 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of North American Vaccine Inc. (NAV), Columbia, Maryland; $250M IPR&D charge; headcount not disclosed
2000-12-31acquisition_additioncompleted2000-03-012000-03-31SwedenRenalbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Althin Medical AB, Ronneby, Sweden; headcount not disclosed
2000-12-31acquisition_additionannounced2001-02-012001-02-01United StatesBioSciencesubsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Sera-Tec Biologicals L.P., ~80 plasmapheresis centers in 28 states plus a central testing laboratory; headcount not disclosed
2000-12-31restructuringcompleted36019982000-12-31WorldwideBioScience and Medication DeliveryUSD 122 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Program initiated in 1998 to end clinical development of HemAssist, exit non-strategic investments, and reorganize activities. Approximately 375 positions targeted; 360 eliminated through December 31, 2000. Program substantially complete.
2000-12-31restructuringcompleted36019982000-12-31WorldwideBioScience and Medication DeliveryUSD 34 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Part of 1998 program to end HemAssist development and exit non-strategic investments. 375 positions targeted; 360 eliminated through Dec 31, 2000. Employee-related costs of $34M charged in 1998.
2000-06-30acquisition_additioncompleted2000-06-30United StatesBioScienceUSD 286 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		June 2000 acquisition of NAV for approximately $420 million, principally paid in 3,770,000 shares; included a $250 million IPR&D charge. No employee headcount added disclosed.
2000-06-30acquisition_additioncompleted2000-03-31SwedenRenalbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		March 2000 acquisition of hemodialysis products manufacturer for approximately $134 million including assumed debt. No employee headcount added disclosed.
2000-06-30divestiture_reductioncompleted2000-03-31GlobalCardiovascular (discontinued operation)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Tax-free spin-off of Edwards Lifesciences Corporation to Baxter stockholders; approximately $961 million of net assets transferred. No employee headcount removed disclosed.
2000-03-31divestiture_reductioncompleted2000-03-312000-03-31GlobalCardiovascular (Edwards Lifesciences)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Tax-free spin-off of Edwards Lifesciences Corporation distributed to Baxter stockholders of record on March 29, 2000; no employee headcount disclosed.
2000-03-31acquisition_additioncompleted2000-03-312000-03-31InternationalRenalbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquired Althin Medical A.B., a hemodialysis products manufacturer, for approximately $120 million; no employee headcount disclosed.
2000-03-31divestiture_reductioncompleted2000-03-312000-03-31GlobalCardiovascular BusinessUSD 12 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Spin-off of Edwards Lifesciences Corporation completed March 31, 2000. $12 million in costs associated with effecting the business distribution recorded. Specific headcount transferred not disclosed.
2000-03-31acquisition_additioncompleted2000-03-312000-03-31GlobalRenalUSD 120 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Althin Medical A.B. completed in March 2000 for approximately $120 million. Specific headcount added not disclosed.
1999-12-31divestiture_reductionannounced1999-07-112000-03-31GlobalCardioVasculardiscontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Board approved spin-off of CardioVascular business as Edwards Lifesciences Corporation; no headcount disclosed for the spun-off business
1999-12-31acquisition_additionannounced1999-11-012000-06-30United StatesBlood TherapiesUSD 390 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Stock-for-stock acquisition of North American Vaccine, Inc. valued at approximately $390 million; expected to close first six months of 2000; substantial portion of purchase price expected to be allocated to IPR&D
1999-12-31acquisition_additioncompleted1999-12-012000-03-31SwedenRenalUSD 130 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Cash and stock acquisition of Althin Medical A.B. valued at approximately $130 million including assumed debt; closed March 2000 (subsequent to fiscal year end)
1999-12-31restructuringcompleted3751998-091999-12-31WorldwideBlood Therapies, I.V. Systems/Medical ProductsUSD 34 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		1998 program to end HemAssist development and exit non-strategic investments. 340 positions eliminated through Dec 31, 1999. Employee-related costs of $34M charged in 1998.
1999-12-31restructuringcompleted1,2001995-091999-12-31Puerto Rico, United StatesI.V. Systems/Medical ProductsUSD 27 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		1995 program to eliminate excess plant capacity. Reserves fully utilized during 1999 as employee severance was paid.
1999-09-30restructuringin_progress3751998-09WorldwideBlood Therapies; I.V. Systems/Medical ProductsUSD 122 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Pretax charge comprised about $34M severance for 375 positions, about $74M asset writedowns, about $14M contract obligations. About 270 positions eliminated as of 1999-09-30; roughly $5M of reserves remain. MD&A describes the program as substantially complete.
1999-09-30plant_closurecompleted1,2001995-091999-03-31Puerto RicoI.V. Systems/Medical Products (intravenous solutions)USD 103 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Charge primarily covered closure of the Carolina, Puerto Rico intravenous-solutions plant and warehouse to eliminate excess capacity. Remaining reserves were used in Q1 1999 for severance and wind-down; about 1,200 positions eliminated, with some direct-labor roles added at other sites.
1999-09-30restructuringin_progress1998Dialysis and intravenous solutions and containersUSD 19 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Bieffe Medital acquisition-date reserves for headcount rationalization and contract exits. About $1M used during the nine months ended 1999-09-30; about $15M remained, of which roughly $4M is employee-related and $11M contract termination and other costs. No employee count disclosed.
1999-09-30restructuringin_progress1997EuropeSales and MarketingUSD 79 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Immuno International AG reserves for headcount rationalization, activity exits and contract terminations. About $8M used during the nine months ended 1999-09-30; about $42M remained, including roughly $15M employee-related. Reductions span functions and geographies but principally European sales and marketing. No employee count disclosed.
1999-09-30restructuringin_progressUSD 25 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Clintec Nutrition Company acquisition-date reserves, principally severance from headcount eliminations. About $1M used during the nine months ended 1999-09-30; about $18M remained at 1999-09-30. Acquisition date and employee count not disclosed in this filing.
1999-09-30restructuringin_progress3751998-09-01WorldwideBlood Therapies and I.V. Systems/Medical ProductsUSD 34 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		1998 program to end HemAssist development and exit non-strategic investments. 375 positions targeted; 270 eliminated as of Sept 30, 1999. $34M severance charge recorded in 1998.
1999-09-30plant_closurecompleted1,2001995-09-011999-03-31Puerto RicoI.V. Systems/Medical ProductsUSD 103 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		1995 program to close intravenous-solutions plant in Carolina, Puerto Rico. 1,200 positions eliminated. Program completed in Q1 1999.
1999-09-30restructuringin_progress1998-01-01EuropeSales and MarketingUSD 15 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Post-acquisition rationalization of Immuno headcount. $15M of remaining $42M reserves pertains to employee-related costs.
1999-09-30restructuringin_progress1998-01-01VariousVariousUSD 4 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Post-acquisition rationalization of Bieffe headcount. $4M of remaining $15M reserves pertains to employee-related costs.
1999-09-30restructuringin_progress1998-01-01VariousVariousUSD 18 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Post-acquisition rationalization of Clintec headcount. Reserve balance of $18M relates principally to employee-related costs.
1999-06-30restructuringin_progress4001998-09WorldwideBlood Therapies; I.V. Systems/Medical ProductsUSD 38 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Total $131M pretax charge for asset writedowns and severance; ~330 of ~400 positions eliminated as of 1999-06-30, ~$19M reserves remaining (~$6M employee-related). Tied to ending HemAssist (DCLHb) clinical development and exiting non-strategic Asia investments.
1999-06-30plant_closurecompleted1,2001995-091999-03-31Carolina, Puerto RicoI.V. Systems — intravenous solutions plant and warehouseUSD 103 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program completed; remaining reserves utilized in Q1 1999 for severance and wind-down. Some direct-labor positions added at other facilities.
1999-06-30divestiture_reductionannounced1999-07-112000-06-30WorldwideCardiovascular businesssubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Board approved tax-free spin-off of cardiovascular business; distribution expected in first six months of 2000. No headcount disclosed; portion of Baxter debt expected to be indirectly assumed by new company.
1999-06-30restructuringin_progress4001998-09-01WorldwideBlood Therapies and I.V. Systems/Medical ProductsUSD 38 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		1998 program: 330 positions eliminated to date; $19 million reserves remaining at June 30, 1999, of which $6 million pertain to employee-related costs.
1999-06-30plant_closurecompleted1,2001995-09-011999-03-31Puerto RicoI.V. Systems/Medical Productsrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		1995 program: Closure of intravenous-solutions plant and warehouse in Carolina, Puerto Rico. Remaining reserves utilized during Q1 1999 as severance paid and wind-down completed.
1999-03-31restructuringin_progress4001998-09-01WorldwideBlood Therapies; I.V. Systems/Medical ProductsUSD 131 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Pretax charge primarily for asset writedowns and employee severance; $38M related to severance. Approximately 200 positions eliminated to date; ~$96M of reserves utilized to date, of which ~$19M pertained to employee-related costs. Driven by termination of HemAssist (DCLHb) clinical development, exit of non-strategic investments (primarily Asia), and reorganization of certain activities.
1999-03-31plant_closurecompleted1,2001995-09-011999-03-31Puerto RicoI.V. Systems (intravenous solutions plant and warehouse)USD 103 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Closure of Carolina, Puerto Rico IV-solutions plant and warehouse to eliminate excess capacity. Remaining reserves utilized during Q1 1999 as severance paid and wind-down completed. Some positions added at other facilities to support increased production.
1999-03-31restructuringin_progress4001998-09WorldwideBlood Therapies, I.V. Systems/Medical ProductsUSD 38 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		September 1998 program to end HemAssist development and exit non-strategic investments. 200 positions eliminated to date; $19M of reserves utilized for employee costs.
1999-03-31plant_closurecompleted1,2001995-091999-03-31Puerto RicoI.V. Systems/Medical Productsrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		1995 restructuring program completed in Q1 1999 with payment of remaining severance and wind-down activities.
1998-12-31restructuringin_progress4001998-091999WorldwidePrincipally Blood Therapies and I.V. Systems/Medical ProductsUSD 131 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		September 1998 decisions to end HemAssist (DCLHb) clinical development, exit non-strategic investments primarily in Asia, and reorganize certain activities. Total pretax charge primarily asset writedowns and severance; approximately $38 million is severance tied to the roughly 400 positions. About 170 positions eliminated to date; program expected substantially completed in early 1999. Also discussed in MD&A.
1998-12-31plant_closurein_progress1,2001995-091999Puerto Rico (primarily)Manufacturing and warehousingUSD 103 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Multi-year program announced September 1995 to eliminate excess plant capacity and reduce manufacturing costs, mainly via closure of a plant and warehouse in Puerto Rico, with asset writedowns and severance. The approximately 1,200 positions eliminated is cumulative through fiscal year-end 1998; production and warehousing consolidated into other facilities; completion expected in early 1999.
1998-12-31restructuringin_progress4001998-09-301999-12-31WorldwideBlood Therapies; I.V. Systems/Medical ProductsUSD 38 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Total $131M charge includes $38M severance for ~400 positions; ~170 eliminated to date. Related to ending HemAssist clinical development, exiting non-strategic Asian investments, and reorganizing activities. Both 1995 and 1998 programs expected substantially complete in early 1999.
1998-12-31restructuringin_progress4001998-09-011999-03-31WorldwideBlood Therapies, I.V. Systems/Medical ProductsUSD 131 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Charge relates to ending HemAssist clinical development, exiting non-strategic investments, and reorganizing activities. Approximately 170 positions eliminated to date; program expected to complete in early 1999.
1998-12-31restructuringin_progress1,2001995-09-011999-03-31Puerto Rico, United StatesManufacturingrestructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		1995 program to eliminate excess plant capacity. Approximately 1,200 positions eliminated. Program expected to be substantially completed in early 1999.
1998-12-31restructuringin_progress4001998-091999-03WorldwideBlood Therapies; I.V. Systems/Medical ProductsUSD 131 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Charge related to ending HemAssist development, exiting non-strategic investments, and reorganizing activities. Approximately $38 million relates to employee severance for 400 positions. Program expected to be substantially completed in early 1999.
1998-12-31restructuringin_progress1,2001995-091999-03Puerto Rico; United StatesManufacturingrestructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		1995 program to eliminate excess plant capacity. Approximately 1,200 positions eliminated. Expected to be completed in early 1999. No new charge recorded in 1998; remaining reserves utilized.
1998-09-30restructuringin_progress4001998-09-16WorldwidePrimarily manufacturing (Neuchatel, Switzerland facility) plus non-strategic investments in Asia and other reorganized activitiesUSD 40 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		September 1998 decision to end clinical development of first-generation HemAssist (DCLHb), exit non-strategic investments and reorganize activities; total pre-tax charge $131 million, of which about $40 million is severance for roughly 400 positions; remainder is primarily asset writedowns at the Neuchatel facility. Decision reported on Form 8-K filed 1998-09-16.
1998-09-30restructuringin_progress1,2001995-091999Puerto Rico and United StatesIntravenous-solutions manufacturing and warehousing (Carolina, Puerto Rico plant closure); organizational structure changesrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		1995 restructuring program ($103 million charge) to eliminate excess plant capacity; approximately 1,200 positions to be eliminated in total, about 900 eliminated to date, completion anticipated early 1999; approximately $7 million of reserves utilized during the nine months ended 1998-09-30. Delayed by governmental regulatory reviews of equipment and production transfers.
1998-09-30restructuringin_progress4001998-09WorldwideBiopharmaceuticals / Oxygen-carrying therapeuticsUSD 40 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Part of $131M total charge for ending first-gen oxygen-carrying therapeutic program and exiting non-strategic investments.
1998-09-30restructuringin_progress1,2001995-091999-03Puerto Rico / United StatesManufacturing / Intravenous solutionsrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		1995 program to eliminate excess plant capacity; 900 positions eliminated to date, completion anticipated early 1999.
1998-06-30restructuringin_progress1,2001995-091999Puerto Rico and United StatesIntravenous solutions manufacturing and warehousingUSD 103 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program announced September 1995 targets approximately 1,200 positions for elimination in total; approximately 500 positions had been eliminated as of June 30, 1998. Charge predominantly relates to closing the Carolina, Puerto Rico plant and warehouse. About $2 million of reserves were used in the first half of 1998; completion delayed by regulatory reviews of equipment and production transfers. No total workforce figure is disclosed, so percent-of-workforce cannot be computed.
1998-06-30acquisition_additioncompleted1998-05United StatesBiopharmaceuticals (recombinant hemoglobin technology)USD 116 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Purchase price approximately $206 million, principally settled in stock; approximately $116 million allocated to in-process R&D and expensed. Headcount added through the acquisition is not disclosed.
1998-06-30acquisition_additioncompleted1998-04United StatesPharmaceutical Products Division (anesthesia gases and drugs)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquired for approximately $91 million; fair value of identifiable net assets exceeded purchase price by about $149 million. Headcount added through the acquisition is not disclosed.
1998-06-30acquisition_additionin_progress1998EuropeDialysis and intravenous solutions and containersbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Majority interest acquired in early 1998 for a total purchase price of approximately $244 million including assumed debt; remaining shares purchased in July 1998 (subsequent to quarter end). Headcount added through the acquisition is not disclosed.
1998-06-30restructuringin_progress1,2001995-091999Puerto RicoManufacturingUSD 103 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Initiated in September 1995 to eliminate excess plant capacity. Approximately 500 positions eliminated to date; substantial completion anticipated in 1999. Delays due to regulatory reviews.
1998-03-31restructuringin_progress1,2001995-091999-12-31Puerto Rico, United StatesManufacturing (intravenous solutions)USD 103 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program targets elimination of approximately 1,200 positions; approximately 370 eliminated to date. About $1 million of reserves used in Q1 1998. Completion delayed by regulatory reviews for equipment and production transfers; anticipated 1999.
1998-03-31acquisition_additioncompleted1998-01EuropeDialysis and intravenous solutions (Bieffe Medital S.p.A.)USD 244 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Majority interest acquired for approximately $244 million including assumed debt; headcount not disclosed. Purchase of remaining shares expected mid-1998.
1998-03-31acquisition_additionannounced1998-04Pharmaceutical Products Division of Ohmeda health-care business (BOC Group)USD 104 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquired April 1998 for approximately $104 million; manufacturer of gases and drugs for anesthesia. Headcount not disclosed.
1998-03-31acquisition_additionannounced1998-05Biopharmaceuticals — recombinant hemoglobin technology (Somatogen, Inc.)USD 200 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquired May 1998 for approximately $200 million, principally in stock, plus contingent deferred cash payment of up to about $42 million. Significant portion of purchase price to be expensed as in-process R&D in Q2 1998. Headcount not disclosed.
1998-03-31restructuringin_progress1,2001995-091999Puerto Rico and United StatesManufacturing and Organizational StructureUSD 103 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Program initiated in September 1995 to eliminate excess plant capacity and reduce manufacturing costs. Approximately 370 positions eliminated to date. Completion anticipated in 1999.
1997-12-31restructuringin_progress1,9501993-111998Worldwide (United States, Europe, Japan, Canada)Company-wideUSD 216 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Cumulative through fiscal year-end 1997: approximately 1,950 positions eliminated since program inception, exceeding the 1,640 originally targeted; program expected substantially complete in 1998. Costs covered severance, outplacement, relocation and retention. Combined remaining restructuring reserves were $44 million at December 31, 1997 ($15 million cash utilized in 1997).
1997-12-31restructuringin_progress1,2001995-091999Primarily Carolina, Puerto RicoI.V. Systems/Medical Products (intravenous-solutions manufacturing)USD 103 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Program estimated to eliminate approximately 1,200 positions in total; about 350 eliminated cumulatively through year-end 1997. Predominantly closure of the intravenous-solutions plant and warehouse in Carolina, Puerto Rico, plus organizational changes; timetable delayed by governmental regulatory reviews of equipment and production transfers. Completion anticipated in 1999.
1997-12-31acquisition_additioncompleted1997Global (Switzerland-based; strengthens Europe and emerging markets)Blood Therapiesbusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquired in the first fiscal quarter of 1997 for approximately $600 million plus $280 million of assumed net debt; headcount added not disclosed. Purchase price included a ~$220 million in-process R&D charge and ~$58 million withheld for legal contingencies.
1997-12-31acquisition_additioncompleted1997-03United StatesCardioVascularbusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquired March 1997 for $239 million, principally settled with 4,801,711 Baxter common shares issued from treasury; headcount added not disclosed.
1997-12-31divestiture_reductioncompleted1997-12Immunotherapy divisionbusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		December 1997: certain assets of the Immunotherapy division were divested into a new cell-therapy joint venture with VIMRX Pharmaceuticals; Baxter holds a minority position plus warrants and recognized a $32 million pretax gain. Employee transfer count not disclosed.
1997-12-31acquisition_additionannounced1997-071998-06EuropeRenal / I.V. Systems/Medical Products (dialysis and IV solutions)subsequent_events
f5-10k / GLM-5.3-flash-HTML		Definitive agreement signed July 1997 for approximately $235 million including assumed debt; ~$48 million of installments paid in 1997. Recorded in early 1998 when Baxter became majority shareholder; remaining shares expected mid-1998. Headcount not disclosed.
1997-12-31acquisition_additionannounced1998-011998Pharmaceutical Products (anesthesia gases and drugs)subsequent_events
f5-10k / GLM-5.3-flash-HTML		January 1998 definitive agreement to acquire the Pharmaceutical Products Division of BOC Group's Ohmeda business for approximately $104 million; subject to antitrust review, expected to close in 1998. Headcount not disclosed.
1997-12-31acquisition_additionannounced1998-021998United StatesBlood Therapies (recombinant hemoglobin technology)Item_1_Business
f5-10k / GLM-5.3-flash-HTML		February 1998 definitive agreement to acquire publicly-held Somatogen, Inc.; substantial portion of purchase price expected to be expensed as in-process R&D; subject to Somatogen shareholder approval and antitrust review, expected to close in 1998. Headcount not disclosed.
1997-12-31restructuringin_progress1,9501993-11-011998-12-31United States, Europe, Japan, CanadaMultipleUSD 216 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Cumulative through fiscal year-end; 1993 program eliminated ~1,950 positions since inception, exceeding original target of 1,640. Program expected substantially complete in 1998.
1997-12-31plant_closurein_progress3501995-09-011999-12-31Puerto RicoI.V. Systems — intravenous solutions manufacturingUSD 103 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Cumulative through fiscal year-end; 1995 program targets ~1,200 total positions, ~350 eliminated to date. Closure of IV solutions plant and warehouse in Carolina, Puerto Rico. Completion delayed by regulatory reviews; anticipated 1999.
1997-12-31acquisition_additioncompleted1997-03-011997-03-31Switzerland, EuropeBlood TherapiesUSD 600 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition cost ~$600M plus $280M net debt assumed. Headcount not disclosed. $220M allocated to in-process R&D expensed.
1997-12-31acquisition_additioncompleted1997-03-011997-03-31United StatesCardioVascularUSD 239 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Purchase price $239M settled with 4,801,711 shares of Baxter common stock. Headcount not disclosed. $132M allocated to in-process R&D expensed.
1997-12-31acquisition_additionannounced1998-01-011998-12-31InternationalAnesthesia (Pharmaceutical Products Division of Ohmeda)USD 104 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement signed January 1998 to acquire Pharmaceutical Products Division of BOC Group's Ohmeda for ~$104M. Subject to antitrust review; expected to close in 1998. Headcount not disclosed.
1997-12-31acquisition_additionannounced1998-02-011998-12-31United StatesBlood Therapies — recombinant hemoglobinsubsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement signed February 1998 to acquire Somatogen, Inc. Substantial portion of purchase price expected to be expensed as in-process R&D. Subject to shareholder approval and antitrust review.
1997-12-31restructuringin_progress1,9501993-111998-12-31WorldwideVariousUSD 216 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		1993 program. Cumulative positions eliminated to date. Expected substantially completed in 1998.
1997-12-31restructuringin_progress3501995-091999-12-31Puerto RicoManufacturingUSD 103 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		1995 program. 350 positions eliminated to date of approximately 1,200 total estimated. Completion anticipated in 1999.
1997-12-31restructuringin_progress1,9501993-111998-12-31WorldwideUSD 216 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		1993 program. Cumulative positions eliminated through fiscal year-end 1997. Exceeds original target of 1,640 positions.
1997-12-31restructuringin_progress3501995-091999-12-31Puerto RicoManufacturingUSD 103 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		1995 program. Positions eliminated to date. Total estimated elimination is 1,200 positions. Primarily relates to closure of intravenous-solutions plant and warehouse in Carolina, Puerto Rico.
1997-09-30restructuringin_progress1,8761993-111998-12-31United States, Europe, Japan, CanadaMultiple — reorganizations and consolidationsUSD 216 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Cumulative positions eliminated since program inception (1,876), exceeding the 1,640 originally targeted; not a current-quarter figure. Remaining reserve was $23 million at 1997-09-30.
1997-09-30plant_closurein_progress1,4501995-091998-12-31Carolina, Puerto Rico (with transfers to other facilities in Puerto Rico and the United States)Manufacturing — intravenous solutions plant and warehouseUSD 103 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Total positions to be eliminated under the 1995 program; approximately 344 positions had been eliminated as of 1997-09-30. Completion delayed by regulatory reviews on equipment and production transfers. Remaining reserve was $32 million at 1997-09-30.
1997-09-30acquisition_additioncompleted1996-121997-06-30EuropeBiopharmaceutical products and services for transfusion medicinebusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Three-part acquisition valued at approximately $600 million plus assumption of approximately $280 million of net debt; final share purchase completed in Q3 1997. Headcount added not disclosed.
1997-09-30acquisition_additioncompleted1997-031997-03-31United StatesSpecialized products used in open-heart surgerybusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Purchase price approximately $239 million settled in stock. Headcount added not disclosed.
1997-09-30acquisition_additionannounced1997-07-31EuropeDialysis and intravenous solutions and containersother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement signed to acquire Bieffe Medital for approximately $245 million including assumed debt; subject to Italian anti-trust clearance. Headcount not disclosed.
1997-09-30otherannounced1997-10United StatesImmunotherapy division — new cell therapies joint company with VIMRx Pharmaceuticalsother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Baxter transferring certain Immunotherapy division assets into a new company in exchange for a minority stake; workforce implications not quantified. Subject to VIMRx shareholder approval expected before year-end 1997.
1997-09-30restructuringin_progress1,8761993-111998-12-31United States, Europe, Japan, CanadaUSD 216 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Cumulative positions eliminated since inception of 1993 program. Exceeds original target of 1,640.
1997-09-30restructuringin_progress3441995-091998-12-31Puerto Rico, United StatesManufacturingUSD 103 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Positions eliminated to date out of targeted 1,450. Related to closure of intravenous solutions plant in Carolina, Puerto Rico.
1997-06-30restructuringin_progress1,8001993-111997-12-31United States, Europe, Japan, CanadaMultiple (reorganizations and consolidations)USD 216 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Cumulative positions eliminated since program inception, not a quarterly figure; exceeds original target of 1,640. Additional positions expected during 1997.
1997-06-30plant_closurein_progress3401995-091998-12-31Carolina, Puerto RicoManufacturing (intravenous solutions plant and warehouse)USD 103 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		340 positions eliminated to date out of approximately 1,450 planned; cumulative since program inception. Program delayed by regulatory approval timing.
1997-06-30restructuringin_progress1993-111997-12-31United States, Europe, Japan, CanadaUSD 216 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Program initiated in Nov 1993. Since inception, approx 1,800 positions eliminated (exceeds original target of 1,640). Additional eliminations expected in 1997.
1997-06-30plant_closurein_progress1,4501995-091998-12-31Puerto RicoManufacturingUSD 103 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Closure of IV solutions plant and warehouse in Carolina, Puerto Rico. Approx 340 positions eliminated to date. Delays due to regulatory approvals.
1997-03-31restructuringin_progress1,8001993-111997-12-31United States, Europe, Japan, CanadaEnterpriseUSD 216 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Cumulative positions eliminated since program inception (~1,800), exceeding the original 1,640 target; additional eliminations expected during 1997. Charge recorded November 1993.
1997-03-31plant_closurein_progress1,4501995-091998-12-31Puerto Rico (United States)Manufacturing — intravenous solutions plant and warehouse, Carolina, PRUSD 103 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program targets elimination of ~1,450 positions via plant closure and capacity consolidation; ~340 positions eliminated to date as of March 31, 1997. Charge recorded September 1995.
1997-03-31acquisition_additioncompleted1996-121997-06-30Europe (Switzerland)Biopharmaceutical products and transfusion medicine servicesbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Three-part acquisition valued at ~$570M plus ~$280M assumed net debt; 68% of equity and voting rights acquired in Q1 1997. No headcount disclosed. Final part expected by mid-1997.
1997-03-31acquisition_additioncompleted1997-03-311997-03-31United StatesCardiovascular — specialized open-heart surgery productsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquired March 1997 for ~$239M settled in 4,801,711 shares issued from treasury. No headcount disclosed.
1997-03-31divestiture_reductioncompleted1996-09-301996-09-30United StatesHealth-care cost management and distribution businesses (Allegiance Corporation)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Tax-free spin-off of Allegiance Corporation completed September 1996; workforce associated with those businesses removed from continuing operations. No headcount disclosed.
1997-03-31restructuringin_progress1,8001993-11-011997-12-31United States, Europe, Japan, CanadaUSD 216 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Cumulative positions eliminated since inception of 1993 program; exceeds original target of 1,640.
1997-03-31restructuringin_progress3401995-09-011998-12-31Puerto RicoManufacturingUSD 103 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Positions eliminated to date from 1995 program targeting 1,450 positions; relates to plant closure in Carolina, Puerto Rico.
1996-12-31divestiture_reductioncompleted1996-09-30Health-care cost management and distribution business (Allegiance Corporation)Item_1_Business
f5-10k / GLM-5.3-flash-HTML		Tax-free spin-off completed September 30, 1996; stockholders of record September 26, 1996 received all Allegiance shares. Workforce transferred to Allegiance not quantified.
1996-12-31acquisition_additionin_progress1996-12EuropeBiopharmaceutical products and services for transfusion medicineItem_1_Business
f5-10k / GLM-5.3-flash-HTML		Three-part transaction commenced December 1996; purchase price approximately $600 million, largely to be expensed as in-process R&D in Q1 1997. Headcount acquired not disclosed.
1996-12-31acquisition_additioncompleted1996-12-061997-03-14Specialized products used in open-heart surgery (cardiovascular medicine)Item_1_Business
f5-10k / GLM-5.3-flash-HTML		Definitive agreement December 1996 for approximately $236 million in Company common stock; completed March 14, 1997, after fiscal year-end. Headcount acquired not disclosed.
1996-12-31divestiture_reductioncompleted1996-09-301996-09-30GlobalHealth-care cost management and distribution (Allegiance Corporation)Item_1_Business
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Tax-free spin-off of Allegiance Corporation to Baxter stockholders of record on 1996-09-26; headcount not disclosed
1996-12-31acquisition_additionin_progress1996-12-01EuropeBiopharmaceutical products and services for transfusion medicine (Immuno International AG)USD 600 (millions)Item_1_Business
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Purchase price approximately $600 million; substantial portion allocated to in-process R&D expensed in Q1 1997; headcount not disclosed
1996-12-31acquisition_additioncompleted1996-12-061997-03-14United StatesSpecialized products used in open-heart surgery (Research Medical, Inc.)USD 236 (millions)Item_1_Business
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition completed 1997-03-14 for approximately $236 million of Company common stock; headcount not disclosed
1996-12-31divestiture_reductioncompleted1996-09-301996-09-30GlobalHealth-care cost management and distributionItem_1_Business
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Spin-off of Allegiance Corporation, the health-care cost management and distribution business, completed on September 30, 1996. Specific headcount removed not disclosed in this filing.
1996-12-31divestiture_reductioncompleted1996-09-301996-09-30GlobalHealth-care cost management and distributionItem_1_Business
f5-10k / Qwen3.6-27B-Q8_0		Spin-off of Allegiance Corporation, the health-care cost management and distribution business, completed on September 30, 1996. Specific headcount removed not disclosed in this filing.
1996-09-30restructuringin_progress1,5731993-11-011997-12-31United States, Europe, Japan, CanadaCompany-wideUSD 230 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		1,573 of approximately 1,640 affected positions eliminated; remaining reductions through 1996 and 1997 as facility closures complete. Charge recorded November 1993.
1996-09-30plant_closurein_progress3221995-09-011998-12-31Puerto RicoManufacturing — intravenous solutions plant and warehouse, CarolinaUSD 103 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		322 of approximately 1,450 affected positions eliminated; most remaining reductions expected by end of 1998. Charge recorded September 1995 to eliminate excess plant capacity.
1996-09-30divestiture_reductioncompleted1996-09-301996-09-30United StatesAllegiance Corporation — health-care cost management businessother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Tax-free spin-off completed September 30, 1996; approximately $1.5 billion of net assets transferred. No employee headcount disclosed.
1996-09-30acquisition_additioncompleted1996-01-311996-01-31United StatesCardiovascular services — PSICOR, Inc. perfusion servicesUSD 80 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquired at $17.50 per share, approximately $80 million. No headcount added disclosed.
1996-09-30otherannounced1996-08-291997-03-31Europe, United StatesTransfusion medicine / biopharmaceuticals — Immuno International AG allianceUSD 715 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Strategic alliance valued at approximately $715 million; expected to close Q1 1997 pending U.S. FTC approval. No headcount disclosed.
1996-09-30restructuringin_progress1,6401993-11-011997-12-31WorldwideUSD 230 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		1993 program; 1,573 positions eliminated as of Q3 1996. Remaining reductions expected in 1996-1997.
1996-09-30restructuringin_progress1,4501995-09-011998-12-31Puerto RicoManufacturingUSD 103 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		1995 program; 322 positions eliminated as of Q3 1996. Primarily relates to closure of IV solutions plant in Carolina, Puerto Rico.
1996-09-30divestiture_reductioncompleted1996-09-301996-09-30WorldwideHealth-care cost managementrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Spin-off of Allegiance Corporation. Employee count not disclosed, but pension curtailment gain noted.
1996-06-30restructuringin_progress1,6401993-11-011997-12-31United States, Europe, Japan, CanadaCompany-wideUSD 230 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		1993 program; 1,363 of approximately 1,640 affected positions eliminated as of June 30, 1996; remaining reductions through 1996 and 1997; approximately $110 million of savings expected in 1996
1996-06-30plant_closurein_progress1,4501995-09-011998-12-31Puerto RicoManufacturing (intravenous solutions plant and warehouse, Carolina, Puerto Rico)USD 93 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		1995 manufacturing consolidation program; approximately 300 of approximately 1,450 positions eliminated as of June 30, 1996; charge recorded in Q3 1995; production and warehousing transferred to other facilities in Puerto Rico and the United States
1996-06-30restructuringin_progress1995-09-01Not specifiedOrganizational structure changesUSD 10 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Provision for employee severance related to organizational structure changes initiated alongside the Puerto Rico manufacturing consolidation; headcount not disclosed
1996-06-30restructuringin_progress1,6401993-11-011997-12-31Worldwide (United States, Europe, Japan, Canada)VariousUSD 230 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		1993 program. 1,363 positions eliminated as of June 30, 1996. Remaining reductions expected in 1996-1997.
1996-06-30plant_closurein_progress1,4501995-09-011998-12-31Puerto RicoManufacturingUSD 93 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		1995 program. Consolidation of manufacturing operations. 300 positions eliminated as of June 30, 1996.
1996-06-30restructuringin_progress1995-09-01WorldwideOrganizational structureUSD 10 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Additional organizational structure changes initiated in 1995. Employee count not specified.
1996-03-31restructuringin_progress1,6401993-11-011997-12-31United States, Europe, Japan, CanadaCompany-wideUSD 230 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Cumulative positions eliminated to date: approximately 1,300 of 1,640 total affected. Program announced Nov 1993 with $230M pretax provision. Remaining reductions expected through 1996 and 1997.
1996-03-31plant_closurein_progress1,4501995-09-011998-12-31Puerto RicoManufacturing — intravenous solutions plant and warehouse in Carolina, Puerto RicoUSD 93 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Manufacturing consolidation to eliminate excess capacity. Cumulative positions eliminated to date: approximately 250 of 1,450. Charge recorded Q3 1995. Production transferring to other facilities in Puerto Rico and the U.S.
1996-03-31restructuringin_progress1995-09-01Not specifiedOrganizational structure changesUSD 10 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Separate $10M provision for employee severance related to organizational structure changes initiated alongside the Puerto Rico manufacturing consolidation.
1996-03-31acquisition_additioncompleted1995-11-221996-01-31United StatesPerfusion servicesUSD 80 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of PSICOR, Inc. at $17.50/share (~$80M), completed end of January 1996. No headcount disclosed.
1996-03-31divestiture_reductioncompleted1995-09-011995-09-30Not specifiedIndustrial and Life Sciences divisionother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Divestiture of Industrial and Life Sciences division to VWR Corporation in September 1995. No headcount disclosed.
1996-03-31divestiture_reductionannounced1995-11-281996-12-31Not specifiedHealth-care cost management business (cost management services, U.S. distribution, surgical products, respiratory therapy)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Planned tax-free spin-off of health-care cost management business to Baxter stockholders, expected late 1996. Approximately $1.2B of Baxter debt to be indirectly assumed by the new entity. No headcount disclosed.
1996-03-31restructuringin_progress1,6401993-111997-12-31Worldwide (US, Europe, Japan, Canada)USD 230 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		1993 program. 1,300 positions eliminated as of Q1 1996. $13M reserves utilized in Q1 1996.
1996-03-31restructuringin_progress1,4501995-091998-12-31Puerto RicoManufacturingUSD 93 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		1995 program. Consolidation of manufacturing operations. 250 positions eliminated as of Q1 1996. $5M reserves utilized in Q1 1996.
1996-03-31restructuringin_progress1995USD 10 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Organizational structure changes. $10M provision for employee severance recorded in 1995.
1995-12-31restructuringin_progress1,2501993-111997United States, Europe, Japan and CanadaCompany-wide (all businesses)USD 60 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Multi-year program; figures are cumulative through fiscal year-end 1995 — approximately 1,250 of approximately 1,640 affected positions eliminated, with the majority of remaining reductions planned for 1996-1997. The 1995 associated charge represents reserve utilization ($36 million cash, $24 million non-cash) against the original $230 million pretax November 1993 provision; $93 million of reserves remained at December 31, 1995. Counts pertain to continuing operations.
1995-12-31plant_closurein_progress1,4501995-091998-12-31Puerto Rico (production consolidated into remaining facilities in Puerto Rico and the United States)Manufacturing (intravenous solutions plant and warehouse, Carolina, Puerto Rico)USD 93 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Q3 1995 pretax charge comprises approximately $67 million asset write-downs from facility closures, $17 million employee-related severance and $9 million other costs; approximately 1,450 positions to be eliminated and roughly $26 million of cash outlays expected over the following two years.
1995-12-31restructuringin_progress1995-09Organizational structure changes (corporate)USD 10 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Provision for cash payments related to employee severance from organizational structure changes initiated in addition to the Puerto Rico manufacturing consolidation; affected headcount not separately disclosed.
1995-12-31divestiture_reductioncompletedIndustrial and Life Sciences divisiondiscontinued_operations_footnote
f5-10k / GLM-5.3-flash-HTML		Division divested to VWR Corporation during 1995, generating a $268 million net pretax gain recorded in discontinued operations; affected employee count not disclosed. Division results are included within the discontinued health-care cost management business data (previously divested businesses).
1995-12-31divestiture_reductionannounced1995-11-281996Health-care cost management business (cost-management services, U.S. distribution, surgical products, respiratory-therapy operations)USD 34 (millions)discontinued_operations_footnote
f5-10k / GLM-5.3-flash-HTML		Board approved in principle a tax-free spin-off via stock distribution to Baxter shareholders, expected in late 1996; affected employee count not disclosed. Q4 1995 pretax charge of $34 million for costs of effecting the distribution ($26 million net of an $8 million tax benefit).
1995-12-31restructuringin_progress1,6401993-11-011997-12-31Worldwide (US, Europe, Japan, Canada)MultipleUSD 230 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Cumulative program totals since November 1993 inception. Approximately 1,250 of 1,640 positions eliminated through 1995; remaining reductions expected in 1996-1997. $230M original pretax charge; $93M reserve balance remaining at 12/31/1995.
1995-12-31plant_closurein_progress1,4501995-09-011998-12-31Puerto RicoManufacturing (IV solutions plant and warehouse, Carolina, PR)USD 93 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		1995 restructuring program to consolidate manufacturing operations in Puerto Rico. Charge includes $67M valuation adjustments for facility closures. Approximately $26M cash expected over two years including severance. Initiated Q3 1995.
1995-12-31restructuringin_progress1995-09-01Not specifiedOrganizational structure changesUSD 10 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Separate from Puerto Rico consolidation; provision for cash payments related to employee severance from other organizational structure changes. Position count not disclosed.
1995-12-31divestiture_reductionannounced1995-11-281996-12-31Primarily United StatesHealth-care cost management business (cost management services, U.S. distribution, surgical products, respiratory therapy)USD 34 (millions)Item_1_Business
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Spin-off of health-care cost management business approved by board November 28, 1995. Expected to occur late 1996 as tax-free distribution. $34M pretax charge in Q4 1995 for costs of effecting distribution. Headcount to be transferred not disclosed.
1995-12-31restructuringin_progress1,6401993-111997-12-31Worldwide (US, Europe, Japan, Canada)Continuing OperationsUSD 230 (millions)Item_1_Business
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		1993 program. 1,250 positions eliminated by end of 1995; majority of remaining reductions expected in 1996-1997. $60M of reserves utilized in 1995.
1995-12-31restructuringin_progress1,4501995-091998-12-31Puerto RicoManufacturingUSD 93 (millions)Item_1_Business
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		1995 program to consolidate manufacturing operations in Puerto Rico. $93M pretax charge includes $67M valuation adjustments. $10M additional provision for other organizational changes.
1995-12-31restructuringin_progress1,6401993-111997-12-31Worldwide (United States, Europe, Japan, Canada)USD 230 (millions)Item_1_Business
f5-10k / Qwen3.6-27B-Q8_0		1993 program: Approximately 1,640 positions affected. As of 1995, approximately 1,250 positions eliminated. Majority of remaining reductions expected in 1996 and 1997. Initial pretax provision of $230 million recorded in 1993.
1995-12-31restructuringin_progress1,4501995-091998-12-31Puerto RicoManufacturingUSD 93 (millions)Item_1_Business
f5-10k / Qwen3.6-27B-Q8_0		1995 program: Consolidation of manufacturing operations in Puerto Rico. Approximately 1,450 positions to be eliminated. Pretax restructuring charge of $93 million recorded in Q3 1995, including $67 million for valuation adjustments.
1995-09-30plant_closurein_progress1,4501995-09-301997-12-31Puerto RicoManufacturing — intravenous solutions plant and warehouse in Carolina, Puerto RicoUSD 93 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Exact announcement date not disclosed; charge recorded in Q3 1995 following a global manufacturing capacity study. Charge comprises $17M employee-related (severance), $67M asset write-downs, $9M other. Severance relates to approximately 1,450 positions to be eliminated; production and warehousing to transfer to other Puerto Rico and U.S. facilities.
1995-09-30restructuringin_progress1995-09-30Not specifiedOrganizational structure changesUSD 10 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Provision for employee severance arising from organizational structure changes initiated in Q3 1995; number of employees affected not disclosed. Exact announcement date not disclosed.
1995-09-30restructuringin_progress2,9001993-111996-12-31Primarily United StatesMedical/laboratory products and distribution segmentMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Cumulative positions eliminated since inception of the November 1993 program, of approximately 4,500 positions affected; remaining reductions expected through 1995 and 1996. In first nine months of 1995 the Company utilized $128M of restructuring reserves, including $98M cash payments. Original $700M pretax provision recorded in November 1993.
1995-09-30divestiture_reductioncompleted1995-09-15Primarily United StatesIndustrial and Life Sciences Divisionother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Division sold to VWR Corporation for approximately $400M cash plus $29M deferred payments, resulting in a $268M net pretax gain. Headcount removed through the divestiture not disclosed; Baxter continues supplying self-manufactured products to VWR under a long-term distribution agreement.
1995-09-30restructuringin_progress1,4501995-09-301997-12-31Puerto RicoManufacturingUSD 93 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Consolidation of manufacturing operations; charge predominantly for closing IV solutions plant and warehouse in Carolina.
1995-09-30restructuringin_progress1995-09-30GlobalGeneral CorporateUSD 10 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Organizational structure changes; provision for employee severance.
1995-09-30restructuringin_progress1993-11-011996-12-31GlobalMedical/Laboratory Products and DistributionUSD 76 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Adjustment to 1993 restructuring reserves related to divestiture of diagnostics manufacturing businesses.